ammonium hydroxide has been researched along with Hyperammonemia in 486 studies
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.
Hyperammonemia: Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperammonemia can occur after acute overdose or chronic use of valproic acid (VPA)." | 9.41 | Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy. ( Kim, DW; Kwack, DW, 2023) |
| "The objective was to evaluate the efficacy and safety of sodium benzoate in the management of hyperammonemia and hepatic encephalopathy (HE) in decompensated chronic liver disease." | 9.34 | Efficacy and Safety of Sodium Benzoate in The Management of Hyperammonemia in Decompensated Chronic Liver Disease of the Childhood-A Double-blind Randomized Controlled Trial. ( Alam, S; Khanna, R; Lal, BB; Snehavardhan, P; Sood, V, 2020) |
| "Intestinal mannitol is as effective and safe as conventional treatment for reducing hyperammonemia, oxidative stress, and hepatic encephalopathy of CLD patients in the emergency room." | 9.27 | Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED. ( Cruz-Domínguez, MP; Jara, LJ; Montes-Cortés, DH; Novelo-Del Valle, JL; Olivares-Corichi, IM; Rosas-Barrientos, JV, 2018) |
| "Valproate (VPA) administration may be associated with adverse metabolic effects, among is hyperammonemia, which could suggest metabolic abnormalities as carnitine deficiency." | 9.14 | The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. ( Abdella, MM; Hamed, SA, 2009) |
| "Valproic acid (VPA)-induced hyperammonemia (HA) is a rare adverse effect reported even at therapeutic VPA levels." | 8.31 | Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey. ( Aghamollaii, V; Ghayyem, H; Hassani, M; Hosseini, H; Mayeli, M; Shafie, M; Shakiba, A, 2023) |
| "Further research should be conducted into the prevalence and pathophysiology of methamphetamine-induced encephalopathy in the absence of hyperammonemia." | 8.31 | Methamphetamine-induced encephalopathy in the absence of hyperammonemia. ( Bowman, J; Dong, F; Fitzgerald, K; Neeki, MM; Rabbany, JM, 2023) |
| "This study was to investigate the effects of ammonia and manganese in the metabolism of minimal hepatic encephalopathy (MHE)." | 8.31 | The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study. ( Li, Y; Liu, XF; Lu, JJ; Qiang, JW; Yang, XY, 2023) |
| " Urea cycle disorders with hyperammonemia remain difficult to treat and eventually necessitate liver transplantation." | 8.12 | Glutaminase 2 knockdown reduces hyperammonemia and associated lethality of urea cycle disorder mouse model. ( Burczynski, ME; Chen, H; Cheng, X; Halasz, G; Kim, S; Lin, AZ; Mao, X; Murphy, AJ; Na, E; Okamoto, H; Sleeman, MW, 2022) |
| "AbstractThe aim of this study was to explore the effect of lamotrigine (LTG) on blood ammonia level in patients with epilepsy and identify risk factors affecting blood ammonia level." | 8.12 | Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine. ( Chen, J; Chen, X; Chen, Y; Miao, J; Wang, R; Zeng, J; Zhuang, X, 2022) |
| "Acetaminophen-induced hepatotoxicity can result in hyperammonemia, but it is not clear if elevated ammonia concentrations predict encephalopathy." | 8.12 | Hyperammonemia in acetaminophen toxicity. ( Marino, RT; Sidlak, AM, 2022) |
| "Routine use of lactulose to treat mild to moderate hyperammonemia in this patient population was not associated with improved outcomes." | 8.12 | Use of Lactulose to Treat Hyperammonemia in ICU Patients Without Chronic Liver Disease or Significant Hepatocellular Injury. ( Cutler, NS; MacGregor, DA; Sadowski, BW, 2022) |
| "Hyperammonemia is a common side effect of valproic acid (VPA) and can occur after generalized seizures, but the clinical significance is unclear." | 8.02 | Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid. ( Britton, JW; Hocker, SE; Smith, KM; Toledano, M, 2021) |
| "Hyperammonemia is an important adverse event associated with 5-fluorouracil (5FU) from 5FU metabolite accumulation." | 7.96 | Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. ( Funakoshi, T; Horimatsu, T; Ikeda, A; Imamaki, H; Kataoka, S; Matsubara, T; Muto, M; Nakagawa, S; Nishikawa, Y; Oura, M; Ozaki, Y; Watanabe, N; Yanagita, M; Yonezawa, A, 2020) |
| "This study was aimed at identifying genetic and non-genetic risk factors for valproic acid (VPA)-induced hyperammonaemia in Chinese paediatric patients with epilepsy." | 7.88 | Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy. ( Li, X; Zhang, T; Zhao, L; Zhu, X, 2018) |
| " The current investigation was designed to evaluate the role of taurine treatment on the brain and liver mitochondrial function in a rat model of hepatic encephalopathy and hyperammonemia." | 7.85 | Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia. ( Abasvali, M; Abdoli, N; Asadi, B; Azarpira, N; Heidari, R; Jafari, F; Jamshidzadeh, A; Khodaei, F; Latifpour, Z; Mardani, E; Najibi, A; Ommati, MM; Yeganeh, Y; Zarei, A; Zarei, M, 2017) |
| "High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal." | 7.85 | Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| "Valproic acid (VPA), which is widely used to treat epilepsy, migraine, and bipolar disorder, can causes severe hyperammonemia." | 7.81 | Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. ( Hirai, K; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y, 2015) |
| " L-Carnitine is a vitamin-like substance and several reports have described the usefulness of L-carnitine supplementation in cases of cirrhosis, with confirmed effectiveness against refractory hepatic encephalopathy." | 7.81 | Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma. ( Hasegawa, H; Ishihara, T; Iwasa, M; Kobayashi, Y; Mifuji-Moroka, R; Sekoguchi-Fujikawa, N; Sugimoto, R; Takei, Y; Tanaka, H; Yoshikawa, K, 2015) |
| "Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 7.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
| "Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia." | 7.80 | 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. ( Hayashi, H; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Miyakawa, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y; Yazawa, R, 2014) |
| "Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy." | 7.80 | Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. ( Chang, CC; Chang, WN; Chen, NC; Chuang, YC; Huang, CR; Lin, CH; Lu, CH; Lu, YT; Tseng, YL, 2014) |
| "Combined administration of ornithine and phenylacetate (OP) is proposed as a novel treatment of hyperammonemia and hepatic encephalopathy." | 7.79 | Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia. ( Bak, LK; Dadsetan, S; Jalan, R; Keiding, S; Ott, P; Schousboe, A; Sørensen, M; Vilstrup, H; Waagepetersen, HS, 2013) |
| " The present study was undertaken to examine the protective influence of rutin, a polyphenolic flavonoid, on oxidative stress during ammonium chloride (AC)-induced hyperammonemia by measuring the levels of oxidative damage as well as antioxidant status." | 7.78 | Influence of rutin on biochemical alterations in hyperammonemia in rats. ( Mahmoud, AM, 2012) |
| "In propionic aciduria and methylmalonic aciduria, hyperammonemia as a symptom of metabolic decompensation is one of the major clinical problems." | 7.76 | N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. ( Donati, MA; Filippi, L; Fiorini, P; Gozzini, E; la Marca, G; Malvagia, S, 2010) |
| "Adult-onset type II citrullinemia is an inborn error of urea cycle metabolism that can lead to hyperammonemic encephalopathy and coma." | 7.74 | Magnetic resonance spectroscopy in adult-onset citrullinemia: elevated glutamine levels in comatose patients. ( Au, WL; Lim, CC; Wong, YC; Xu, M; Ye, J, 2007) |
| "Fulminant hyperammonaemia as a threshold effect of coma-inducing dose of sodium thiopental has been revealed in rats." | 7.73 | Fulminant hyperammonaemia induced by thiopental coma in rats. ( Ivnitsky, JJ; Malakhovsky, VN; Rejniuk, VL; Schäfer, TV, 2006) |
| "To describe a case of oral valproic acid-induced hyperammonemia and thrombocytopenia in an elderly patient." | 7.72 | Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman. ( Babin, S; Mallet, L; Morais, JA, 2004) |
| "Juvenile visceral steatosis (JVS) mouse is an animal model of human primary carnitine deficiency caused by a mutation of the gene encoding carnitine transporter, and suffers from various symptoms, such as fatty liver, growth retardation, hyperammonemia, hypoglycemia, and cardiac hypertrophy." | 7.71 | Hyperammonemia in carnitine-deficient adult JVS mice used by starvation. ( Horiuchi, M; Jalil, A; Kobayashi, K; Li, XX; Saheki, T; Yoshida, G, 2002) |
| "The objective of this study was to evaluate a new method for the treatment of acute hyperammonemia with a helium-oxygen mixture (heliox)." | 7.71 | Heliox use in the treatment of acute hyperammonemia. ( Barr, J; Chen-Levy, Z; Eshel, G; Lahat, E, 2001) |
| "The urea cycle disorders are a group of inherited biochemical diseases caused by a complete or partial deficiency of any one of the enzymes or transport proteins required to convert toxic ammonia into urea and to produce arginine and citrulline." | 6.58 | Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders. ( Mew, NA; Summar, ML, 2018) |
| "Valproic acid (VPA) is a short-chain fatty acid widely prescribed in the treatment of seizure disorders and epilepsy syndromes, although its therapeutic value may be undermined by its toxicity." | 5.91 | Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. ( Fagiolino, P; Ibarra, M; Maldonado, C; Schiavo, A; Trocóniz, IF; Vázquez, M, 2023) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 5.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| "Leukoencephalopathy was resolved following the administration of L-arginine and lactulose with a decrease in plasma ammonia levels and glutamine-glutamate peak on magnetic resonance spectroscopy." | 5.72 | Reversible Leukoencephalopathy in a Man with Childhood-onset Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome. ( Fukuyama, T; Hoshino, Y; Kaneko, T; Kodaira, M; Matsuno, A; Sekijima, Y; Takano, K; Yazaki, M, 2022) |
| " One of the biggest problems of these compounds, however, is their very short bioavailability due to instant metabolism and rapid excretion." | 5.51 | Poly(ornithine)-based self-assembling drug for recovery of hyperammonemia and damage in acute liver injury. ( Ibayashi, Y; Lee, Y; Nagasaki, Y; Ngo, DN; Nishikawa, Y; Vong, LB, 2019) |
| " Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication." | 5.48 | Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia. ( Bukofzer, S; Clasen, K; Durkalski, V; Fontana, RJ; Ganger, D; Gottfried, M; Hameed, B; Hanje, AJ; Koch, D; Lee, WM; Little, L; Ravis, WR; Sherker, A; Stravitz, RT; Subramanian, RM, 2018) |
| "Hyperammonemia is a common complication of a wide variety of both inherited and acquired liver diseases." | 5.48 | Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia. ( Allegri, G; Annunziata, P; Ballabio, A; Brunetti-Pierri, N; Häberle, J; Melck, D; Motta, A; Nusco, E; Paris, D; Pastore, N; Polishchuk, E; Soria, LR; Thöny, B, 2018) |
| "Hyperammonemia can occur after acute overdose or chronic use of valproic acid (VPA)." | 5.41 | Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy. ( Kim, DW; Kwack, DW, 2023) |
| "Hyperammonemia is a major etiological toxic factor in the development of hepatic encephalopathy." | 5.39 | Brain alanine formation as an ammonia-scavenging pathway during hyperammonemia: effects of glutamine synthetase inhibition in rats and astrocyte-neuron co-cultures. ( Bak, LK; Dadsetan, S; Keiding, S; Kukolj, E; Ott, P; Schousboe, A; Sørensen, M; Vilstrup, H; Waagepetersen, HS, 2013) |
| "Although hyperammonemia was suspected as the cause of the patient's mental changes, there was no evidence of chronic liver disease." | 5.38 | Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency. ( Choi, DE; Lee, KW; Na, KR; Shin, YT, 2012) |
| "The objective was to evaluate the efficacy and safety of sodium benzoate in the management of hyperammonemia and hepatic encephalopathy (HE) in decompensated chronic liver disease." | 5.34 | Efficacy and Safety of Sodium Benzoate in The Management of Hyperammonemia in Decompensated Chronic Liver Disease of the Childhood-A Double-blind Randomized Controlled Trial. ( Alam, S; Khanna, R; Lal, BB; Snehavardhan, P; Sood, V, 2020) |
| "The diagnosis of hereditary ornithine transcarbamylase deficiency was confirmed by liver biopsy in the immediate post-mortem period." | 5.31 | [Fulminant coma: think hyperammonemia and urea cycle disorders]. ( Augris, C; Benabdelmalek, F; Caramella, JP; Jouvet, P; Vauquelin, P, 2002) |
| "Intestinal mannitol is as effective and safe as conventional treatment for reducing hyperammonemia, oxidative stress, and hepatic encephalopathy of CLD patients in the emergency room." | 5.27 | Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED. ( Cruz-Domínguez, MP; Jara, LJ; Montes-Cortés, DH; Novelo-Del Valle, JL; Olivares-Corichi, IM; Rosas-Barrientos, JV, 2018) |
| "Valproic acid (VPA) has been associated with hyperammonemia with and without encephalopathy." | 5.14 | Hyperammonemia following intravenous valproate loading. ( Beasley, MT; Cofield, S; DeWolfe, JL; Faught, E; Knowlton, RC; Limdi, NA, 2009) |
| "Valproate (VPA) administration may be associated with adverse metabolic effects, among is hyperammonemia, which could suggest metabolic abnormalities as carnitine deficiency." | 5.14 | The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. ( Abdella, MM; Hamed, SA, 2009) |
| "Arginine treatment is able to reduces attacks of hyperammonemia in boys with late-onset OTCD and to increase their growth." | 5.12 | Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency. ( Adachi, M; Kanazawa, M; Kobayashi, K; Kubota, M; Kurokawa, K; Murakami, T; Murayama, K; Nagasaka, H; Ogawa, A; Ogawa, E; Takatani, T; Takayanagi, M; Yamamoto, S; Yorifuji, T, 2006) |
| "We report the results of a 25-year, open-label, uncontrolled study of sodium phenylacetate and sodium benzoate therapy (Ammonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in whom there were 1181 episodes of acute hyperammonemia." | 5.12 | Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. ( Berry, GT; Berry, SA; Brusilow, SW; Enns, GM; Hamosh, A; Rhead, WJ, 2007) |
| " Recent studies provide new evidence for the use of lactulose, probiotics and rifaximin, as well as closure of large portosystemic shunts in the treatment of hepatic encephalopathy." | 4.90 | Treatment of hyperammonemia in liver failure. ( Jalan, R; Jover-Cobos, M; Khetan, V, 2014) |
| "Valproic acid (VPA)-induced hyperammonemia (HA) is a rare adverse effect reported even at therapeutic VPA levels." | 4.31 | Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey. ( Aghamollaii, V; Ghayyem, H; Hassani, M; Hosseini, H; Mayeli, M; Shafie, M; Shakiba, A, 2023) |
| "Further research should be conducted into the prevalence and pathophysiology of methamphetamine-induced encephalopathy in the absence of hyperammonemia." | 4.31 | Methamphetamine-induced encephalopathy in the absence of hyperammonemia. ( Bowman, J; Dong, F; Fitzgerald, K; Neeki, MM; Rabbany, JM, 2023) |
| "Hyperammonemia has been reported following asparaginase administration, consistent with the mechanisms of asparaginase, which catabolizes asparagine to aspartic acid and ammonia, and secondarily converts glutamine to glutamate and ammonia." | 4.31 | Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia. ( Altintas, B; Eldem, I; Langley, R; Lee, A; Nguyen, H; Shinawi, M; Willis, D, 2023) |
| "This study was to investigate the effects of ammonia and manganese in the metabolism of minimal hepatic encephalopathy (MHE)." | 4.31 | The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study. ( Li, Y; Liu, XF; Lu, JJ; Qiang, JW; Yang, XY, 2023) |
| " Urea cycle disorders with hyperammonemia remain difficult to treat and eventually necessitate liver transplantation." | 4.12 | Glutaminase 2 knockdown reduces hyperammonemia and associated lethality of urea cycle disorder mouse model. ( Burczynski, ME; Chen, H; Cheng, X; Halasz, G; Kim, S; Lin, AZ; Mao, X; Murphy, AJ; Na, E; Okamoto, H; Sleeman, MW, 2022) |
| "We used desflurane and remifentanil for general anesthesia to avoid hyperammonemia and delayed emergence." | 4.12 | Desflurane and remifentanil anesthesia in a child with citrin deficiency: A case report. ( Jung, SM; Kim, K, 2022) |
| "AbstractThe aim of this study was to explore the effect of lamotrigine (LTG) on blood ammonia level in patients with epilepsy and identify risk factors affecting blood ammonia level." | 4.12 | Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine. ( Chen, J; Chen, X; Chen, Y; Miao, J; Wang, R; Zeng, J; Zhuang, X, 2022) |
| "Life-threatening hyperammonemia occurs in both inherited and acquired liver diseases affecting ureagenesis, the main pathway for detoxification of neurotoxic ammonia in mammals." | 4.12 | O-GlcNAcylation enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis. ( Arena, P; Attanasio, S; Boffa, I; Brunetti-Pierri, N; Cuomo, P; D'Alessio, AM; De Angelis, A; Desviat, LR; Ferenbach, AT; Häberle, J; Lipshutz, GS; Makris, G; Martínez-Pizarro, A; Motta, A; Nitzahn, M; Nusco, E; Paris, D; Pravata, VM; Richard, E; Rüfenacht, V; Soria, LR; van Aalten, DMF, 2022) |
| "Acetaminophen-induced hepatotoxicity can result in hyperammonemia, but it is not clear if elevated ammonia concentrations predict encephalopathy." | 4.12 | Hyperammonemia in acetaminophen toxicity. ( Marino, RT; Sidlak, AM, 2022) |
| "Routine use of lactulose to treat mild to moderate hyperammonemia in this patient population was not associated with improved outcomes." | 4.12 | Use of Lactulose to Treat Hyperammonemia in ICU Patients Without Chronic Liver Disease or Significant Hepatocellular Injury. ( Cutler, NS; MacGregor, DA; Sadowski, BW, 2022) |
| "We report the case of a 79-year-old male who had undergone surgery for a mucus-secreting, stage-III pancreatic adenocarcinoma 2 years previously, who was recently started on capecitabine monotherapy for radiographic local progression." | 4.12 | Capecitabine-induced hyperammonemic encephalopathy. ( Armesto González, EM; Cano Calderero, FX; Cerrella Cano, C; Junquera Alonso, E; Seoane Blanco, L; Terroba Alonso, M, 2022) |
| "Hyperammonemia is a common side effect of valproic acid (VPA) and can occur after generalized seizures, but the clinical significance is unclear." | 4.02 | Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid. ( Britton, JW; Hocker, SE; Smith, KM; Toledano, M, 2021) |
| "Ornithine transcarbamylase deficiency (OTCD) is pleomorphic congenital hyperammonemia, in which the prognosis of the patient is determined both by genotype and environmental factors." | 3.96 | Clinical and biochemical characteristics of patients with ornithine transcarbamylase deficiency. ( Cai, YN; Jiang, MY; Li, XZ; Lin, YT; Liu, L; Mei, HF; Peng, MZ; Shao, YX; Sheng, HY; Su, L; Yin, X, 2020) |
| "Hyperammonemia is an important adverse event associated with 5-fluorouracil (5FU) from 5FU metabolite accumulation." | 3.96 | Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. ( Funakoshi, T; Horimatsu, T; Ikeda, A; Imamaki, H; Kataoka, S; Matsubara, T; Muto, M; Nakagawa, S; Nishikawa, Y; Oura, M; Ozaki, Y; Watanabe, N; Yanagita, M; Yonezawa, A, 2020) |
| "Arginase deficiency is caused by biallelic mutations in arginase 1 (ARG1), the final step of the urea cycle, and results biochemically in hyperargininemia and the presence of guanidino compounds, while it is clinically notable for developmental delays, spastic diplegia, psychomotor function loss, and (uncommonly) death." | 3.91 | Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. ( Allegri, G; Burke, KE; Cederbaum, SD; Häberle, J; Lipshutz, GS; Liu, XB; Martini, PGV; Truong, B; Zhu, X, 2019) |
| "The purpose of the study was to evaluate the influence of establishing a protocol for the use of combined sodium benzoate and sodium phenylacetate (SBSP) (Ammonul®) to treat acute hyperammonemia." | 3.91 | Influence of implementing a protocol for an intravenously administered ammonia scavenger on the management of acute hyperammonemia in a pediatric intensive care unit. ( Brossier, D; Goyer, I; Jouvet, P; Marquis, C; Mitchell, G; Ozanne, B; Ziani, L, 2019) |
| "Patients with neonatal urea cycle defects (UCDs) typically experience severe hyperammonemia during the first days of life, which results in serious neurological injury or death." | 3.88 | Prenatal treatment of ornithine transcarbamylase deficiency. ( Akula, VP; Alcorn, D; Benitz, WE; Bernstein, JA; Berquist, WE; Blumenfeld, YJ; Castillo, RO; Concepcion, W; Cowan, TM; Cox, KL; Cusmano, K; Enns, GM; Esquivel, CO; Hintz, SR; Homeyer, M; Hudgins, L; Hurwitz, M; Lyell, DJ; Palma, JP; Schelley, S; Summar, ML; Wilnai, Y, 2018) |
| "This study was aimed at identifying genetic and non-genetic risk factors for valproic acid (VPA)-induced hyperammonaemia in Chinese paediatric patients with epilepsy." | 3.88 | Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy. ( Li, X; Zhang, T; Zhao, L; Zhu, X, 2018) |
| "The underlying pathophysiology of liver dysfunction in urea cycle disorders (UCDs) is still largely elusive." | 3.85 | Metabolically based liver damage pathophysiology in patients with urea cycle disorders - A new hypothesis. ( Garavelli, L; Ivanovski, A; Ivanovski, I; Ivanovski, P; Ješić, M, 2017) |
| " The current investigation was designed to evaluate the role of taurine treatment on the brain and liver mitochondrial function in a rat model of hepatic encephalopathy and hyperammonemia." | 3.85 | Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia. ( Abasvali, M; Abdoli, N; Asadi, B; Azarpira, N; Heidari, R; Jafari, F; Jamshidzadeh, A; Khodaei, F; Latifpour, Z; Mardani, E; Najibi, A; Ommati, MM; Yeganeh, Y; Zarei, A; Zarei, M, 2017) |
| ", drowsiness, coma) were selected for treatment with l-arginine." | 3.85 | L-Arginine in the treatment of valproate overdose - five clinical cases. ( Eyer, F; Felgenhauer, N; Fernando, M; Rabe, C; Schrettl, V, 2017) |
| "High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal." | 3.85 | Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| "Hyperammonemia is a common finding in children with methylmalonic acidemia." | 3.83 | A neuronal disruption in redox homeostasis elicited by ammonia alters the glycine/glutamate (GABA) cycle and contributes to MMA-induced excitability. ( Braga, DV; da Silva, AM; da Silva, LR; da Silveira Junior, ME; de Oliveira Ferreira, AP; Della-Pace, ID; Dobrachinski, F; Fighera, MR; Furian, AF; Gabbi, P; Grisólia, AB; Marchesan, S; Oliveira, MS; Ribeiro, LR; Rodrigues, FS; Royes, LF; Soares, FA, 2016) |
| "Valproic acid (VPA), which is widely used to treat epilepsy, migraine, and bipolar disorder, can causes severe hyperammonemia." | 3.81 | Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. ( Hirai, K; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y, 2015) |
| " L-Carnitine is a vitamin-like substance and several reports have described the usefulness of L-carnitine supplementation in cases of cirrhosis, with confirmed effectiveness against refractory hepatic encephalopathy." | 3.81 | Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma. ( Hasegawa, H; Ishihara, T; Iwasa, M; Kobayashi, Y; Mifuji-Moroka, R; Sekoguchi-Fujikawa, N; Sugimoto, R; Takei, Y; Tanaka, H; Yoshikawa, K, 2015) |
| "Hyperammonemia is a common finding in children with methylmalonic acidemia and propionic acidemia, but its contribution to the development of the neurological symptoms in the affected patients is poorly known." | 3.80 | Disruption of redox homeostasis and brain damage caused in vivo by methylmalonic acid and ammonia in cerebral cortex and striatum of developing rats. ( de Oliveira, FH; Grings, M; Hickmann, FH; Leipnitz, G; Monteiro, WO; Sitta, Â; Soares, LE; Viegas, CM; Wajner, M; Zanatta, Â, 2014) |
| "Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 3.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
| "Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia." | 3.80 | 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. ( Hayashi, H; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Miyakawa, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y; Yazawa, R, 2014) |
| "Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy." | 3.80 | Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. ( Chang, CC; Chang, WN; Chen, NC; Chuang, YC; Huang, CR; Lin, CH; Lu, CH; Lu, YT; Tseng, YL, 2014) |
| "Combined administration of ornithine and phenylacetate (OP) is proposed as a novel treatment of hyperammonemia and hepatic encephalopathy." | 3.79 | Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia. ( Bak, LK; Dadsetan, S; Jalan, R; Keiding, S; Ott, P; Schousboe, A; Sørensen, M; Vilstrup, H; Waagepetersen, HS, 2013) |
| " The present study was undertaken to examine the protective influence of rutin, a polyphenolic flavonoid, on oxidative stress during ammonium chloride (AC)-induced hyperammonemia by measuring the levels of oxidative damage as well as antioxidant status." | 3.78 | Influence of rutin on biochemical alterations in hyperammonemia in rats. ( Mahmoud, AM, 2012) |
| " Current knowledge suggests that hyperammonemia, related to liver failure, is a main factor contributing to the cerebral alterations in HE and that hyperammonemia might impair signal transduction associated with post-translational modification of proteins such as tyrosine-nitration and phosphorylation." | 3.78 | Exploratory investigation on nitro- and phospho-proteome cerebellum changes in hyperammonemia and hepatic encephalopathy rat models. ( Airoldi, L; Boix, J; Brunelli, L; Campagna, R; Cauli, O; Felipo, V; Llansola, M; Pastorelli, R, 2012) |
| " Cyclophosphamide caused hyperammonemia; glutamine/ammonia and urea/ammonia ratios in the blood decreased." | 3.78 | Aggravation of cyclophosphamide-induced acute neurological disorders under conditions of artificial acidification of chyme in rats. ( Ivnitsky, JJ; Malakhovsky, VN; Rejuniuk, VL; Schaefer, TV, 2012) |
| "Hyperammonemia is a frequent side-effect of valproic acid (VPA) therapy, which points to an imbalance between ammoniagenesis and ammonia disposal via the urea cycle." | 3.77 | New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. ( Aires, CC; de Almeida, IT; Duran, M; Ijlst, L; Silva, MF; van Cruchten, A; Wanders, RJ, 2011) |
| "Patients with extrahepatic portal vein obstruction have inflammation and hyperammonemia made evident by higher blood TNF-α, IL-6, ammonia, and brain glutamine levels." | 3.77 | Pro-inflammatory cytokines are raised in extrahepatic portal venous obstruction, with minimal hepatic encephalopathy. ( Gupta, RK; Saraswat, VA; Srivastava, A; Thomas, MA; Yachha, SK; Yadav, SK, 2011) |
| "In propionic aciduria and methylmalonic aciduria, hyperammonemia as a symptom of metabolic decompensation is one of the major clinical problems." | 3.76 | N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. ( Donati, MA; Filippi, L; Fiorini, P; Gozzini, E; la Marca, G; Malvagia, S, 2010) |
| " Significant decrease of myo-inositol in adults is probably due to cellular osmoregulation secondary to long-standing hyperammonemia." | 3.76 | Brain MR imaging and 1H-MR spectroscopy changes in patients with extrahepatic portal vein obstruction from early childhood to adulthood. ( Gupta, RK; Rathore, RK; Saksena, S; Saraswat, VA; Srivastava, A; Thomas, MA; Yadav, SK, 2010) |
| " plantarum strains were administered in ornithine transcarbamoylase-deficient Sparse-fur mice, a model of constitutive hyperammonemia, in a carbon tetrachloride rat model of chronic liver insufficiency and in a thioacetamide-induced acute liver failure mice model." | 3.74 | Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents. ( Demetter, P; Devière, J; Goffin, P; Gustot, T; Hols, P; Moreno, C; Nicaise, C; Prozzi, D; Quertinmont, E; Suain, V; Viaene, E, 2008) |
| "An infant with a suspected inborn metabolism error was treated with a metabolic cocktail of intravenous sodium phenylacetate (NaPh) and sodium benzoate (NaBz) for hyperammonemia." | 3.74 | Phenylacetate and benzoate clearance in a hyperammonemic infant on sequential hemodialysis and hemofiltration. ( Barletta, GM; Bunchman, TE; Crumb, TL; Gardner, JJ; McBryde, KD; Winters, JW, 2007) |
| "Adult-onset type II citrullinemia is an inborn error of urea cycle metabolism that can lead to hyperammonemic encephalopathy and coma." | 3.74 | Magnetic resonance spectroscopy in adult-onset citrullinemia: elevated glutamine levels in comatose patients. ( Au, WL; Lim, CC; Wong, YC; Xu, M; Ye, J, 2007) |
| "Sodium thiopental in the comatogenic (but not soporogenic) dose caused hyperammoniemia in rats." | 3.74 | Hyperammoniemia in rats with barbiturate coma. ( Ivnitskii, YY; Malakhovskii, VN; Ovsep'yan, RV; Reinyuk, VL; Shefer, TV, 2007) |
| " The resistance of rats to the lethal effect of barbiturate tended to decrease under conditions of experimental hyperammonemia induced by intraperitoneal injection of ammonium acetate in a nonlethal dose (6 mmol/kg)." | 3.74 | Effect of atmospheric ammonia on mortality rate of rats with barbiturate intoxication. ( Ivnitsky, JJ; Ovsep'yan, RV; Rejniuk, VL; Schafer, TV, 2007) |
| "To investigate the incidences of urea cycle defects (UCDs) in the patients with hyperammonemia and study their etiology, clinical and laboratory features." | 3.73 | [Clinical and laboratory screening studies on urea cycle defects]. ( Bao, XH; Chang, XZ; Li, L; Li, M; Qi, Y; Qian, N; Qin, J; Song, JQ; Sun, F; Wang, S; Wang, SQ; Wu, XR; Yang, HY; Yang, YL; Zhang, YH, 2005) |
| "Fulminant hyperammonaemia as a threshold effect of coma-inducing dose of sodium thiopental has been revealed in rats." | 3.73 | Fulminant hyperammonaemia induced by thiopental coma in rats. ( Ivnitsky, JJ; Malakhovsky, VN; Rejniuk, VL; Schäfer, TV, 2006) |
| " ALF pigs developed hyperammonemia and increased glutamine levels, whereas glutamate levels were decreased." | 3.73 | Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure. ( Davies, NA; Deutz, NE; Hodges, S; Jalan, R; Nedredal, GI; Revhaug, A; Romero-Gomez, M; Rose, C; Sen, S; Ten Have, GA; Williams, R; Ytrebø, LM, 2006) |
| "To describe a case of oral valproic acid-induced hyperammonemia and thrombocytopenia in an elderly patient." | 3.72 | Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman. ( Babin, S; Mallet, L; Morais, JA, 2004) |
| "We compared the effect of hyperammonemia on NADH levels in brain slices and on the rate of oxygen consumption from isolated nonsynaptic brain mitochondria in ammonia-sensitive Wistar rats with that in ammonia-tolerant gulf toadfish (Opsanus beta)." | 3.71 | Comparison of the effects of ammonia on brain mitochondrial function in rats and gulf toadfish. ( Pérez-Pinzón, MA; Veauvy, CM; Walsh, PJ; Wang, Y, 2002) |
| "Juvenile visceral steatosis (JVS) mouse is an animal model of human primary carnitine deficiency caused by a mutation of the gene encoding carnitine transporter, and suffers from various symptoms, such as fatty liver, growth retardation, hyperammonemia, hypoglycemia, and cardiac hypertrophy." | 3.71 | Hyperammonemia in carnitine-deficient adult JVS mice used by starvation. ( Horiuchi, M; Jalil, A; Kobayashi, K; Li, XX; Saheki, T; Yoshida, G, 2002) |
| "The objective of this study was to evaluate a new method for the treatment of acute hyperammonemia with a helium-oxygen mixture (heliox)." | 3.71 | Heliox use in the treatment of acute hyperammonemia. ( Barr, J; Chen-Levy, Z; Eshel, G; Lahat, E, 2001) |
| "Serum or CSF glutamine levels are initially elevated in a majority of patients with suspected VHE, sometimes in the absence of hyperammonemia." | 3.71 | Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. ( Cawthon, DF; Caylor, LM; Kraemer, DL; Morgan, JD; Ojemann, LM; Vossler, DG; Wilensky, AJ, 2002) |
| "Hyperammonemia is a life-threatening condition mainly due to the neurotoxicity of ammonia." | 3.01 | Expanding the Spectrum of Extracorporeal Strategies in Small Infants with Hyperammonemia. ( Ceschia, G; Longo, G; Parolin, M; Ronco, C; Vidal, E, 2023) |
| "An effective and rapid treatment of hyperammonemia is crucial to prevent irreversible neurological damage and it depends on the understanding of the pathophysiology of the diseases, as well as of the available therapeutic approaches." | 2.82 | Hyperammonemia in Inherited Metabolic Diseases. ( Deon, M; Lopes, FF; Ribas, GS; Vargas, CR, 2022) |
| "Pregnancy is an important risk factor for women with CTLN1." | 2.82 | Hyperammonemia in a pregnant woman with citrullinemia type I: a case report and literature review. ( Ding, Y; Dou, X; He, R; Zhang, C; Zhou, Y, 2022) |
| "Isovaleric aciduria (IVA), propionic aciduria (PA) and methylmalonic aciduria (MMA) are inherited organic acidurias (OAs) in which impaired organic acid metabolism induces hyperammonaemia arising partly from secondary deficiency of N-acetylglutamate (NAG) synthase." | 2.82 | Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study. ( Baruteau, J; Cano, A; Chakrapani, A; Coker, M; Couce, ML; Del Toro, M; Delgado, MB; Donati, MA; Garcia-Cazorla, A; Gil-Ortega, D; Gomez-de Quero, P; Guffon, N; Hofstede, FC; Kalkan-Ucar, S; Lama-More, R; Le Mouhaer, J; Martinez-Pardo Casanova, M; Molina, A; Papadia, F; Pichard, S; Plisson, C; Rosello, P; Valayannopoulos, V, 2016) |
| "Hyperammonemia is a feature of liver failure, which is associated with increased risk of infection." | 2.73 | Ammonia impairs neutrophil phagocytic function in liver disease. ( Davies, NA; Hodges, SJ; Jalan, R; Pitsillides, AA; Shawcross, DL; Stadlbauer, V; Wheeler-Jones, C; Wright, GA, 2008) |
| "Minimal hepatic encephalopathy (MHE) is common in cirrhosis but its pathophysiologic basis remains undefined." | 2.73 | Role of ammonia and inflammation in minimal hepatic encephalopathy. ( Jalan, R; Olde Damink, SW; Shawcross, DL; Wright, G, 2007) |
| "Hyperammonemia is a life-threatening condition." | 2.72 | Extracorporeal Ammonia Clearance for Hyperammonemia in Critically Ill Patients: A Scoping Review. ( Baldwin, I; Bellomo, R; Eastwood, GM; Naorungroj, T; Yanase, F, 2021) |
| "Hyperammonemia is a universal finding after gastrointestinal hemorrhage in cirrhosis." | 2.71 | Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis. ( Balata, S; Deutz, NE; Ferguson, K; Hayes, PC; Jalan, R; Marshall, I; Olde Damink, SW; Wardlaw, J; Williams, R, 2003) |
| "VPA is widely used for the treatment of generalized epilepsy." | 2.61 | [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. ( Araki, M; Mukai, T; Naka, H; Shishido, T; Tokinobu, H; Yamada, H, 2019) |
| "Sarcopenia is a common complication of cirrhosis with a negative impact on posttransplant outcome, health-related quality of life (HRQOL), and patient survival." | 2.61 | L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle. ( Butterworth, RF, 2019) |
| "The current treatments for hyperammonemia, such as antibiotics or lactulose, are designed to decrease the intestinal production of ammonia and/or its absorption into the body and are not effective, besides being often accompanied by side effects." | 2.58 | The Pharmabiotic Approach to Treat Hyperammonemia. ( Chung, HJ; Hong, ST; Kim, HJ; Liu, J; Lkhagva, E, 2018) |
| "The urea cycle disorders are a group of inherited biochemical diseases caused by a complete or partial deficiency of any one of the enzymes or transport proteins required to convert toxic ammonia into urea and to produce arginine and citrulline." | 2.58 | Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders. ( Mew, NA; Summar, ML, 2018) |
| "Hyperammonemia is an important cause of cerebral edema in both adults with liver failure and children with inborn errors of metabolism." | 2.53 | The Role of RRT in Hyperammonemic Patients. ( Fenves, AZ; Gupta, S; Hootkins, R, 2016) |
| "Search terms included hepatic encephalopathy, ammonia hypothesis, brain and ammonia, liver failure and ammonia, acute-on-chronic liver failure and ammonia, cirrhosis and ammonia, portosytemic shunt, ammonia and lactulose, rifaximin, zinc, and nutrition." | 2.52 | Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. ( Jiang, ZG; Patwardhan, VR; Tapper, EB, 2015) |
| "Recent advances in treating hyperammonemia include using synergistic combination treatments, broadening the indication of orphan drugs, and developing novel approaches to regenerate functional liver tissue." | 2.52 | Recent advances in the treatment of hyperammonemia. ( Leroux, JC; Matoori, S, 2015) |
| "Hyperammonemia is necessary for development of the cerebral complications to liver disease including hepatic encephalopathy and cerebral edema but the mechanisms are unclear." | 2.50 | Cerebral effects of ammonia in liver disease: current hypotheses. ( Ott, P; Vilstrup, H, 2014) |
| "Most treatments of hyperammonemia target the organs and metabolic processes involved in ammonia detoxification." | 2.50 | Pharmacotherapy for hyperammonemia. ( Hadjihambi, A; Jalan, R; Khetan, V, 2014) |
| "Hyperammonemia in end-stage acute liver failure (ALF) is often associated with cerebral edema and astrocyte pathology/swelling." | 2.49 | Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase. ( Cooper, AJ, 2013) |
| "In patients with acute liver failure cerebral microdialysis studies show a linear correlation between the lactate to pyruvate ratio and the glutamine concentration, as well as to some of the adenosine triphosphate degradation products." | 2.49 | Changes in cerebral oxidative metabolism in patients with acute liver failure. ( Bjerring, PN; Larsen, FS, 2013) |
| " We, therefore, speculate that the beneficial effect of long term intake of BCAA on HE demonstrated in clinical studies may be related to an improved muscle mass and nutritional status rather than to an ammonia lowering effect of BCAA themselves." | 2.49 | Branched-chain amino acids and muscle ammonia detoxification in cirrhosis. ( Aagaard, NK; Dam, G; Ott, P; Vilstrup, H, 2013) |
| "Any delay in recognition and start of treatment of hyperammonemia may have deleterious consequences for the patient." | 2.47 | Clinical practice: the management of hyperammonemia. ( Häberle, J, 2011) |
| "Systemic hyperammonemia has been largely found in patients with cirrhosis and hepatic encephalopathy, and ammonia plays a major role in the pathogenesis of hepatic encephalopathy." | 2.45 | Gut ammonia production and its modulation. ( Galán, JJ; Jover, M; Romero-Gómez, M; Ruiz, A, 2009) |
| "Gene therapy for OTC deficiency is effective in animals, and work is ongoing to improve persistence and safety." | 2.45 | Ammonia toxicity and its prevention in inherited defects of the urea cycle. ( Walker, V, 2009) |
| " Some neuroprotective strategies such as the potential use of NMDA receptor antagonists, nitric oxide inhibitors, creatine and acetyl-l-carnitine have been suggested to counteract these toxic effects." | 2.44 | Hyperammonemia-induced toxicity for the developing central nervous system. ( Braissant, O; Cagnon, L, 2007) |
| "When hyperammonemia is not thought to be the result of liver failure, treatment for an occult disorder of metabolism must begin prior to the confirmation of an etiology." | 2.44 | Hyperammonemia in the ICU. ( Clay, AS; Hainline, BE, 2007) |
| "Hyperammonemic disorders such as acute liver failure (ALF) or urea cycle enzymopathies are associated with hyperexcitability, seizures, brain edema and increased extracellular brain glutamate." | 2.43 | Effect of ammonia on astrocytic glutamate uptake/release mechanisms. ( Rose, C, 2006) |
| "Hepatic encephalopathy has been linked to H." | 2.42 | Helicobacter pylori and hepatic encephalopathy. ( Chawla, YK; Dhiman, RK; Duseja, A; Sachdev, A, 2003) |
| "Symptoms of hyperammonemia are age-dependent and some are reversible." | 2.42 | Ammonia toxicity to the brain and creatine. ( Bachmann, C; Boulat, O; Braissant, O; Henry, H; Villard, AM, 2004) |
| "Hyperammonemia is mainly found in hepatic encephalopathy and in genetic defects of the urea cycle or other pathways of the intermediary metabolism." | 2.41 | Mechanisms of hyperammonemia. ( Bachmann, C, 2002) |
| "Valproic acid (VPA) is a short-chain fatty acid widely prescribed in the treatment of seizure disorders and epilepsy syndromes, although its therapeutic value may be undermined by its toxicity." | 1.91 | Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. ( Fagiolino, P; Ibarra, M; Maldonado, C; Schiavo, A; Trocóniz, IF; Vázquez, M, 2023) |
| "Ornithine transcarbamylase deficiency is an X-linked disorder which results in the accumulation of ammonia causing irritability and vomiting." | 1.91 | Acute onset of ornithine transcarbamylase deficiency after total anomalous pulmonary venous connection repair to a 2-day-old neonate. ( Fuchigami, T; Iwata, Y; Katagiri, J; Yoshida, H, 2023) |
| "Neonatal hyperammonemia is a disorder of ammonia metabolism that occurs in the neonatal period." | 1.91 | [Expert consensus on the diagnosis and treatment of neonatal hyperammonemia]. ( , 2023) |
| "This can cause neurotoxicity, cerebral edema, and seizures." | 1.91 | Treatment of hyperammonemia using in-line renal replacement and hyperosmolar therapies within an extracorporeal membrane oxygenation circuit. ( Grazioli, A; Iacono, A; Krupnik, AS; Madathil, RJ; Podell, JE; Shah, SR, 2023) |
| "But although the drugs developed to treat hyperammonemia resulting from urea cycle disorders were successfully developed and approved by the FDA, the compound suggested as a treatment for hepatic encephalopathy was unable to attract sufficient interest and investment to be tested for use in humans." | 1.72 | Saul Brusilow: Understanding and treating diseases of ammonia toxicity. ( Brusilow, WSA, 2022) |
| "Acute liver failure was present in 4 (25%) and acute-on-chronic liver failure in 8 (75%)." | 1.72 | Ammonia Clearance with Different Continuous Renal Replacement Therapy Techniques in Patients with Liver Failure. ( Baldwin, I; Bellomo, R; Fealy, N; Fisher, C; Naorungroj, T, 2022) |
| "Propionic acidemia is an inborn error of metabolism caused by a deficiency in the mitochondrial enzyme propionyl-CoA carboxylase that converts the propionyl CoA to methyl malonyl CoA." | 1.72 | Interorgan amino acid interchange in propionic acidemia: the missing key to understanding its physiopathology. ( Arrieta, F; Belanger-Quintana, A; Del Valle, M; Fernandez-Felix, BM; Garcia, F; Martinez-Pardo, M; Ruiz-Sala, P; Stanescu, S, 2022) |
| "Patients who developed encephalopathy had higher median ammonia levels, but there was no association between the severity of hyperammonemia and liver tumor burden or presence of liver insufficiency." | 1.72 | Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases. ( Brabander, T; Charehbili, A; de Herder, WW; den Hoed, CM; Feelders, RA; Hofland, J; Langendonk, J; Refardt, J; Zandee, WT, 2022) |
| "Hyperammonemia is known to cause various neurological dysfunctions such as seizures and cognitive impairment." | 1.72 | Ammonia induces amyloidogenesis in astrocytes by promoting amyloid precursor protein translocation into the endoplasmic reticulum. ( Harada, F; Iida, I; Ito, G; Kishikawa, S; Komatsu, A; Maeda, T; Moss, SJ; Nasu, Y; Terunuma, M, 2022) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 1.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| "The most prevalent UCD detected were ornithine transcarbamylase deficiency, followed by citrullinemia type 1, hyperargininemia, carbamoyl phosphate synthase 1 deficiency, and argininosuccinic aciduria." | 1.72 | Clinical findings of patients with hyperammonemia affected by urea cycle disorders with hepatic encephalopathy. ( de Moura Coelho, D; Dos Reis, BG; Faverzani, JL; Lopes, FF; Ribas, GS; Sitta, A; Vargas, CR; Wajner, M, 2022) |
| "The prednisolone was stopped 5 days before hospital admission." | 1.72 | Late-Onset Ornithine Transcarbamylase Deficiency Complicated with Extremely High Serum Ammonia Level: Prompt Induction of Hemodialysis as the Key to Successful Treatment. ( Kakiuchi, T; Kurogi, K; Nishi, TM; Tago, M; Yamamoto, S; Yamashita, S; Yamashita, SI, 2022) |
| "Hyperammonemia from Ureaplasma parvum septic arthritis has never been reported previously." | 1.72 | Hyperammonemia in a septic patient with Ureaplasma parvum arthritis: a case report. ( Huang, X; Mao, M; Pan, L; Pan, X; Qiu, J; Wang, C; Xu, J; Yan, C, 2022) |
| "Leukoencephalopathy was resolved following the administration of L-arginine and lactulose with a decrease in plasma ammonia levels and glutamine-glutamate peak on magnetic resonance spectroscopy." | 1.72 | Reversible Leukoencephalopathy in a Man with Childhood-onset Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome. ( Fukuyama, T; Hoshino, Y; Kaneko, T; Kodaira, M; Matsuno, A; Sekijima, Y; Takano, K; Yazaki, M, 2022) |
| "Hyperammonemia is a deleterious and inevitable consequence of liver failure." | 1.62 | Treatment of Hyperammonemia by Transplanting a Symbiotic Pair of Intestinal Microbes. ( Heo, HJ; Hong, ST; Kim, HJ; Kim, S; Lee, S; Liu, J; Rho, JR; Zhai, C, 2021) |
| " Glycerol phenylbutyrate (GPB) is safe and effective in reducing ammonia levels in patients with UCD above 2 months of age." | 1.62 | Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders. ( Ah Mew, N; Bannick, AA; Berry, SA; Canavan, C; Conway, RL; Diaz, GA; Hainline, B; Inbar-Feigenberg, M; Kok, T; Lichter-Konecki, U; Longo, N; McCandless, SE; Porter, MH; Schulze, A; Vescio, T; Zori, R, 2021) |
| "Hyperammonemia is one of the contributing factors of hepatic encephalopathy (HE)." | 1.56 | Comparative accuracy and precision of two commercial laboratory analyzers for the quantification of ammonia in cerebrospinal fluid. ( Bhatti, SFM; de Rooster, H; Devriendt, N; Meyer, E; Or, M; Paepe, D; Vallarino, N, 2020) |
| "Six of the 8 patients with cerebral edema had hyperammonemia related to ACLF, giving an incidence of 14% in this subset of patients." | 1.56 | Characteristics and outcomes of critically ill patients with severe hyperammonemia. ( Jacoby, KJ; Leatherman, JW; Prekker, ME; Singh, P, 2020) |
| "Hyperammonemia is a key contributing factor for cerebral edema in acute liver failure." | 1.56 | Correction and Control of Hyperammonemia in Acute Liver Failure: The Impact of Continuous Renal Replacement Timing, Intensity, and Duration. ( Bellomo, R; Fisher, C; Warrillow, S, 2020) |
| "Hepatic involvement in hereditary hemorrhagic telangiectasia (HHT) is common and can be associated with severe clinical consequences, including portal hypertension, cardiac failure, and encephalopathy." | 1.56 | Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. ( Al-Samkari, H; Bloom, PP; Kuter, DJ; Luther, J; Mojtahed, A; Rodriguez-Lopez, J; Witkin, AS, 2020) |
| "5-FU-induced hyperammonaemic encephalopathy started 2 [1-4] days after 5-FU infusion onset." | 1.56 | 5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey. ( Boige, V; Boilève, A; Chouchana, L; Ducreux, M; Gaboriau, L; Hillaire-Buys, D; Hollebecque, A; Jozwiak, M; Lillo-Le Louët, A; Malka, D; Thomas, L, 2020) |
| "Urea cycle disorders are congenital metabolism errors that affect ammonia elimination." | 1.56 | Perioperative management of children with urea cycle disorders. ( Del Río, C; Martín-Hernández, E; Quijada-Fraile, P; Rubio, P; Ruiz, A, 2020) |
| "Hyperammonemia was diagnosed in all cases during the evaluation of altered mental status, with 22% presenting with seizures." | 1.56 | A retrospective study of adult patients with noncirrhotic hyperammonemia. ( Baker, JJ; Barkoudah, E; Berry, GT; Khoury, CC; Krier, JB; Lin, AP; Mogensen, KM; Peake, RW; Sahai, I; Stergachis, AB; Sweetser, DA, 2020) |
| "Conclusion Rifaximin administration for hepatic encephalopathy improved the CONUT and ALBI scores." | 1.56 | Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy. ( Azumi, M; Endo, S; Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Nozawa, Y; Sano, T; Yoshida, T, 2020) |
| " They were also offered an increased dosage of stiripentol if treatment with carnitine improved the encephalopathy." | 1.56 | Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine. ( Andrade, DM; Marques, P; Sadoway, T; Selvarajah, A; Tabarestani, S; Zulfiqar Ali, Q, 2020) |
| "BACKGROUND Hyperammonemia has been reported in some critically ill patients with sepsis who do not have hepatic failure." | 1.56 | Prognosis of Patients with Sepsis and Non-Hepatic Hyperammonemia: A Cohort Study. ( Gao, Y; Ge, Z; Guo, S; Li, Y; Lu, X; Yu, S; Zhao, L; Zhu, H, 2020) |
| "Hyperammonemia is a common cause of metabolic encephalopathy, mainly related to hepatic cirrhosis." | 1.51 | Malnutrition-related hyperammonemic encephalopathy presenting with burst suppression: a case report. ( Fumeaux, T; Leidi, A; Pisaturo, M, 2019) |
| " One of the biggest problems of these compounds, however, is their very short bioavailability due to instant metabolism and rapid excretion." | 1.51 | Poly(ornithine)-based self-assembling drug for recovery of hyperammonemia and damage in acute liver injury. ( Ibayashi, Y; Lee, Y; Nagasaki, Y; Ngo, DN; Nishikawa, Y; Vong, LB, 2019) |
| "She was diagnosed with ornithine transcarbamylase deficiency (OTCD) by analyses of plasma amino acids, urinary orotic acid, and the OTC gene mutation." | 1.51 | Hyperammonemia in a Woman with Late-onset Ornithine Transcarbamylase Deficiency. ( Harada, M; Hiura, M; Honma, Y; Ishii, M; Koya, Y; Matsumoto, S; Senju, M; Shibata, M, 2019) |
| "Citrullinemia Type 1 (also known as classic citrullinemia) is a rare autosomal recessive urea cycle disorder due to reduced activity of argininosuccinate synthetase 1; characterized by hyperammonemia leading to neurological damage." | 1.51 | Citrullinemia Type 1: Behavioral Improvement with Late Liver Transplantation. ( Bagde, A; Bakshi, R; Janwadkar, A; Mirza, D; Nagral, A; Shirole, N; Vasanth, S; Yewale, V, 2019) |
| "To report a successfully treated hyperammonemia due to a portosystemic shunt in adult patient." | 1.51 | Acute hyperammonemic encephalopathy due to a portosystemic shunt in a non-cirrhotic adult patient. ( Ezquerro-Sáenz, S; Fuster-Cabré, M; Lapetra-Labé, AM; Medrano-Peña, J; Requena-Calleja, MÁ, 2019) |
| " Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication." | 1.48 | Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia. ( Bukofzer, S; Clasen, K; Durkalski, V; Fontana, RJ; Ganger, D; Gottfried, M; Hameed, B; Hanje, AJ; Koch, D; Lee, WM; Little, L; Ravis, WR; Sherker, A; Stravitz, RT; Subramanian, RM, 2018) |
| "Hyperammonemia is a common complication of a wide variety of both inherited and acquired liver diseases." | 1.48 | Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia. ( Allegri, G; Annunziata, P; Ballabio, A; Brunetti-Pierri, N; Häberle, J; Melck, D; Motta, A; Nusco, E; Paris, D; Pastore, N; Polishchuk, E; Soria, LR; Thöny, B, 2018) |
| "All neonates treated for hyperammonemia at a single children's hospital between 1992 and 2016 were identified." | 1.48 | Rapid resolution of hyperammonemia in neonates using extracorporeal membrane oxygenation as a platform to drive hemodialysis. ( Conroy, PC; Grubb, PH; Hamid, R; Hardison, D; Lovvorn, HN; Pietsch, JB; Robinson, JR, 2018) |
| "Hyperammonemia is a common finding in patients with methylmalonic acidemia." | 1.48 | Ammonia role in glial dysfunction in methylmalonic acidemia. ( Arend, J; Barbosa, S; do Nascimento, PS; Dos Santos, ARS; Fighera, MR; Furian, AF; Gabbi, P; Haupental, F; Nogueira, V; Oliveira, MS; Rodrigues, FS; Royes, LFF, 2018) |
| "To characterize seizures and evaluate the utility of continuous EEG recording during hyperammonemia due to inborn errors of metabolism." | 1.48 | The utility of EEG monitoring in neonates with hyperammonemia due to inborn errors of metabolism. ( Gaillard, WD; Gropman, AL; Massaro, A; Prust, M; Tsuchida, TN; Vezina, G; Wiwattanadittakul, N, 2018) |
| "We report five adult patients with frontal lobe epilepsy (FLE) who were treated with VPA and in whom a primary adverse effect was unstable gait and falls." | 1.46 | Gait instability in valproate-treated patients: Call to measure ammonia levels. ( Elger, CE; Kipervasser, S; Korczyn, AD; Nass, RD; Neufeld, MY; Quesada, CM, 2017) |
| "Muscle mass loss and hepatic encephalopathy (complex neuropsychiatric disorder) are serious complications of chronic liver disease (cirrhosis) which impact negatively on clinical outcome and quality of life and increase mortality." | 1.46 | The bile duct ligated rat: A relevant model to study muscle mass loss in cirrhosis. ( Bemeur, C; Bosoi, CR; Deutz, NE; Ochoa-Sanchez, R; Oliveira, MM; Rose, CF; Ten Have, GA; Tremblay, M, 2017) |
| "The pathogenesis of hepatic encephalopathy (HE) in cirrhosis is multifactorial and ammonia is thought to play a key role." | 1.46 | Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease. ( Davies, N; De Chiara, F; Gourine, AV; Habtetion, A; Hadjihambi, A; Hosford, PS; Jalan, R; Karagiannis, A, 2017) |
| "Hyperammonemia is a consistent abnormality in cirrhosis that results in impaired skeletal muscle protein synthesis and breakdown (proteostasis)." | 1.46 | Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. ( Dasarathy, S; Davuluri, G; Deutz, NEP; Engelen, MPKJ; Kumar, A; Prayson, R; Silva, RNE; Ten Have, GAM, 2017) |
| "Hyperammonemia is a rare, often fatal complication after transplantation." | 1.43 | Hyperammonemia Syndrome After Lung Transplantation: A Single Center Experience. ( Bain, KB; Byers, DE; Chen, C; Hachem, RR; Iuppa, JA; Patterson, GA; Trulock, EP; Witt, CA; Yusen, RD, 2016) |
| " Rifaximin, a poorly absorbed antibiotic that targets gut flora, significantly improved symptoms of HE." | 1.43 | Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin. ( Fukui, N; Isobe, M; Okada, M; Saito, T; Suzuki, H; Tamaoki, S, 2016) |
| "Patients were grouped into generalized convulsive seizures (GCS), psychogenic nonepileptic seizures with convulsions (PNES-C), or focal seizures (FS) based on vEEG." | 1.43 | Postictal ammonia as a biomarker for electrographic convulsive seizures: A prospective study. ( Albadareen, R; Gronseth, G; Hammond, N; He, J; Landazuri, P; Uysal, U, 2016) |
| " Both biochemical and morphological studies clearly revealed that chrysin protects against cell injury induced by ammonia intoxication in a dose-response manner with respect to endogenous antioxidants and hypoammonemic effects." | 1.43 | Chrysin, a flavonoid attenuates histological changes of hyperammonemic rats: A dose dependent study. ( Ramakrishnan, A; Renuka, M; Vijayakumar, N, 2016) |
| "Diverse treatments exist for the treatment of hyperammonemia, but they have limited efficacy, adverse effects and elevated cost." | 1.42 | Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia. ( Montiel-Martínez, AG; Muñoz-Fuentes, RM; Palomares, LA; Pastor, AR; Torres-Vega, MA; Vargas-Jerónimo, RY; Zamorano-Carrillo, A, 2015) |
| "Hyperammonemia is less severe in arginase 1 deficiency compared with other urea cycle defects." | 1.42 | Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy. ( Cantero, G; Cantero-Nieto, G; Cederbaum, SD; Chan, E; Hu, C; Lipshutz, GS; Park, H; Tai, DS; Yudkoff, M, 2015) |
| "The cause of hyperammonemia is urinary retention obstruction." | 1.42 | Hyperammonemia in Urinary Tract Infections. ( Fukui, M; Kato, K; Kenzaka, T; Kitao, A; Kosami, K; Minami, K; Okayama, M; Yahata, S, 2015) |
| "A total of 135 patients with liver cirrhosis and HE had serum ammonia levels measured on admission." | 1.40 | Ammonia levels and the severity of hepatic encephalopathy. ( Khokhar, N; Qureshi, MO; Shafqat, F, 2014) |
| "We report a case of reversible hepatic myelopathy." | 1.40 | [Reversible hepatic myelopathy: a case report]. ( Fukada, K; Hazama, T; Hirozawa, D; Hoshi, T; Sawada, J; Yaegaki, T, 2014) |
| "Glycine is an important ammoniagenic amino acid, which is increased in acute liver failure (ALF)." | 1.40 | L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway. ( Fuskevåg, OM; Jalan, R; Kristiansen, RG; Mæhre, H; Revhaug, A; Rose, CF; Ytrebø, LM, 2014) |
| "In adults, hyperammonemia is generally associated with hepatic dysfunction or as a complication of urinary diversions when infected or obstructed." | 1.39 | Simultaneous double hemodialysis for the control of refractory hyperammonemia. ( Brucculeri, M; Gabbard, W; Jooma, N; Masson, J, 2013) |
| "Hyperammonemia is a major etiological toxic factor in the development of hepatic encephalopathy." | 1.39 | Brain alanine formation as an ammonia-scavenging pathway during hyperammonemia: effects of glutamine synthetase inhibition in rats and astrocyte-neuron co-cultures. ( Bak, LK; Dadsetan, S; Keiding, S; Kukolj, E; Ott, P; Schousboe, A; Sørensen, M; Vilstrup, H; Waagepetersen, HS, 2013) |
| "Carglumic acid was well tolerated with no side effects noted." | 1.39 | Use of carglumic acid in the treatment of hyperammonaemia during metabolic decompensation of patients with propionic acidaemia. ( Abacan, M; Boneh, A, 2013) |
| "Hyperammonemia is a metabolic derangement that can be potentially fatal." | 1.39 | A rare case of hyperammonemia complication of high-protein parenteral nutrition. ( Bhat, Z; Cadnapaphorncai, P; Kahlon, R; Pillai, U; Sondheimer, J, 2013) |
| "The BDL rats developed chronic liver failure and exhibited a decreased discrimination index for short term memory (STM) when compared to the control group." | 1.39 | Impairment of short term memory in rats with hepatic encephalopathy due to bile duct ligation. ( Escobar, TD; Forgiarini, LF; Hammes, TO; Keiding, S; Leke, R; Meyer, FS; Oliveira, DL; Schousboe, A; Silveira, TR, 2013) |
| "Specific treatments of hyperammonemia are rarely used in liver failure when compared with urea cycle defect even though use of ammonia scavengers may help to decrease ammonemia." | 1.38 | Threshold for toxicity from hyperammonemia in critically ill children. ( Alvarez, F; Cousineau, J; Ducruet, T; Jouvet, P; Lambert, M; Mitchell, G; Nelson, J; Ozanne, B; Phan, V, 2012) |
| "We analyzed the presence of mild cognitive impairment (CI) by using the PHES battery of psychometric tests and measured the levels of ammonia and of the inflammatory cytokines IL-6 and IL-18 in blood of patients with different types of liver or dermatological diseases resulting in different grades of hyperammonemia and/or inflammation." | 1.38 | Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. ( Cassinello, N; Civera, M; Felipo, V; Garcia-Torres, ML; Jordá, E; Martinez-Valls, J; Molina, I; Montesinos, E; Montoliu, C; Olmo, JA; Ortega, J; Serra, MA; Urios, A; Wassel, A, 2012) |
| "Hyperammonemia was significantly related to patient variables that had a poor outcome (R=0." | 1.38 | Prognostic value of venous blood ammonia in patients with out-of-hospital cardiac arrest. ( Kasai, A; Kikushima, K; Mastsuzaki, M; Matsuzaki, M; Nagao, K; Soga, T; Tachibana, E; Watanabe, K; Yagi, T, 2012) |
| "Patients admitted to the hospital with acute liver failure (ALF) and high arterial levels of ammonia are more likely to have complications and poor outcomes than patients with lower levels of ammonia." | 1.38 | Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure. ( Acharya, SK; Khanal, S; Kumar, R; Panda, SK; Prakash, S; Sharma, H, 2012) |
| "Although hyperammonemia was suspected as the cause of the patient's mental changes, there was no evidence of chronic liver disease." | 1.38 | Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency. ( Choi, DE; Lee, KW; Na, KR; Shin, YT, 2012) |
| "Hyperammonemia is considered to be the main cause of decreased levels of the branched-chain amino acids (BCAA), valine, leucine, and isoleucine, in liver cirrhosis." | 1.37 | Acute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentrations: different sensitivity of red and white muscle. ( Holecek, M; Kandar, R; Kovarik, M; Sispera, L, 2011) |
| "The standard treatment protocol for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in childhood includes intravenous therapy with asparaginase (Asp), which may cause hyperammonemia." | 1.37 | Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. ( Beblo, S; Bierbach, U; Jörck, C; Kiess, W; Mütze, U; Weigel, JF, 2011) |
| " The study consisted of three experiments: The first was a dose-finding study of four different dosing regimens of magnesium sulfate (MgSO4) in healthy rats." | 1.37 | Hypermagnesemia does not prevent intracranial hypertension and aggravates cerebral hyperperfusion in a rat model of acute hyperammonemia. ( Bernal, W; Bjerring, PN; Eefsen, M; Larsen, FS; Wendon, J, 2011) |
| "The aetiology of minimal hepatic encephalopathy (mHE) remains unclear." | 1.37 | Absence of neuropsychological impairment in hyperammonaemia in healthy young adults; possible synergism in development of hepatic encephalopathy (HE) symptoms? ( Castle, PC; Smeeton, NJ; Watt, PW; Wilkinson, DJ, 2011) |
| "Transient hyperammonemia is associated with postictal confusion." | 1.37 | Transient hyperammonemia associated with postictal state in generalized convulsion. ( Lee, CW; Lin, TJ; Liu, KT; Yang, SC; Yeh, IJ, 2011) |
| "The pathophysiology of cerebral edema in ALF is incompletely understood." | 1.37 | Ammonia-induced brain swelling and neurotoxicity in an organotypic slice model. ( Back, A; Bai, T; Brorson, JR; Chiranand, P; Frank, JI; Goldenberg, FD; Tupper, KY, 2011) |
| "Hyperammonemia was detected in 8 patients treated with valproic acid." | 1.36 | Serum biotinidase activity in children treated with valproic acid and carbamazepine. ( Castiñeiras-Ramos, DE; Castro-Gago, M; Díaz-Mayo, I; Eirís-Puñal, J; Gómez-Lado, C, 2010) |
| "Newborns with inborn errors of metabolism often present with hyperammonaemic coma, requiring prompt diagnosis and specific medical therapy, nutritional support and efficient toxin removal." | 1.36 | Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism. ( Arbeiter, AK; Bonzel, KE; Büscher, R; Dohna-Schwake, C; Hanssler, L; Hoyer, PF; Kranz, B; Neudorf, U; Wingen, AM, 2010) |
| "In acute hepatic encephalopathy, MR imaging abnormalities have been described in the PVWM, thalami, and corticospinal tracts." | 1.36 | Acute hepatic encephalopathy: diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome. ( Brace, JR; Lohman, BD; McKinney, AM; Sarikaya, B; Singewald, T; Spanbauer, J; Uhlmann, E, 2010) |
| "To develop a reliable surgical model of acute hepatic failure and hyperammonemia in rats that avoids porto-systemic shunt and bile duct ligation, applicable to hepatic encephalopathy research." | 1.36 | A new experimental model for acute hepatic failure in rats. ( Bellodi-Privato, M; D'Albuquerque, LA; Kubrusly, MS; Leite, KR; Machado, MC; Molan, NT; Teixeira, AR, 2010) |
| "Transient hyperammonemia was observed in the majority of generalized tonic-clonic seizure patients examined in this study but not in those with other causes of consciousness disturbance." | 1.36 | Postictal transient hyperammonemia as an indicator of seizure disorder. ( Lee, CW; Lin, TJ; Liu, KT; Su, CS; Yang, SC; Yeh, IJ, 2010) |
| "Hyperammonemia is encountered frequently in acutely ill children presenting for emergency care with altered levels of consciousness (ALOC)." | 1.36 | Hyperammonemia in the pediatric emergency care setting. ( Dabnon, M; Fouad, HM; Galal, NM; Saied, A, 2010) |
| "Hyperammonemia is a main contributor to brain herniation and mortality in acute liver failure (ALF)." | 1.35 | Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain. ( Agusti, A; Boix, J; Cauli, O; Felipo, V; Piedrafita, B; Rodrigo, R, 2008) |
| "He developed hyperammonaemic coma (ammonia >400 μmol/L; normal <90 μmol/L) on postnatal day 35." | 1.35 | Amino acids in CSF and plasma in hyperammonaemic coma due to arginase1 deficiency. ( Eichinger-Öttl, U; Ertl, C; Haberlandt, E; Häberle, J; Heinz-Erian, P; Karall, D; Rostásy, K; Scholl-Bürgi, S; Sigl, SB, 2008) |
| "Cotreatment with morin prevented the elevation of liver marker enzymes induced by ammonium chloride." | 1.35 | Morin a flavonoid exerts antioxidant potential in chronic hyperammonemic rats: a biochemical and histopathological study. ( Subash, S; Subramanian, P, 2009) |
| "However, the efficacy of CsA to protect cytotoxic brain edema in ALF is problematic because it poorly crosses the blood-brain barrier, which is relatively intact in ALF." | 1.35 | Inhibitors of the mitochondrial permeability transition reduce ammonia-induced cell swelling in cultured astrocytes. ( Norenberg, MD; Rama Rao, KV; Reddy, PV, 2009) |
| "Although hyperammonemia is also known to induce convulsion, biochemical analysis immediately after GC is not useful for diagnosing hyperammonemia-induced convulsion." | 1.35 | Hyperammonemia is associated with generalized convulsion. ( Nishi, K; Sakamoto, T; Yanagawa, Y, 2008) |
| "LPS induced cytotoxic brain swelling and maintained anatomical integrity of the blood-brain barrier." | 1.34 | Endotoxemia produces coma and brain swelling in bile duct ligated rats. ( Brooks, HF; Davies, C; Davies, NA; Harry, D; Hodges, SJ; Jalan, R; Mani, AR; Moore, KP; Shawcross, DL; Stadlbauer, V; Williams, R; Wright, G; Zou, Z; Zwingmann, C, 2007) |
| "Hyperammonemia is responsible for most neurological alterations in patients with hepatic encephalopathy by mechanisms that remain unclear." | 1.33 | Chronic exposure to ammonia induces isoform-selective alterations in the intracellular distribution and NMDA receptor-mediated translocation of protein kinase C in cerebellar neurons in culture. ( Burgal, M; Costa, LG; Felipo, V; Giordano, G; Montoliu, C; Sanchez-Perez, AM, 2005) |
| "Myo-inositol levels were strongly decreased already at 3h after treatment with NH4Cl; other intracellular osmolytes, such as hypotaurine and choline-containing compounds were also decreased, along with a concomitant increase of both the total concentration and the amount of newly synthesized glutamine, alanine, and glutathione." | 1.33 | Ammonia toxicity under hyponatremic conditions in astrocytes: de novo synthesis of amino acids for the osmoregulatory response. ( Leibfritz, D; Zwingmann, C, 2005) |
| "Because hyperammonemia is thought to contribute to the pathogenesis of hepatic encephalopathy, we examined the effects of ammonia on ATP levels, neuronal morphology, and synaptic function in rat hippocampal slices." | 1.33 | Ammonia-mediated LTP inhibition: effects of NMDA receptor antagonists and L-carnitine. ( Funatsu, M; Izumi, M; Izumi, Y; Matsukawa, M; Zorumski, CF, 2005) |
| "Subclinical hepatic encephalopathy (SHE) were detected 55 in 47." | 1.33 | [The effects of Helicobacter pylori infection on hyperammonaemia and hepatic encephalopathy in cirrhotic patients]. ( Cai, JT; Chen, T; Lü, B; Si, JM; Wang, LJ, 2006) |
| "However, hyperammonemia-induced convulsions were inhibited by GABA in a dose-dependent manner." | 1.32 | Inhibition of acute hyperammonemia-induced convulsions by systemically administered gamma aminobutyric acid in rats. ( Paul, V, 2003) |
| "Hyperammonemia was induced by oral administration of an amino-acid (aa) solution mimicking hemoglobin composition." | 1.32 | Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. ( Davies, NA; Jalan, R; Shawcross, DL; Williams, R, 2004) |
| "The diagnosis of hereditary ornithine transcarbamylase deficiency was confirmed by liver biopsy in the immediate post-mortem period." | 1.31 | [Fulminant coma: think hyperammonemia and urea cycle disorders]. ( Augris, C; Benabdelmalek, F; Caramella, JP; Jouvet, P; Vauquelin, P, 2002) |
| "He roused from his coma, breathed spontaneously, and resumed bottle feeding." | 1.31 | Emergency treatment of neonatal hyperammonaemic coma with mild systemic hypothermia. ( Bridges, S; Evans, D; Leaf, A; Whitelaw, A, 2001) |
| "Currently, the diagnosis of ASL deficiency is based on the measurement of urea cycle intermediates and amino acids by automated quantitative ion exchange chromatography in plasma and urine." | 1.31 | Detection of neonatal argininosuccinate lyase deficiency by serum tandem mass spectrometry. ( Bauer, MF; Bieger, I; Gempel, K; Gerbitz, KD; Hofmann, S; Pontz, BF; Stadler, S, 2001) |
| "A partial but significant inhibition of convulsions was found in these animals." | 1.31 | Evidence for an involvement of the ammonia-decreasing action of L-arginine in suppressing picrotoxin-induced convulsions in rats and its additive action with diazepam. ( Jayakumar, AR; Vanaja, P, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (5.35) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 125 (25.72) | 29.6817 |
| 2010's | 226 (46.50) | 24.3611 |
| 2020's | 109 (22.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ribas, GS | 2 |
| Lopes, FF | 2 |
| Deon, M | 1 |
| Vargas, CR | 2 |
| Brusilow, WSA | 1 |
| Mao, X | 1 |
| Chen, H | 1 |
| Lin, AZ | 1 |
| Kim, S | 2 |
| Burczynski, ME | 1 |
| Na, E | 2 |
| Halasz, G | 1 |
| Sleeman, MW | 1 |
| Murphy, AJ | 1 |
| Okamoto, H | 2 |
| Cheng, X | 2 |
| Fisher, C | 2 |
| Baldwin, I | 2 |
| Fealy, N | 1 |
| Naorungroj, T | 2 |
| Bellomo, R | 3 |
| Liu, J | 2 |
| Zhai, C | 1 |
| Rho, JR | 1 |
| Lee, S | 1 |
| Heo, HJ | 1 |
| Kim, HJ | 2 |
| Hong, ST | 3 |
| Stanescu, S | 2 |
| Belanger-Quintana, A | 3 |
| Fernandez-Felix, BM | 1 |
| Ruiz-Sala, P | 1 |
| Del Valle, M | 1 |
| Garcia, F | 1 |
| Arrieta, F | 1 |
| Martinez-Pardo, M | 2 |
| Deutsch-Link, S | 1 |
| Moon, AM | 1 |
| Jiang, Y | 2 |
| Barritt, AS | 1 |
| Tapper, EB | 2 |
| Fleming, D | 1 |
| Cunningham, SA | 3 |
| Patel, R | 4 |
| Refardt, J | 1 |
| den Hoed, CM | 1 |
| Langendonk, J | 1 |
| Zandee, WT | 1 |
| Charehbili, A | 1 |
| Feelders, RA | 1 |
| de Herder, WW | 1 |
| Brabander, T | 1 |
| Hofland, J | 1 |
| Kim, K | 1 |
| Jung, SM | 1 |
| Ames, EG | 1 |
| Powell, C | 1 |
| Engen, RM | 1 |
| Weaver, DJ | 1 |
| Mansuri, A | 1 |
| Rheault, MN | 1 |
| Sanderson, K | 1 |
| Lichter-Konecki, U | 6 |
| Daga, A | 1 |
| Burrage, LC | 1 |
| Ahmad, A | 1 |
| Wenderfer, SE | 1 |
| Luckritz, KE | 1 |
| Starr, MC | 1 |
| Cater, DT | 1 |
| Wilson, AC | 1 |
| Wallace, S | 1 |
| Bennett, WE | 1 |
| Hains, DS | 1 |
| Komatsu, A | 1 |
| Iida, I | 1 |
| Nasu, Y | 1 |
| Ito, G | 1 |
| Harada, F | 1 |
| Kishikawa, S | 1 |
| Moss, SJ | 1 |
| Maeda, T | 1 |
| Terunuma, M | 1 |
| Fakharbad, MJ | 1 |
| Moshiri, M | 1 |
| Ommati, MM | 2 |
| Talebi, M | 1 |
| Etemad, L | 1 |
| Sørensen, M | 6 |
| Walls, AB | 1 |
| Dam, G | 3 |
| Bak, LK | 5 |
| Andersen, JV | 1 |
| Ott, P | 10 |
| Vilstrup, H | 12 |
| Schousboe, A | 7 |
| Macedo de Oliveira, M | 1 |
| Monnet-Aimard, A | 1 |
| Bosoi, CR | 6 |
| Tremblay, M | 7 |
| Rose, CF | 11 |
| Chen, Y | 3 |
| Chen, J | 1 |
| Zhuang, X | 1 |
| Chen, X | 1 |
| Zeng, J | 1 |
| Wang, R | 2 |
| Miao, J | 1 |
| Zhang, M | 2 |
| Fan, Y | 1 |
| Jiang, H | 1 |
| Shao, J | 1 |
| Li, M | 4 |
| Arrieta Blanco, F | 1 |
| Barrio-Carreras, D | 1 |
| Bergua Martínez, A | 1 |
| Cañedo Villarroya, E | 1 |
| García-Silva, MT | 1 |
| Lama More, R | 1 |
| Martín-Hernández, E | 2 |
| López, AM | 1 |
| Morales-Conejo, M | 1 |
| Pedrón-Giner, C | 1 |
| Quijada-Fraile, P | 2 |
| Casanova, MM | 1 |
| Fukui, K | 1 |
| Takahashi, T | 3 |
| Matsunari, H | 1 |
| Uchikura, A | 1 |
| Watanabe, M | 1 |
| Nagashima, H | 1 |
| Ishihara, N | 1 |
| Kakuma, T | 1 |
| Watanabe, Y | 2 |
| Yamashita, Y | 1 |
| Yoshino, M | 1 |
| Nakamura, H | 1 |
| Takada, K | 1 |
| Murase, K | 1 |
| Ikeda, H | 1 |
| Iyama, S | 1 |
| Manabe, T | 1 |
| Kobune, M | 1 |
| Tranah, TH | 1 |
| Ballester, MP | 1 |
| Carbonell-Asins, JA | 1 |
| Ampuero, J | 1 |
| Alexandrino, G | 1 |
| Caracostea, A | 1 |
| Sánchez-Torrijos, Y | 1 |
| Thomsen, KL | 3 |
| Kerbert, AJC | 1 |
| Capilla-Lozano, M | 1 |
| Romero-Gómez, M | 3 |
| Escudero-García, D | 1 |
| Montoliu, C | 4 |
| Jalan, R | 19 |
| Shawcross, DL | 7 |
| Vakrinou, A | 1 |
| Murphy, E | 2 |
| Sisodiya, SM | 1 |
| Vivekananda, U | 1 |
| Balestrini, S | 1 |
| Szczygieł-Pilut, EE | 1 |
| Zajączkowska-Dutkiewicz, A | 1 |
| Pilut, D | 1 |
| Dutkiewicz, J | 1 |
| Buddington, RK | 1 |
| Buddington, KK | 1 |
| Howard, SC | 1 |
| Soria, LR | 5 |
| Makris, G | 1 |
| D'Alessio, AM | 1 |
| De Angelis, A | 2 |
| Boffa, I | 1 |
| Pravata, VM | 1 |
| Rüfenacht, V | 1 |
| Attanasio, S | 2 |
| Nusco, E | 2 |
| Arena, P | 1 |
| Ferenbach, AT | 1 |
| Paris, D | 2 |
| Cuomo, P | 1 |
| Motta, A | 2 |
| Nitzahn, M | 3 |
| Lipshutz, GS | 6 |
| Martínez-Pizarro, A | 1 |
| Richard, E | 1 |
| Desviat, LR | 1 |
| Häberle, J | 16 |
| van Aalten, DMF | 1 |
| Brunetti-Pierri, N | 7 |
| Sitta, A | 2 |
| de Moura Coelho, D | 1 |
| Faverzani, JL | 1 |
| Dos Reis, BG | 1 |
| Wajner, M | 2 |
| Kann, AE | 1 |
| Ba-Ali, S | 1 |
| Seidelin, JB | 1 |
| Larsen, FS | 6 |
| Hamann, S | 1 |
| Bjerring, PN | 4 |
| Claeys, W | 1 |
| Van Hoecke, L | 1 |
| Geerts, A | 1 |
| Van Vlierberghe, H | 1 |
| Lefere, S | 1 |
| Van Imschoot, G | 1 |
| Van Wonterghem, E | 1 |
| Ghesquière, B | 1 |
| Vandenbroucke, RE | 1 |
| Van Steenkiste, C | 1 |
| Mikkelsen, ACD | 2 |
| Aagaard, NK | 4 |
| Granados-Fuentes, D | 1 |
| Cho, K | 1 |
| Patti, GJ | 1 |
| Costa, R | 1 |
| Herzog, ED | 1 |
| Montagnese, S | 2 |
| Yamamoto, S | 2 |
| Yamashita, S | 1 |
| Kakiuchi, T | 1 |
| Kurogi, K | 1 |
| Nishi, TM | 1 |
| Tago, M | 1 |
| Yamashita, SI | 1 |
| Kim, J | 5 |
| Cho, YS | 3 |
| Chun, BJ | 3 |
| Moon, JM | 3 |
| Kim, DK | 3 |
| Lee, BK | 3 |
| Lee, DH | 4 |
| Ryu, SJ | 3 |
| Jung, E | 3 |
| Hosseini, H | 3 |
| Shafie, M | 3 |
| Shakiba, A | 3 |
| Ghayyem, H | 3 |
| Mayeli, M | 3 |
| Hassani, M | 3 |
| Aghamollaii, V | 3 |
| Zhou, Y | 4 |
| Dou, X | 1 |
| Zhang, C | 1 |
| He, R | 1 |
| Ding, Y | 2 |
| Pan, X | 1 |
| Xu, J | 1 |
| Pan, L | 1 |
| Wang, C | 1 |
| Qiu, J | 1 |
| Huang, X | 1 |
| Yan, C | 1 |
| Mao, M | 1 |
| Aitkenhead, H | 1 |
| Nasr, M | 1 |
| Ahmed-Farid, OAH | 1 |
| Ahmed, RF | 1 |
| Schiavo, A | 1 |
| Maldonado, C | 2 |
| Vázquez, M | 2 |
| Fagiolino, P | 2 |
| Trocóniz, IF | 1 |
| Ibarra, M | 2 |
| Lu, K | 1 |
| Redant, S | 2 |
| Warrillow, S | 2 |
| Honoré, PM | 2 |
| Yoshida, H | 2 |
| Iwata, Y | 1 |
| Fuchigami, T | 1 |
| Katagiri, J | 1 |
| Cheon, SY | 1 |
| Kim, MY | 1 |
| Kim, EJ | 1 |
| Kam, EH | 1 |
| Cho, I | 1 |
| Koo, BN | 1 |
| Kim, SY | 1 |
| Eriksen, PL | 1 |
| Djernes, L | 1 |
| Rabbany, JM | 1 |
| Fitzgerald, K | 1 |
| Bowman, J | 1 |
| Dong, F | 1 |
| Neeki, MM | 1 |
| Choi, J | 1 |
| Kim, JH | 1 |
| Shakerdi, L | 1 |
| Ryan, A | 1 |
| Zhu, R | 1 |
| Liu, L | 2 |
| Zhang, G | 2 |
| Dong, J | 1 |
| Ren, Z | 1 |
| Li, Z | 1 |
| Lee, A | 1 |
| Eldem, I | 1 |
| Altintas, B | 1 |
| Nguyen, H | 1 |
| Willis, D | 1 |
| Langley, R | 1 |
| Shinawi, M | 1 |
| Koda, Y | 1 |
| Shashni, B | 1 |
| Takeda, N | 1 |
| Zhang, X | 1 |
| Tanaka, N | 1 |
| Nishikawa, Y | 4 |
| Nagasaki, Y | 2 |
| Sanz, JH | 1 |
| McCarter, R | 1 |
| Abdelmohcine, A | 1 |
| Amine, SE | 1 |
| Warda, K | 1 |
| Baz, SE | 1 |
| Khanouchi, M | 1 |
| El-Mansoury, B | 1 |
| Agnaou, M | 1 |
| Smimih, K | 1 |
| Zouhairi, N | 1 |
| Chatoui, H | 1 |
| Draoui, A | 1 |
| Saad, F | 1 |
| Ahmed, EM | 1 |
| Ferssiwi, A | 1 |
| Bitar, A | 1 |
| Jayakumar, AR | 4 |
| Fdil, N | 1 |
| Hiba, OE | 1 |
| Liu, XF | 1 |
| Lu, JJ | 1 |
| Li, Y | 3 |
| Yang, XY | 1 |
| Qiang, JW | 1 |
| Kwack, DW | 1 |
| Kim, DW | 1 |
| Ceschia, G | 1 |
| Parolin, M | 1 |
| Longo, G | 1 |
| Ronco, C | 1 |
| Vidal, E | 1 |
| Gallin, M | 1 |
| Damaj, L | 1 |
| Gandemer, V | 1 |
| Bendavid, C | 1 |
| Moreau, C | 1 |
| Kumar, A | 3 |
| Bellar, A | 1 |
| Mishra, S | 1 |
| Sekar, J | 1 |
| Welch, N | 2 |
| Dasarathy, S | 5 |
| Leidi, A | 1 |
| Pisaturo, M | 1 |
| Fumeaux, T | 1 |
| Vong, LB | 1 |
| Ibayashi, Y | 1 |
| Lee, Y | 2 |
| Ngo, DN | 1 |
| Truong, B | 2 |
| Allegri, G | 3 |
| Liu, XB | 1 |
| Burke, KE | 1 |
| Zhu, X | 3 |
| Cederbaum, SD | 3 |
| Martini, PGV | 1 |
| Senzolo, M | 1 |
| Zarantonello, L | 1 |
| Formentin, C | 1 |
| Orlando, C | 1 |
| Beltrame, R | 1 |
| Vuerich, A | 1 |
| Angeli, P | 1 |
| Burra, P | 1 |
| Arora, S | 1 |
| Srivastava, MVP | 1 |
| Singh, MB | 1 |
| Goyal, V | 1 |
| Gupta, N | 1 |
| Prabhakar, A | 1 |
| Aggarwal, B | 1 |
| Agarwal, A | 1 |
| Vishnu, VY | 1 |
| Saunders, JM | 1 |
| González-Maeso, J | 1 |
| Bajaj, JS | 2 |
| Pliego Cosano, R | 1 |
| Moreno Rosauro, JM | 1 |
| Clavero Olmos, M | 1 |
| Devriendt, N | 1 |
| Or, M | 1 |
| Meyer, E | 1 |
| Paepe, D | 1 |
| Vallarino, N | 1 |
| Bhatti, SFM | 1 |
| de Rooster, H | 1 |
| Matoori, S | 4 |
| Bao, Y | 1 |
| Schmidt, A | 1 |
| Fischer, EJ | 1 |
| Ochoa-Sanchez, R | 3 |
| Oliveira, MM | 3 |
| Leroux, JC | 4 |
| Spada, M | 1 |
| Porta, F | 1 |
| Righi, D | 1 |
| Gazzera, C | 1 |
| Tandoi, F | 1 |
| Ferrero, I | 1 |
| Fagioli, F | 1 |
| Sanchez, MBH | 1 |
| Calvo, PL | 1 |
| Biamino, E | 1 |
| Bruno, S | 1 |
| Gunetti, M | 1 |
| Contursi, C | 1 |
| Lauritano, C | 1 |
| Conio, A | 1 |
| Amoroso, A | 1 |
| Salizzoni, M | 1 |
| Silengo, L | 1 |
| Camussi, G | 1 |
| Romagnoli, R | 1 |
| Katayama, K | 1 |
| Cormack, BE | 1 |
| Harding, JE | 1 |
| Crowther, CA | 1 |
| Lynn, A | 1 |
| Nair, A | 1 |
| Hewson, M | 1 |
| Meyer, M | 1 |
| Broadbent, R | 1 |
| Webster, D | 1 |
| Glamuzina, E | 1 |
| Ryder, B | 1 |
| Bloomfield, FH | 1 |
| Jacoby, KJ | 1 |
| Singh, P | 2 |
| Prekker, ME | 1 |
| Leatherman, JW | 1 |
| Bloom, PP | 1 |
| Rodriguez-Lopez, J | 1 |
| Witkin, AS | 1 |
| Al-Samkari, H | 1 |
| Kuter, DJ | 1 |
| Mojtahed, A | 1 |
| Luther, J | 1 |
| Snehavardhan, P | 1 |
| Lal, BB | 1 |
| Sood, V | 1 |
| Khanna, R | 1 |
| Alam, S | 1 |
| Boilève, A | 1 |
| Thomas, L | 1 |
| Lillo-Le Louët, A | 1 |
| Gaboriau, L | 1 |
| Chouchana, L | 1 |
| Ducreux, M | 1 |
| Malka, D | 1 |
| Boige, V | 1 |
| Hollebecque, A | 1 |
| Hillaire-Buys, D | 1 |
| Jozwiak, M | 1 |
| Sepehrinezhad, A | 1 |
| Zarifkar, A | 1 |
| Namvar, G | 1 |
| Shahbazi, A | 1 |
| Williams, R | 6 |
| Brandt, A | 1 |
| Agarwal, N | 1 |
| Giri, D | 1 |
| Yung, Z | 1 |
| Didi, M | 1 |
| Senniappan, S | 1 |
| Del Río, C | 1 |
| Ruiz, A | 2 |
| Rubio, P | 1 |
| Madigan, T | 1 |
| Block, DR | 2 |
| Carey, WA | 1 |
| Kaemingk, BD | 1 |
| Veltman, TR | 1 |
| Tsai, CJ | 1 |
| Gomez-Ospina, N | 1 |
| Kanan, MW | 1 |
| Chu, G | 1 |
| Peng, MZ | 1 |
| Li, XZ | 1 |
| Mei, HF | 1 |
| Sheng, HY | 1 |
| Yin, X | 1 |
| Jiang, MY | 1 |
| Cai, YN | 1 |
| Su, L | 1 |
| Lin, YT | 1 |
| Shao, YX | 1 |
| Miramontes, E | 1 |
| Mozdziak, P | 1 |
| Petitte, JN | 1 |
| Kulus, M | 1 |
| Wieczorkiewicz, M | 1 |
| Kempisty, B | 1 |
| Stergachis, AB | 1 |
| Mogensen, KM | 1 |
| Khoury, CC | 1 |
| Lin, AP | 1 |
| Peake, RW | 1 |
| Baker, JJ | 1 |
| Barkoudah, E | 1 |
| Sahai, I | 1 |
| Sweetser, DA | 1 |
| Berry, GT | 3 |
| Krier, JB | 1 |
| Shah, PA | 1 |
| Cho, J | 1 |
| Albitar, HAH | 1 |
| Pajot, G | 1 |
| Liu, M | 1 |
| Ravi, K | 1 |
| Eid, T | 1 |
| Hassel, B | 1 |
| Danbolt, NC | 1 |
| Forster, V | 2 |
| Agostoni, V | 2 |
| Bettschart-Wolfensberger, R | 1 |
| Bektas, RN | 1 |
| Thöny, B | 3 |
| Kabbaj, M | 2 |
| Drews, L | 1 |
| Zimmermann, M | 1 |
| Westhoff, P | 1 |
| Brilhaus, D | 1 |
| Poss, RE | 1 |
| Bergmann, L | 1 |
| Wiek, C | 1 |
| Brenneisen, P | 1 |
| Piekorz, RP | 1 |
| Mettler-Altmann, T | 1 |
| Weber, APM | 1 |
| Reichert, AS | 1 |
| Marques, PT | 1 |
| Zulfiqar Ali, Q | 2 |
| Selvarajah, A | 2 |
| Faghfoury, H | 1 |
| Wennberg, RA | 1 |
| Andrade, DM | 2 |
| Ozaki, Y | 1 |
| Imamaki, H | 1 |
| Ikeda, A | 1 |
| Oura, M | 1 |
| Nakagawa, S | 2 |
| Funakoshi, T | 2 |
| Kataoka, S | 1 |
| Horimatsu, T | 2 |
| Yonezawa, A | 2 |
| Matsubara, T | 2 |
| Yanagita, M | 2 |
| Muto, M | 2 |
| Watanabe, N | 1 |
| Nilsson, CH | 1 |
| Svensson, MB | 1 |
| Säve, SJ | 1 |
| Van Meervenne, SA | 1 |
| Kenneson, A | 1 |
| Singh, RH | 2 |
| Ishikawa, T | 1 |
| Endo, S | 1 |
| Imai, M | 1 |
| Azumi, M | 1 |
| Nozawa, Y | 1 |
| Sano, T | 1 |
| Iwanaga, A | 1 |
| Honma, T | 1 |
| Yoshida, T | 1 |
| Marques, P | 1 |
| Tabarestani, S | 1 |
| Sadoway, T | 1 |
| Cavino, K | 1 |
| Sung, B | 1 |
| Su, Q | 1 |
| Gromada, J | 1 |
| Yan, T | 1 |
| Li, F | 1 |
| Xiong, W | 1 |
| Wu, B | 1 |
| Xiao, F | 1 |
| He, B | 1 |
| Jia, Y | 1 |
| Yanase, F | 1 |
| Eastwood, GM | 1 |
| Zhao, L | 2 |
| Gao, Y | 1 |
| Guo, S | 1 |
| Lu, X | 1 |
| Yu, S | 1 |
| Ge, Z | 1 |
| Zhu, H | 1 |
| Clément, MA | 1 |
| Bémeur, C | 3 |
| Longo, N | 5 |
| Diaz, GA | 3 |
| Schulze, A | 3 |
| Inbar-Feigenberg, M | 1 |
| Conway, RL | 1 |
| Bannick, AA | 1 |
| McCandless, SE | 3 |
| Zori, R | 2 |
| Hainline, B | 1 |
| Ah Mew, N | 2 |
| Canavan, C | 1 |
| Vescio, T | 1 |
| Kok, T | 1 |
| Porter, MH | 1 |
| Berry, SA | 4 |
| Aamann, L | 2 |
| Jones, H | 1 |
| Mookerjee, RP | 2 |
| Hamilton-Dutoit, S | 1 |
| Frystyk, J | 1 |
| Zhou, Q | 1 |
| Song, JN | 1 |
| Chen, XZ | 1 |
| Zhang, XZ | 1 |
| Sun, Y | 1 |
| Santos, AC | 1 |
| Land, MGP | 1 |
| Lima, EC | 1 |
| Sato, T | 1 |
| Ishii, T | 1 |
| Kato, M | 1 |
| Oyanagi, T | 1 |
| Nakatsuka, S | 1 |
| Kuroda, T | 1 |
| Hasegawa, T | 1 |
| Kido, J | 1 |
| Matsumoto, S | 2 |
| Nakajima, Y | 1 |
| Wada, Y | 1 |
| Mochizuki, N | 1 |
| Murayama, K | 2 |
| Lee, T | 1 |
| Mochizuki, H | 1 |
| Horikawa, R | 1 |
| Kasahara, M | 1 |
| Nakamura, K | 2 |
| Butterworth, RF | 7 |
| Smith, KM | 1 |
| Britton, JW | 1 |
| Hocker, SE | 1 |
| Toledano, M | 1 |
| Marino, RT | 1 |
| Sidlak, AM | 1 |
| Cutler, NS | 1 |
| Sadowski, BW | 1 |
| MacGregor, DA | 1 |
| Solipuram, V | 1 |
| Baretti, M | 1 |
| Kim, AY | 1 |
| Chen, LX | 1 |
| Fahrner, JA | 1 |
| Gunay-Aygun, M | 1 |
| Peng, XP | 1 |
| Hardenbergh, D | 1 |
| Ferguson, A | 1 |
| Griffith, P | 1 |
| Wang, Y | 3 |
| Brancati, M | 1 |
| Gopalakrishna, H | 1 |
| Kato, T | 1 |
| Shubert, C | 1 |
| Laheru, D | 1 |
| Yarchoan, M | 1 |
| Cerrella Cano, C | 1 |
| Junquera Alonso, E | 1 |
| Terroba Alonso, M | 1 |
| Cano Calderero, FX | 1 |
| Seoane Blanco, L | 1 |
| Armesto González, EM | 1 |
| Adamek, M | 1 |
| Teitge, F | 1 |
| Baumann, I | 1 |
| Jung-Schroers, V | 1 |
| El Rahman, SA | 1 |
| Paley, R | 1 |
| Piackova, V | 1 |
| Gela, D | 1 |
| Kocour, M | 1 |
| Rakers, S | 1 |
| Bergmann, SM | 1 |
| Ganter, M | 1 |
| Steinhagen, D | 1 |
| Vinegrad, N | 1 |
| Staretz-Chacham, O | 1 |
| Barski, L | 1 |
| Bartal, C | 1 |
| Grazioli, A | 1 |
| Podell, JE | 1 |
| Iacono, A | 1 |
| Krupnik, AS | 1 |
| Madathil, RJ | 1 |
| Shah, SR | 1 |
| Hoshino, Y | 1 |
| Kodaira, M | 1 |
| Matsuno, A | 1 |
| Kaneko, T | 1 |
| Fukuyama, T | 1 |
| Takano, K | 2 |
| Yazaki, M | 2 |
| Sekijima, Y | 1 |
| Kipervasser, S | 1 |
| Elger, CE | 1 |
| Korczyn, AD | 1 |
| Nass, RD | 1 |
| Quesada, CM | 1 |
| Neufeld, MY | 1 |
| Galland, F | 1 |
| Negri, E | 1 |
| Da Ré, C | 1 |
| Fróes, F | 1 |
| Strapazzon, L | 1 |
| Guerra, MC | 1 |
| Tortorelli, LS | 1 |
| Gonçalves, CA | 1 |
| Leite, MC | 1 |
| Pozdeev, VI | 1 |
| Lang, E | 1 |
| Görg, B | 3 |
| Bidmon, HJ | 3 |
| Shinde, PV | 1 |
| Kircheis, G | 1 |
| Herebian, D | 1 |
| Pfeffer, K | 1 |
| Lang, F | 1 |
| Häussinger, D | 3 |
| Lang, KS | 1 |
| Lang, PA | 1 |
| Díaz-Fontenla, F | 1 |
| Castillo-Pradillo, M | 1 |
| Díaz-Gómez, A | 1 |
| Ibañez-Samaniego, L | 1 |
| Gancedo, P | 1 |
| Guzmán-de-Villoria, JA | 1 |
| Fernández-García, P | 1 |
| Bañares-Cañizares, R | 1 |
| García-Martínez, R | 1 |
| Mendes, NF | 1 |
| Mariotti, FFN | 1 |
| de Andrade, JS | 1 |
| de Barros Viana, M | 1 |
| Céspedes, IC | 1 |
| Nagaoka, MR | 1 |
| Le Sueur-Maluf, L | 1 |
| Meyburg, J | 1 |
| Opladen, T | 1 |
| Spiekerkötter, U | 1 |
| Schlune, A | 1 |
| Schenk, JP | 1 |
| Schmidt, J | 1 |
| Weitz, J | 1 |
| Okun, J | 1 |
| Bürger, F | 1 |
| Omran, TB | 1 |
| Abdoh, G | 1 |
| Al Rifai, H | 1 |
| Monavari, A | 2 |
| Konstantopoulou, V | 1 |
| Kölker, S | 1 |
| Yudkoff, M | 3 |
| Hoffmann, GF | 1 |
| Stravitz, RT | 1 |
| Gottfried, M | 1 |
| Durkalski, V | 1 |
| Fontana, RJ | 1 |
| Hanje, AJ | 1 |
| Koch, D | 1 |
| Hameed, B | 1 |
| Ganger, D | 1 |
| Subramanian, RM | 1 |
| Bukofzer, S | 1 |
| Ravis, WR | 1 |
| Clasen, K | 1 |
| Sherker, A | 1 |
| Little, L | 1 |
| Lee, WM | 1 |
| Ivanovski, I | 1 |
| Ješić, M | 1 |
| Ivanovski, A | 1 |
| Garavelli, L | 1 |
| Ivanovski, P | 1 |
| Weiss, N | 2 |
| Tripon, S | 1 |
| Lodey, M | 1 |
| Guiller, E | 1 |
| Junot, H | 1 |
| Monneret, D | 1 |
| Mayaux, J | 1 |
| Brisson, H | 1 |
| Mallet, M | 2 |
| Rudler, M | 2 |
| Imbert-Bismut, F | 1 |
| Thabut, D | 2 |
| Dabrowska, K | 1 |
| Skowronska, K | 1 |
| Popek, M | 1 |
| Obara-Michlewska, M | 1 |
| Albrecht, J | 6 |
| Zielinska, M | 2 |
| Melck, D | 1 |
| Pastore, N | 1 |
| Annunziata, P | 2 |
| Polishchuk, E | 1 |
| Ballabio, A | 1 |
| Montes-Cortés, DH | 1 |
| Novelo-Del Valle, JL | 1 |
| Olivares-Corichi, IM | 1 |
| Rosas-Barrientos, JV | 1 |
| Jara, LJ | 1 |
| Cruz-Domínguez, MP | 1 |
| Celik, M | 1 |
| Akdeniz, O | 1 |
| Ozgun, N | 1 |
| Lkhagva, E | 1 |
| Chung, HJ | 2 |
| Wilnai, Y | 1 |
| Blumenfeld, YJ | 1 |
| Cusmano, K | 1 |
| Hintz, SR | 1 |
| Alcorn, D | 1 |
| Benitz, WE | 1 |
| Berquist, WE | 1 |
| Bernstein, JA | 1 |
| Castillo, RO | 1 |
| Concepcion, W | 1 |
| Cowan, TM | 1 |
| Cox, KL | 1 |
| Lyell, DJ | 1 |
| Esquivel, CO | 1 |
| Homeyer, M | 1 |
| Hudgins, L | 1 |
| Hurwitz, M | 1 |
| Palma, JP | 1 |
| Schelley, S | 1 |
| Akula, VP | 1 |
| Summar, ML | 2 |
| Enns, GM | 2 |
| Kongsuphon, N | 1 |
| Soukavanitch, M | 1 |
| Teeraaumpornpunt, N | 1 |
| Konmun, J | 1 |
| Ativitavas, T | 1 |
| Ngamphaiboon, N | 1 |
| Robinson, JR | 1 |
| Conroy, PC | 1 |
| Hardison, D | 1 |
| Hamid, R | 1 |
| Grubb, PH | 1 |
| Pietsch, JB | 1 |
| Lovvorn, HN | 1 |
| Speas, AL | 1 |
| Lyles, SE | 1 |
| Wirth, KA | 1 |
| Fahey, CE | 1 |
| Kow, K | 1 |
| Lejeune, AT | 1 |
| Milner, RJ | 1 |
| Mew, NA | 1 |
| Hediger, N | 1 |
| Landolt, MA | 1 |
| Diez-Fernandez, C | 2 |
| Huemer, M | 1 |
| Giacalone, G | 1 |
| Eggenschwiler, S | 1 |
| Lussi, M | 1 |
| De Gottardi, A | 1 |
| Zamboni, N | 1 |
| Hayasaka, K | 1 |
| Numakura, C | 1 |
| Yamakawa, M | 1 |
| Mitsui, T | 1 |
| Watanabe, H | 1 |
| Haga, H | 1 |
| Ohira, H | 1 |
| Ochiai, Y | 1 |
| Tahara, T | 1 |
| Nakahara, T | 1 |
| Yamashiki, N | 1 |
| Nakayama, T | 2 |
| Kon, T | 1 |
| Mitsubuchi, H | 1 |
| Jin, YY | 1 |
| Li, X | 1 |
| Zhang, T | 1 |
| Khoja, S | 2 |
| Hermann, K | 1 |
| Borzone, R | 1 |
| Willis, B | 1 |
| Rudd, M | 1 |
| Palmer, DJ | 2 |
| Ng, P | 2 |
| Gabbi, P | 2 |
| Nogueira, V | 1 |
| Haupental, F | 1 |
| Rodrigues, FS | 2 |
| do Nascimento, PS | 1 |
| Barbosa, S | 1 |
| Arend, J | 1 |
| Furian, AF | 2 |
| Oliveira, MS | 2 |
| Dos Santos, ARS | 1 |
| Royes, LFF | 1 |
| Fighera, MR | 2 |
| Gökceoğlu, AU | 1 |
| Taşar, MA | 1 |
| Yalaki, Z | 1 |
| Güneş, A | 1 |
| Bakır, A | 1 |
| Holeček, M | 4 |
| Vodeničarovová, M | 1 |
| Ferreira, RT | 1 |
| Gonçalves, SC | 1 |
| Pedrosa, ML | 1 |
| Silva, ME | 1 |
| Bassini, A | 1 |
| Coelho, WS | 1 |
| de Magalhães-Neto, AM | 1 |
| Prado, ES | 1 |
| Cameron, LC | 1 |
| Li, C | 1 |
| Zhang, Q | 1 |
| Qian, Y | 1 |
| Crossland, H | 1 |
| Smith, K | 1 |
| Atherton, PJ | 1 |
| Wilkinson, DJ | 2 |
| Wiwattanadittakul, N | 1 |
| Prust, M | 1 |
| Gaillard, WD | 1 |
| Massaro, A | 1 |
| Vezina, G | 1 |
| Tsuchida, TN | 1 |
| Gropman, AL | 2 |
| Kim, JY | 1 |
| Cho, H | 1 |
| Camilleri, L | 1 |
| Oliveira, M | 1 |
| Bennett, EE | 1 |
| Hummel, K | 1 |
| Smith, AG | 1 |
| Martinelli, D | 1 |
| Goffredo, BM | 1 |
| Falvella, FS | 1 |
| Marano, M | 1 |
| Koya, Y | 1 |
| Shibata, M | 1 |
| Senju, M | 1 |
| Honma, Y | 1 |
| Hiura, M | 1 |
| Ishii, M | 1 |
| Harada, M | 1 |
| Chakrapani, A | 3 |
| Kurtz, CB | 1 |
| Millet, YA | 1 |
| Puurunen, MK | 1 |
| Perreault, M | 1 |
| Charbonneau, MR | 1 |
| Isabella, VM | 1 |
| Kotula, JW | 1 |
| Antipov, E | 1 |
| Dagon, Y | 1 |
| Denney, WS | 1 |
| Wagner, DA | 1 |
| West, KA | 1 |
| Degar, AJ | 1 |
| Brennan, AM | 1 |
| Miller, PF | 1 |
| Deplazes, S | 1 |
| Rimann, N | 1 |
| Causton, B | 1 |
| Scherer, T | 1 |
| Leff, JW | 1 |
| Klimovskaia, A | 1 |
| Fingerhut, R | 1 |
| Krijt, J | 1 |
| Kožich, V | 1 |
| Nuoffer, JM | 2 |
| Grisch-Chan, HM | 1 |
| Giva, S | 1 |
| Finnegan, J | 1 |
| Ihidero, P | 1 |
| Maguire, G | 1 |
| Power, B | 1 |
| Knerr, I | 1 |
| Brossier, D | 1 |
| Goyer, I | 1 |
| Ziani, L | 1 |
| Marquis, C | 1 |
| Mitchell, G | 2 |
| Ozanne, B | 2 |
| Jouvet, P | 3 |
| Item, CB | 1 |
| Schanzer, A | 1 |
| Metz, T | 1 |
| Greber-Platzer, S | 1 |
| Lischka, J | 1 |
| Janwadkar, A | 1 |
| Shirole, N | 1 |
| Nagral, A | 1 |
| Bakshi, R | 1 |
| Vasanth, S | 1 |
| Bagde, A | 1 |
| Yewale, V | 1 |
| Mirza, D | 1 |
| Qvartskhava, N | 2 |
| Jin, CJ | 1 |
| Buschmann, T | 1 |
| Albrecht, U | 1 |
| Bode, JG | 1 |
| Monhasery, N | 1 |
| Oenarto, J | 1 |
| Saheki, T | 3 |
| Moriyama, M | 2 |
| Kuroda, E | 1 |
| Funahashi, A | 1 |
| Yasuda, I | 1 |
| Setogawa, Y | 1 |
| Gao, Q | 1 |
| Ushikai, M | 1 |
| Furuie, S | 1 |
| Yamamura, KI | 1 |
| Nakamura, Y | 2 |
| Eto, K | 1 |
| Kadowaki, T | 1 |
| Sinasac, DS | 2 |
| Furukawa, T | 1 |
| Horiuchi, M | 3 |
| Tai, YH | 1 |
| Kant, S | 1 |
| Davuluri, G | 3 |
| Alchirazi, KA | 1 |
| Heit, C | 1 |
| Gangadhariah, M | 1 |
| Kim, A | 1 |
| McMullen, MR | 1 |
| Willard, B | 1 |
| Luse, DS | 1 |
| Nagy, LE | 1 |
| Vasiliou, V | 1 |
| Marini, AM | 1 |
| Weiner, ID | 2 |
| Wu, YH | 1 |
| Chen, IC | 1 |
| Lin, JY | 1 |
| Dai, ZK | 1 |
| van Straten, G | 1 |
| van Dalen, D | 1 |
| Mesu, SJ | 1 |
| Rothuizen, J | 1 |
| Teske, E | 1 |
| Spee, B | 1 |
| Favier, RP | 1 |
| van Geijlswijk, IM | 1 |
| Yamada, H | 1 |
| Shishido, T | 1 |
| Mukai, T | 1 |
| Araki, M | 1 |
| Naka, H | 1 |
| Tokinobu, H | 1 |
| Buyeverov, AO | 1 |
| Bogomolov, PO | 1 |
| Mayev, IV | 1 |
| Matsievich, MV | 1 |
| Uvarova, OV | 1 |
| Taoro-González, L | 1 |
| Cabrera-Pastor, A | 1 |
| Sancho-Alonso, M | 1 |
| Arenas, YM | 1 |
| Meseguer-Estornell, F | 1 |
| Balzano, T | 1 |
| ElMlili, N | 1 |
| Felipo, V | 9 |
| Fuster-Cabré, M | 1 |
| Ezquerro-Sáenz, S | 1 |
| Requena-Calleja, MÁ | 1 |
| Medrano-Peña, J | 1 |
| Lapetra-Labé, AM | 1 |
| Cai, Z | 1 |
| Wu, F | 1 |
| Lin, H | 1 |
| Tan, M | 1 |
| Beretta-Piccoli, X | 1 |
| Mugisha, A | 1 |
| Attou, R | 1 |
| Kaefer, K | 1 |
| De Bels, D | 1 |
| Tolwani, A | 1 |
| Kwon, M | 1 |
| Alvarez, F | 2 |
| Moreno Franco, P | 1 |
| Patel, A | 1 |
| Canabal, JM | 1 |
| Haddad, TJ | 1 |
| Erasmus, DB | 1 |
| Mallea, JM | 1 |
| Narula, T | 1 |
| Brucculeri, M | 1 |
| Gabbard, W | 1 |
| Masson, J | 1 |
| Jooma, N | 1 |
| Raturi, S | 1 |
| Venkatesh, IH | 1 |
| Nagesh, NK | 1 |
| Venkatagiri, P | 1 |
| Dadsetan, S | 3 |
| Kukolj, E | 1 |
| Keiding, S | 6 |
| Waagepetersen, HS | 4 |
| Mehrotra, A | 1 |
| Trigun, SK | 2 |
| Apushkin, M | 1 |
| Das, A | 1 |
| Joseph, C | 1 |
| Leung, EK | 1 |
| Yeo, KT | 1 |
| Baron, JM | 1 |
| Baron, BW | 1 |
| Slack, AJ | 1 |
| Auzinger, G | 1 |
| Willars, C | 1 |
| Dew, T | 1 |
| Musto, R | 1 |
| Corsilli, D | 1 |
| Sherwood, R | 1 |
| Wendon, JA | 1 |
| Bernal, W | 2 |
| Abacan, M | 1 |
| Boneh, A | 1 |
| Rockey, DC | 1 |
| Vierling, JM | 1 |
| Mantry, P | 1 |
| Ghabril, M | 1 |
| Brown, RS | 1 |
| Alexeeva, O | 1 |
| Zupanets, IA | 1 |
| Grinevich, V | 1 |
| Baranovsky, A | 1 |
| Dudar, L | 1 |
| Fadieienko, G | 1 |
| Kharchenko, N | 1 |
| Klaryts'ka, I | 1 |
| Morozov, V | 1 |
| Grewal, P | 1 |
| McCashland, T | 1 |
| Reddy, KG | 1 |
| Reddy, KR | 1 |
| Syplyviy, V | 1 |
| Bass, NM | 1 |
| Dickinson, K | 1 |
| Norris, C | 1 |
| Coakley, D | 1 |
| Mokhtarani, M | 3 |
| Scharschmidt, BF | 3 |
| Rivera-Espinosa, L | 1 |
| Floriano-Sánchez, E | 1 |
| Pedraza-Chaverrí, J | 1 |
| Coballase-Urrutia, E | 1 |
| Sampieri, AI | 1 |
| Ortega-Cuellar, D | 1 |
| Cárdenas-Rodríguez, N | 1 |
| Carmona-Aparicio, L | 1 |
| Yamane, K | 1 |
| Shinohara, K | 1 |
| Doi, K | 1 |
| Inokuchi, R | 1 |
| Hiruma, T | 1 |
| Nakajima, S | 1 |
| Noiri, E | 1 |
| Yahagi, N | 1 |
| Jones, PM | 1 |
| Córdoba, J | 1 |
| Ventura-Cots, M | 1 |
| Noiret, L | 2 |
| Baigent, S | 1 |
| Kaneko, M | 1 |
| Ogasawara, K | 1 |
| Go, H | 1 |
| Imamura, T | 2 |
| Momoi, N | 1 |
| Hosoya, M | 1 |
| DU, K | 1 |
| Luan, Z | 1 |
| Qu, SQ | 1 |
| Yang, H | 1 |
| Yang, YX | 1 |
| Wang, ZY | 1 |
| Jin, HY | 1 |
| Liu, WP | 1 |
| Cooper, AJ | 3 |
| Kuhara, T | 1 |
| Jover-Cobos, M | 1 |
| Khetan, V | 2 |
| Tallis, S | 1 |
| Caltana, LR | 1 |
| Souto, PA | 1 |
| Delfante, AE | 1 |
| Lago, NR | 1 |
| Brusco, A | 1 |
| Perazzo, JC | 1 |
| Pellicer Corbí, M | 1 |
| Herranz Muñoz, C | 1 |
| Baldominos Utrilla, G | 1 |
| Fernández-Pacheco García-Valdecasas, M | 1 |
| Viegas, CM | 1 |
| Zanatta, Â | 1 |
| Grings, M | 1 |
| Hickmann, FH | 1 |
| Monteiro, WO | 1 |
| Soares, LE | 1 |
| Leipnitz, G | 1 |
| de Oliveira, FH | 1 |
| Qureshi, MO | 1 |
| Khokhar, N | 1 |
| Shafqat, F | 2 |
| Lee, HJ | 1 |
| Halliday, N | 1 |
| Bray, GP | 1 |
| Hirozawa, D | 1 |
| Fukada, K | 1 |
| Yaegaki, T | 1 |
| Hoshi, T | 1 |
| Sawada, J | 1 |
| Hazama, T | 1 |
| Mondal, P | 1 |
| Olmos, I | 1 |
| Alvariza, S | 1 |
| Guevara, N | 1 |
| Magallanes, L | 1 |
| Olano, I | 1 |
| Wang, Q | 3 |
| Yu, Z | 2 |
| Li, D | 1 |
| Jia, B | 1 |
| Li, J | 1 |
| Guan, K | 1 |
| Kan, Q | 2 |
| Inoue, K | 3 |
| Suzuki, E | 2 |
| Yamamoto, Y | 2 |
| Yazawa, R | 1 |
| Takahashi, Y | 2 |
| Imai, K | 2 |
| Miyakawa, K | 1 |
| Inoue, Y | 2 |
| Tsuji, D | 2 |
| Hayashi, H | 2 |
| Itoh, K | 2 |
| Hadjihambi, A | 2 |
| Kosenko, EA | 2 |
| Tikhonova, LA | 1 |
| Reddy, VP | 2 |
| Aliev, G | 1 |
| Kaminsky, YG | 2 |
| Haack, N | 1 |
| Dublin, P | 1 |
| Rose, CR | 1 |
| Hashim, IA | 1 |
| Cuthbert, JA | 1 |
| Tseng, YL | 1 |
| Huang, CR | 1 |
| Lin, CH | 1 |
| Lu, YT | 1 |
| Lu, CH | 1 |
| Chen, NC | 1 |
| Chang, CC | 1 |
| Chang, WN | 1 |
| Chuang, YC | 1 |
| Kristiansen, RG | 2 |
| Fuskevåg, OM | 1 |
| Mæhre, H | 1 |
| Revhaug, A | 2 |
| Ytrebø, LM | 3 |
| Torres-Vega, MA | 1 |
| Vargas-Jerónimo, RY | 1 |
| Montiel-Martínez, AG | 1 |
| Muñoz-Fuentes, RM | 1 |
| Zamorano-Carrillo, A | 1 |
| Pastor, AR | 1 |
| Palomares, LA | 1 |
| Hu, C | 1 |
| Tai, DS | 1 |
| Park, H | 1 |
| Cantero, G | 1 |
| Cantero-Nieto, G | 1 |
| Chan, E | 2 |
| Lee, B | 3 |
| Rhead, W | 2 |
| Feigenbaum, A | 2 |
| Le Mons, C | 2 |
| Bartley, JA | 1 |
| Nagamani, SC | 2 |
| Berquist, W | 2 |
| Gallagher, R | 1 |
| Bartholomew, D | 1 |
| Harding, CO | 2 |
| Korson, MS | 1 |
| Smith, W | 2 |
| Cederbaum, S | 1 |
| Wong, D | 1 |
| Merritt, JL | 1 |
| Vockley, J | 1 |
| Vockley, G | 1 |
| Kronn, D | 1 |
| Summar, M | 2 |
| Milikien, DA | 1 |
| Marino, M | 2 |
| Coakley, DF | 2 |
| Walker, V | 3 |
| Uygun, V | 1 |
| Karasu, G | 1 |
| Daloğlu, H | 1 |
| Hazar, V | 1 |
| Yeşilipek, A | 1 |
| Jiang, ZG | 1 |
| Patwardhan, VR | 1 |
| Bharat, A | 1 |
| Scott Budinger, GR | 1 |
| Kreisel, D | 1 |
| DeWet, CJ | 1 |
| Gelman, AE | 1 |
| Waites, K | 1 |
| Crabb, D | 1 |
| Xiao, L | 1 |
| Bhorade, S | 1 |
| Ambalavanan, N | 1 |
| Dilling, DF | 1 |
| Lowery, EM | 1 |
| Astor, T | 1 |
| Hachem, R | 1 |
| Krupnick, AS | 1 |
| DeCamp, MM | 1 |
| Ison, MG | 1 |
| Shen, TC | 1 |
| Albenberg, L | 1 |
| Bittinger, K | 1 |
| Chehoud, C | 1 |
| Chen, YY | 1 |
| Judge, CA | 1 |
| Chau, L | 1 |
| Ni, J | 1 |
| Sheng, M | 1 |
| Lin, A | 1 |
| Wilkins, BJ | 1 |
| Buza, EL | 1 |
| Lewis, JD | 1 |
| Daikhin, Y | 1 |
| Nissim, I | 1 |
| Bushman, FD | 1 |
| Wu, GD | 1 |
| Guo, C | 1 |
| Han, C | 1 |
| Kenzaka, T | 1 |
| Kato, K | 1 |
| Kitao, A | 1 |
| Kosami, K | 1 |
| Minami, K | 1 |
| Yahata, S | 1 |
| Fukui, M | 1 |
| Okayama, M | 1 |
| Chen, C | 1 |
| Bain, KB | 1 |
| Iuppa, JA | 1 |
| Yusen, RD | 1 |
| Byers, DE | 1 |
| Patterson, GA | 1 |
| Trulock, EP | 1 |
| Hachem, RR | 1 |
| Witt, CA | 1 |
| Ali, EZ | 1 |
| Khalid, MK | 1 |
| Yunus, ZM | 1 |
| Yakob, Y | 1 |
| Chin, CB | 1 |
| Abd Latif, K | 1 |
| Hock, NL | 1 |
| Patel, VC | 1 |
| White, H | 1 |
| Støy, S | 1 |
| Howells, JW | 1 |
| Short, PA | 1 |
| Nishimi, S | 1 |
| Ishikawa, K | 1 |
| Sasaki, M | 1 |
| Furukawa, H | 1 |
| Takada, A | 1 |
| Chida, S | 1 |
| Bartley, J | 1 |
| Gallagher, RC | 2 |
| Rowell, R | 1 |
| Hirai, K | 1 |
| McDaniel, J | 1 |
| Hill, EA | 1 |
| Moyer, M | 1 |
| Runkana, A | 1 |
| Prayson, R | 2 |
| van Lunteren, E | 1 |
| Ahn, JO | 1 |
| Li, Q | 1 |
| Lee, YH | 1 |
| Han, SM | 1 |
| Hwang, CY | 1 |
| Youn, HY | 1 |
| Chung, JY | 1 |
| Iwasa, M | 1 |
| Sugimoto, R | 1 |
| Ishihara, T | 1 |
| Sekoguchi-Fujikawa, N | 1 |
| Yoshikawa, K | 1 |
| Mifuji-Moroka, R | 1 |
| Tanaka, H | 1 |
| Kobayashi, Y | 1 |
| Hasegawa, H | 1 |
| Takei, Y | 1 |
| Yap, S | 1 |
| Leong, HY | 1 |
| Abdul Aziz, F | 1 |
| Hassim, H | 1 |
| Sthaneshwar, P | 1 |
| Teh, SH | 1 |
| Abdullah, IS | 1 |
| Ngu, LH | 1 |
| Mohamed, Z | 1 |
| Royes, LF | 1 |
| Ribeiro, LR | 1 |
| Della-Pace, ID | 1 |
| de Oliveira Ferreira, AP | 1 |
| da Silveira Junior, ME | 1 |
| da Silva, LR | 1 |
| Grisólia, AB | 1 |
| Braga, DV | 1 |
| Dobrachinski, F | 1 |
| da Silva, AM | 1 |
| Soares, FA | 1 |
| Marchesan, S | 1 |
| Tamaoki, S | 1 |
| Suzuki, H | 1 |
| Okada, M | 1 |
| Fukui, N | 1 |
| Isobe, M | 1 |
| Saito, T | 1 |
| Valayannopoulos, V | 1 |
| Baruteau, J | 2 |
| Delgado, MB | 1 |
| Cano, A | 1 |
| Couce, ML | 1 |
| Del Toro, M | 1 |
| Donati, MA | 3 |
| Garcia-Cazorla, A | 1 |
| Gil-Ortega, D | 1 |
| Gomez-de Quero, P | 1 |
| Guffon, N | 1 |
| Hofstede, FC | 1 |
| Kalkan-Ucar, S | 1 |
| Coker, M | 1 |
| Lama-More, R | 1 |
| Martinez-Pardo Casanova, M | 1 |
| Molina, A | 1 |
| Pichard, S | 1 |
| Papadia, F | 1 |
| Rosello, P | 1 |
| Plisson, C | 1 |
| Le Mouhaer, J | 1 |
| Laemmle, A | 1 |
| Keogh, A | 1 |
| Stricker, T | 1 |
| Gautschi, M | 1 |
| Baumgartner, MR | 1 |
| Gupta, S | 1 |
| Fenves, AZ | 1 |
| Hootkins, R | 1 |
| Albadareen, R | 1 |
| Gronseth, G | 1 |
| Landazuri, P | 1 |
| He, J | 1 |
| Hammond, N | 1 |
| Uysal, U | 1 |
| Yonai, R | 1 |
| Sato, R | 1 |
| Nasu, M | 1 |
| Hertz, L | 3 |
| Song, D | 1 |
| Peng, L | 3 |
| Senthilkumaran, S | 1 |
| Karthikeyan, N | 1 |
| Menezes, RG | 1 |
| Thirumalaikolundusubramanian, P | 1 |
| Açıkalın, A | 1 |
| Dişel, NR | 1 |
| Wang, W | 1 |
| Gu, L | 2 |
| Verkhratsky, A | 1 |
| Kovács, DÁ | 1 |
| Al Huurman, V | 1 |
| Wojcicki, M | 1 |
| Soonowala, D | 1 |
| Baranski, A | 1 |
| Renuka, M | 1 |
| Vijayakumar, N | 1 |
| Ramakrishnan, A | 1 |
| Wang, X | 1 |
| Karau, MJ | 1 |
| Greenwood-Quaintance, KE | 1 |
| Mandrekar, JN | 1 |
| Guo, X | 1 |
| Gao, L | 1 |
| Lin, W | 1 |
| Wu, Y | 1 |
| Xing, B | 1 |
| Xu, Z | 1 |
| Choi, JJ | 1 |
| Kim, HS | 1 |
| Lee, KC | 1 |
| Shin, Y | 1 |
| Jo, YY | 1 |
| Sato, K | 1 |
| Arai, N | 1 |
| Omori, A | 1 |
| Hida, A | 1 |
| Kimura, A | 1 |
| Takeuchi, S | 1 |
| Orton, DJ | 1 |
| Gifford, JL | 1 |
| Seiden-Long, I | 1 |
| Khan, A | 1 |
| de Koning, L | 1 |
| Ten Have, GA | 2 |
| Deutz, NE | 5 |
| Rackayova, V | 1 |
| Rangroo Thrane, V | 1 |
| Vairappan, B | 1 |
| Jamshidzadeh, A | 1 |
| Heidari, R | 1 |
| Abasvali, M | 1 |
| Zarei, M | 1 |
| Abdoli, N | 1 |
| Khodaei, F | 1 |
| Yeganeh, Y | 1 |
| Jafari, F | 1 |
| Zarei, A | 1 |
| Latifpour, Z | 1 |
| Mardani, E | 1 |
| Azarpira, N | 1 |
| Asadi, B | 1 |
| Najibi, A | 1 |
| De Chiara, F | 1 |
| Hosford, PS | 1 |
| Habtetion, A | 1 |
| Karagiannis, A | 1 |
| Davies, N | 1 |
| Gourine, AV | 1 |
| Schrettl, V | 1 |
| Felgenhauer, N | 1 |
| Rabe, C | 1 |
| Fernando, M | 1 |
| Eyer, F | 1 |
| Silva, RNE | 1 |
| Engelen, MPKJ | 1 |
| Ten Have, GAM | 1 |
| Deutz, NEP | 1 |
| Miyamoto, S | 1 |
| Matsubara, K | 1 |
| Jameson, E | 1 |
| Morris, AA | 4 |
| Santra, S | 1 |
| Vijay, S | 2 |
| Kocadag, H | 1 |
| Beesley, CE | 1 |
| Grunewald, S | 2 |
| Cleary, M | 1 |
| Mundy, H | 1 |
| Abulhoul, L | 1 |
| Broomfield, A | 2 |
| Lachmann, R | 1 |
| Rahman, Y | 1 |
| Robinson, PH | 2 |
| MacPherson, L | 1 |
| Foster, K | 1 |
| Chong, WK | 1 |
| Ridout, DA | 1 |
| Bounford, KM | 1 |
| Waddington, SN | 1 |
| Mills, PB | 1 |
| Gissen, P | 1 |
| Davison, JE | 1 |
| Moffatt-Bruce, SD | 1 |
| Pesavento, T | 1 |
| Von Viger, J | 1 |
| Nunley, D | 1 |
| Pope-Harman, A | 1 |
| Martin, S | 1 |
| Ross, P | 1 |
| Herrera, DJ | 1 |
| Moore, S | 1 |
| Heap, S | 1 |
| Preece, MA | 1 |
| Griffiths, P | 1 |
| Cauli, O | 2 |
| Rodrigo, R | 2 |
| Boix, J | 2 |
| Piedrafita, B | 1 |
| Agusti, A | 1 |
| Wright, GA | 1 |
| Stadlbauer, V | 2 |
| Hodges, SJ | 3 |
| Davies, NA | 5 |
| Wheeler-Jones, C | 1 |
| Pitsillides, AA | 1 |
| Nicaise, C | 1 |
| Prozzi, D | 1 |
| Viaene, E | 1 |
| Moreno, C | 1 |
| Gustot, T | 1 |
| Quertinmont, E | 1 |
| Demetter, P | 1 |
| Suain, V | 1 |
| Goffin, P | 1 |
| Devière, J | 1 |
| Hols, P | 1 |
| Andersson, AK | 1 |
| Adermark, L | 1 |
| Persson, M | 1 |
| Westerlund, A | 1 |
| Olsson, T | 1 |
| Hansson, E | 1 |
| Purdie, NG | 1 |
| Trout, DR | 1 |
| Cieslar, SR | 1 |
| Madsen, TG | 1 |
| Poppi, DP | 1 |
| Cant, JP | 1 |
| Ahmad, I | 1 |
| Khan, AA | 1 |
| Alam, A | 1 |
| Dilshad, A | 1 |
| Butt, AK | 1 |
| Malik, K | 1 |
| Sarwar, S | 1 |
| Eefsen, M | 2 |
| Hansen, BA | 1 |
| Scholl-Bürgi, S | 1 |
| Sigl, SB | 1 |
| Haberlandt, E | 1 |
| Rostásy, K | 1 |
| Ertl, C | 1 |
| Eichinger-Öttl, U | 1 |
| Heinz-Erian, P | 1 |
| Karall, D | 1 |
| Jover, M | 1 |
| Galán, JJ | 1 |
| Olde Damink, SW | 8 |
| Dejong, CH | 4 |
| Rejniuk, VL | 5 |
| Schafer, TV | 5 |
| Ivnitsky, JJ | 5 |
| Subash, S | 1 |
| Subramanian, P | 1 |
| DeWolfe, JL | 1 |
| Knowlton, RC | 1 |
| Beasley, MT | 1 |
| Cofield, S | 1 |
| Faught, E | 1 |
| Limdi, NA | 1 |
| Gau, CL | 1 |
| Rosenblatt, RA | 1 |
| Cerullo, V | 1 |
| Lay, FD | 1 |
| Dow, AC | 1 |
| Livesay, J | 1 |
| Grody, WW | 1 |
| Ikewaki, J | 1 |
| Ogata, M | 1 |
| Kohno, K | 1 |
| Kadota, J | 1 |
| Reddy, PV | 1 |
| Rama Rao, KV | 3 |
| Norenberg, MD | 3 |
| Hamed, SA | 1 |
| Abdella, MM | 1 |
| Castro-Gago, M | 1 |
| Gómez-Lado, C | 1 |
| Eirís-Puñal, J | 1 |
| Díaz-Mayo, I | 1 |
| Castiñeiras-Ramos, DE | 1 |
| Stojanovic, VD | 1 |
| Doronjski, AR | 1 |
| Barisic, N | 1 |
| Kovacevic, BB | 1 |
| Pavlovic, VS | 1 |
| Schwahn, BC | 1 |
| Pieterse, L | 1 |
| Bisset, WM | 1 |
| Galloway, PG | 1 |
| Filippi, L | 1 |
| Gozzini, E | 1 |
| Fiorini, P | 1 |
| Malvagia, S | 1 |
| la Marca, G | 1 |
| Kaminsky, Y | 1 |
| Kosenko, E | 1 |
| Arbeiter, AK | 1 |
| Kranz, B | 1 |
| Wingen, AM | 1 |
| Bonzel, KE | 1 |
| Dohna-Schwake, C | 1 |
| Hanssler, L | 1 |
| Neudorf, U | 1 |
| Hoyer, PF | 1 |
| Büscher, R | 1 |
| Yang, X | 2 |
| Jiang, W | 2 |
| Munk, OL | 1 |
| Bender, D | 1 |
| Yadav, SK | 2 |
| Saksena, S | 1 |
| Srivastava, A | 3 |
| Saraswat, VA | 2 |
| Thomas, MA | 2 |
| Rathore, RK | 1 |
| Gupta, RK | 2 |
| Xue, Z | 1 |
| Li, B | 1 |
| Hu, X | 1 |
| McKinney, AM | 1 |
| Lohman, BD | 1 |
| Sarikaya, B | 1 |
| Uhlmann, E | 1 |
| Spanbauer, J | 1 |
| Singewald, T | 1 |
| Brace, JR | 1 |
| Kotani, Y | 1 |
| Shiota, M | 1 |
| Umemoto, M | 1 |
| Tsuritani, M | 1 |
| Hoshiai, H | 1 |
| Westrope, C | 1 |
| Morris, K | 1 |
| Burford, D | 1 |
| Morrison, G | 1 |
| Teixeira, AR | 1 |
| Machado, MC | 1 |
| Kubrusly, MS | 1 |
| Molan, NT | 1 |
| Bellodi-Privato, M | 1 |
| Leite, KR | 1 |
| D'Albuquerque, LA | 1 |
| Hilgier, W | 1 |
| Wegrzynowicz, M | 3 |
| Ruszkiewicz, J | 1 |
| Oja, SS | 1 |
| Saransaari, P | 1 |
| Liu, KT | 2 |
| Lee, CW | 2 |
| Yang, SC | 2 |
| Yeh, IJ | 2 |
| Lin, TJ | 2 |
| Su, CS | 1 |
| Kandar, R | 1 |
| Sispera, L | 1 |
| Kovarik, M | 1 |
| Jörck, C | 1 |
| Kiess, W | 1 |
| Weigel, JF | 1 |
| Mütze, U | 1 |
| Bierbach, U | 1 |
| Beblo, S | 1 |
| Wright, G | 4 |
| LaBuzetta, JN | 1 |
| Yao, JZ | 1 |
| Bourque, DL | 1 |
| Zivin, J | 1 |
| Galal, NM | 1 |
| Fouad, HM | 1 |
| Saied, A | 1 |
| Dabnon, M | 1 |
| Aires, CC | 1 |
| van Cruchten, A | 1 |
| Ijlst, L | 1 |
| de Almeida, IT | 1 |
| Duran, M | 2 |
| Wanders, RJ | 1 |
| Silva, MF | 1 |
| Kasapkara, CS | 1 |
| Ezgu, FS | 1 |
| Okur, I | 1 |
| Tumer, L | 1 |
| Biberoglu, G | 1 |
| Hasanoglu, A | 1 |
| Ivnitsky, YY | 1 |
| Yachha, SK | 1 |
| Mahmoud, AM | 1 |
| Wendon, J | 1 |
| Leke, R | 2 |
| Nelson, J | 1 |
| Cousineau, J | 1 |
| Lambert, M | 1 |
| Phan, V | 1 |
| Ducruet, T | 1 |
| Mpabanzi, L | 2 |
| van den Broek, MA | 1 |
| Visschers, RG | 1 |
| van de Poll, MC | 1 |
| Nadalin, S | 1 |
| Saner, FH | 1 |
| Malago, M | 1 |
| Laish, I | 1 |
| Ben Ari, Z | 1 |
| Smeeton, NJ | 1 |
| Castle, PC | 1 |
| Watt, PW | 1 |
| Kyong, YY | 1 |
| Choi, KH | 1 |
| Oh, YM | 1 |
| Lee, KU | 1 |
| Skowrońska, M | 1 |
| Hung, TY | 1 |
| Chen, CC | 1 |
| Wang, TL | 1 |
| Su, CF | 1 |
| Wang, RF | 1 |
| Urios, A | 1 |
| Montesinos, E | 1 |
| Molina, I | 1 |
| Garcia-Torres, ML | 1 |
| Civera, M | 1 |
| Olmo, JA | 1 |
| Ortega, J | 1 |
| Martinez-Valls, J | 1 |
| Serra, MA | 1 |
| Cassinello, N | 1 |
| Wassel, A | 1 |
| Jordá, E | 1 |
| Brunelli, L | 1 |
| Campagna, R | 1 |
| Airoldi, L | 1 |
| Llansola, M | 2 |
| Pastorelli, R | 1 |
| Cudalbu, C | 2 |
| Lanz, B | 1 |
| Duarte, JM | 1 |
| Morgenthaler, FD | 1 |
| Pilloud, Y | 1 |
| Mlynárik, V | 1 |
| Gruetter, R | 1 |
| Back, A | 1 |
| Tupper, KY | 1 |
| Bai, T | 1 |
| Chiranand, P | 1 |
| Goldenberg, FD | 1 |
| Frank, JI | 1 |
| Brorson, JR | 1 |
| Blanco Vela, CI | 1 |
| Poo Ramírez, JL | 1 |
| Huynh, J | 1 |
| Parent-Robitaille, C | 1 |
| Kasai, A | 1 |
| Nagao, K | 1 |
| Kikushima, K | 1 |
| Watanabe, K | 1 |
| Tachibana, E | 1 |
| Soga, T | 1 |
| Matsuzaki, M | 1 |
| Mastsuzaki, M | 1 |
| Yagi, T | 1 |
| Deutz, N | 1 |
| Hayes, PC | 4 |
| Kumar, R | 1 |
| Sharma, H | 1 |
| Prakash, S | 1 |
| Panda, SK | 1 |
| Khanal, S | 1 |
| Acharya, SK | 1 |
| Choi, DE | 1 |
| Lee, KW | 1 |
| Shin, YT | 1 |
| Na, KR | 1 |
| Pillai, U | 1 |
| Kahlon, R | 1 |
| Sondheimer, J | 1 |
| Cadnapaphorncai, P | 1 |
| Bhat, Z | 1 |
| Hong, L | 1 |
| Schutz, J | 1 |
| Nance, M | 1 |
| Medeiros, WM | 1 |
| Carvalho, AC | 1 |
| Peres, P | 1 |
| De Luca, FA | 1 |
| Gun, C | 1 |
| Zhang, Y | 1 |
| Landau, YE | 1 |
| Miller, DT | 1 |
| Marsden, D | 1 |
| Kellogg, MD | 1 |
| Yoon, YA | 1 |
| Ki, CS | 1 |
| Lee, SY | 1 |
| Kim, JW | 1 |
| Lee, YW | 1 |
| Park, HD | 1 |
| Braissant, O | 3 |
| McLin, VA | 1 |
| Oliveira, DL | 1 |
| Forgiarini, LF | 1 |
| Escobar, TD | 1 |
| Hammes, TO | 1 |
| Meyer, FS | 1 |
| Silveira, TR | 1 |
| Schaefer, TV | 1 |
| Rejuniuk, VL | 1 |
| Malakhovsky, VN | 2 |
| Mardini, H | 1 |
| Record, C | 1 |
| McQueen, F | 1 |
| Izumi, Y | 2 |
| Svrakic, N | 1 |
| O'Dell, K | 1 |
| Zorumski, CF | 2 |
| Calligaris, L | 1 |
| Vidoni, A | 1 |
| Bruno, I | 1 |
| Vidoni, M | 1 |
| Barbi, E | 1 |
| Nagasaka, H | 2 |
| Miida, T | 1 |
| Yorifuji, T | 2 |
| Hirano, K | 1 |
| Inui, A | 1 |
| Fujisawa, T | 1 |
| Tsukahara, H | 1 |
| Inomata, Y | 1 |
| Veauvy, CM | 1 |
| Walsh, PJ | 1 |
| Pérez-Pinzón, MA | 1 |
| Bachmann, C | 2 |
| Augris, C | 1 |
| Benabdelmalek, F | 1 |
| Vauquelin, P | 1 |
| Caramella, JP | 1 |
| Paul, V | 1 |
| Murphy, JV | 1 |
| Li, XX | 1 |
| Kobayashi, K | 3 |
| Jalil, A | 1 |
| Yoshida, G | 1 |
| Boscá, L | 1 |
| Hortelano, S | 1 |
| Balata, S | 2 |
| Ferguson, K | 1 |
| Marshall, I | 2 |
| Wardlaw, J | 2 |
| García, MV | 2 |
| López-Mediavilla, C | 2 |
| Juanes de la Peña, MC | 2 |
| Medina, JM | 2 |
| Redhead, DN | 1 |
| Hynd, P | 1 |
| Jalan, RA | 1 |
| Soeters, PB | 1 |
| Zullo, A | 1 |
| Hassan, C | 1 |
| Morini, S | 1 |
| García, MJ | 1 |
| Wermuth, B | 1 |
| Torres, J | 1 |
| Pallarés, E | 1 |
| Ugarte, M | 1 |
| FRIEDLANDER, WJ | 1 |
| POSER, CM | 1 |
| PEARL, DC | 1 |
| McDERMOTT, WV | 1 |
| LABORIT, H | 1 |
| OBRENOVITCH, L | 1 |
| LEGUEN, P | 1 |
| JOUANY, JM | 1 |
| WILSON, WP | 1 |
| TYOR, MP | 2 |
| FONGI, EG | 1 |
| HERRERO, H | 1 |
| BIANCHINI, HM | 1 |
| RIVADULLA, II | 1 |
| OWEN, EE | 1 |
| JOHNSON, JH | 1 |
| STAHL, J | 1 |
| ROHMER, F | 1 |
| BOCKEL, R | 1 |
| KURTZ, D | 1 |
| IMLER, M | 1 |
| AIMARD, G | 2 |
| DUFFRENE, D | 2 |
| MAILLET, P | 1 |
| VILLAROS, J | 1 |
| HAEFELY, W | 1 |
| HUERLIMANN, A | 1 |
| STAUB, H | 1 |
| SCHWARZMANN, V | 1 |
| BERTHAUX, N | 1 |
| TSUKIYAMA, K | 1 |
| MINE, R | 1 |
| KOYAMA, M | 1 |
| FUKUSHIMA, K | 1 |
| FUKAO, R | 1 |
| KITANI, T | 2 |
| FASEL, J | 1 |
| MAGNENAT, P | 2 |
| RUSSELL, A | 1 |
| LEVIN, B | 1 |
| OBERHOLZER, VG | 1 |
| SINCLAIR, L | 1 |
| SOBERON, G | 1 |
| FLORES, G | 1 |
| ROSADO, A | 1 |
| TORRES GALLARDO, J | 1 |
| MORA, J | 1 |
| MAGGIO, R | 1 |
| ZANINI, P | 1 |
| FACCHETTI, A | 1 |
| BRETTE, R | 1 |
| FRANCOIS, B | 1 |
| CILLE, Y | 1 |
| STARER, F | 1 |
| COUCH, R | 1 |
| DEUIL, R | 1 |
| GODARD, F | 1 |
| GENTILHOMME, C | 1 |
| AUBERTIN, E | 1 |
| AUBERTIN, J | 1 |
| WONE, C | 1 |
| COON, WW | 1 |
| ZUIDEMA, GD | 1 |
| KIRSH, MM | 1 |
| WU, KH | 1 |
| SHERMAN, B | 1 |
| HOSHAL, V | 1 |
| DUCHENE-MARULLAZ, P | 1 |
| TALVARD, J | 1 |
| VACHER, J | 1 |
| RIGAMONTI, PP | 1 |
| ZECCA, C | 1 |
| MOLINAROLI, P | 1 |
| PERRET, C | 1 |
| MONTANI, S | 1 |
| Monfort, P | 2 |
| Muñoz, MD | 1 |
| Minauchi, K | 1 |
| Fujie, T | 1 |
| Matsubara, N | 1 |
| Kasahara, H | 1 |
| Ogura, Y | 1 |
| Tamura, M | 1 |
| Yamane, Y | 1 |
| Tanaka, M | 2 |
| Taneichi, K | 1 |
| Rajpoot, DK | 1 |
| Gargus, JJ | 1 |
| Kaku, T | 1 |
| Shiba, M | 1 |
| Yoshimasu, F | 1 |
| Yamada, T | 1 |
| Duseja, A | 1 |
| Sachdev, A | 1 |
| Dhiman, RK | 1 |
| Chawla, YK | 1 |
| Stanley, CA | 2 |
| Villard, AM | 1 |
| Boulat, O | 1 |
| Henry, H | 1 |
| Chow, SL | 1 |
| Gandhi, V | 1 |
| Krywawych, S | 1 |
| Clayton, PT | 1 |
| Leonard, JV | 3 |
| Koch, HG | 2 |
| Romero Gómez, M | 1 |
| Bautista, JD | 1 |
| Grande, L | 1 |
| Ramos Guerrero, RM | 1 |
| Sánchez Muñoz, D | 1 |
| Mallet, L | 1 |
| Babin, S | 1 |
| Morais, JA | 1 |
| McCall, M | 1 |
| Bourgeois, JA | 1 |
| Giordano, G | 1 |
| Sanchez-Perez, AM | 1 |
| Burgal, M | 1 |
| Costa, LG | 1 |
| Erceg, S | 1 |
| Hernández-Viadel, M | 1 |
| Panda, S | 1 |
| Radhakrishnan, K | 1 |
| Cordero, DR | 1 |
| Baker, J | 1 |
| Dorinzi, D | 1 |
| Toffle, R | 1 |
| Kala, G | 2 |
| Zwingmann, C | 3 |
| Leibfritz, D | 1 |
| Ahboucha, S | 1 |
| Araqi, F | 1 |
| Layrargues, GP | 1 |
| Alexander, B | 1 |
| Smart, KA | 1 |
| Segal, MB | 1 |
| Preston, JE | 1 |
| Clemmesen, O | 1 |
| Yang, YL | 1 |
| Sun, F | 1 |
| Qian, N | 1 |
| Song, JQ | 1 |
| Wang, S | 1 |
| Chang, XZ | 1 |
| Yang, HY | 1 |
| Wang, SQ | 1 |
| Li, L | 1 |
| Zhang, YH | 1 |
| Bao, XH | 1 |
| Qi, Y | 1 |
| Qin, J | 1 |
| Wu, XR | 1 |
| Izumi, M | 1 |
| Matsukawa, M | 1 |
| Funatsu, M | 1 |
| Klejman, A | 1 |
| Szatmari, EM | 1 |
| Mioduszewska, B | 1 |
| Hetman, M | 1 |
| Cleary, MA | 1 |
| Dorland, L | 1 |
| de Koning, TJ | 1 |
| Poll-The, BT | 1 |
| Mandell, R | 1 |
| Shih, VE | 1 |
| Berger, R | 1 |
| Olpin, SE | 1 |
| Besley, GT | 1 |
| Ihara, K | 1 |
| Miyako, K | 1 |
| Ishimura, M | 1 |
| Kuromaru, R | 1 |
| Wang, HY | 1 |
| Yasuda, K | 1 |
| Hara, T | 1 |
| Li, MX | 1 |
| Kannan, Y | 1 |
| Iijima, M | 1 |
| Tsui, LC | 1 |
| Mohr, M | 1 |
| Rasmussen, P | 1 |
| Drust, B | 1 |
| Nielsen, B | 1 |
| Nybo, L | 1 |
| Rose, C | 2 |
| Kubota, M | 1 |
| Kurokawa, K | 1 |
| Murakami, T | 1 |
| Kanazawa, M | 1 |
| Takatani, T | 1 |
| Ogawa, A | 1 |
| Ogawa, E | 1 |
| Adachi, M | 1 |
| Takayanagi, M | 1 |
| Sen, S | 1 |
| Hodges, S | 1 |
| Nedredal, GI | 1 |
| Pidoplichko, VI | 1 |
| Dani, JA | 1 |
| Lin, C | 1 |
| Tusa, JK | 1 |
| Wang, LJ | 1 |
| Cai, JT | 1 |
| Chen, T | 1 |
| Lü, B | 1 |
| Si, JM | 1 |
| Talamo, G | 1 |
| Cavallo, F | 1 |
| Zangari, M | 1 |
| Barlogie, B | 1 |
| Lee, CK | 1 |
| Pineda-Roman, M | 1 |
| Kiwan, E | 1 |
| Krishna, S | 1 |
| Tricot, G | 1 |
| Bunchman, TE | 1 |
| Barletta, GM | 1 |
| Winters, JW | 1 |
| Gardner, JJ | 1 |
| Crumb, TL | 1 |
| McBryde, KD | 1 |
| Reinehr, R | 1 |
| Becker, S | 1 |
| Selbach, O | 1 |
| Haas, HL | 1 |
| Schliess, F | 1 |
| Hiroyama, M | 1 |
| Aoyagi, T | 1 |
| Fujiwara, Y | 1 |
| Oshikawa, S | 1 |
| Sanbe, A | 1 |
| Endo, F | 1 |
| Tanoue, A | 1 |
| Brooks, HF | 1 |
| Mani, AR | 1 |
| Harry, D | 1 |
| Zou, Z | 2 |
| Davies, C | 1 |
| Moore, KP | 1 |
| Pedersen, HR | 1 |
| Ring-Larsen, H | 1 |
| Olsen, NV | 1 |
| Rhead, WJ | 1 |
| Brusilow, SW | 1 |
| Hamosh, A | 1 |
| Wong, YC | 1 |
| Au, WL | 1 |
| Xu, M | 1 |
| Ye, J | 1 |
| Lim, CC | 1 |
| Velioğlu, SK | 1 |
| Gazioğlu, S | 1 |
| Cagnon, L | 1 |
| Bodega, G | 1 |
| Suárez, I | 1 |
| Paniagua, C | 1 |
| Vacas, E | 1 |
| Fernández, B | 1 |
| Pela, I | 1 |
| Seracini, D | 1 |
| Lavoratti, G | 1 |
| Pasquini, E | 1 |
| Materassi, M | 1 |
| Clay, AS | 1 |
| Hainline, BE | 1 |
| Vaquero, J | 1 |
| Yanagawa, Y | 1 |
| Nishi, K | 1 |
| Sakamoto, T | 1 |
| Mangin, JM | 1 |
| Gordish-Dressman, H | 1 |
| Hoffman, EP | 1 |
| Gallo, V | 1 |
| Konopacka, A | 1 |
| Reinyuk, VL | 1 |
| Shefer, TV | 1 |
| Malakhovskii, VN | 1 |
| Ovsep'yan, RV | 2 |
| Ivnitskii, YY | 1 |
| Meinardi, MC | 1 |
| van den Berg, GB | 1 |
| Groenhuijzen, A | 1 |
| Driessen, JT | 1 |
| Maas, HA | 1 |
| Wolfhagen, FH | 1 |
| Jones, S | 1 |
| Reed, CA | 1 |
| Walter, JH | 1 |
| Tremolizzo, L | 1 |
| Galbussera, A | 1 |
| Frigo, M | 1 |
| Apale, P | 1 |
| Capra, M | 1 |
| Appollonio, I | 1 |
| Ferrarese, C | 1 |
| Bertrand, P | 1 |
| Faro, A | 1 |
| Cantwell, P | 1 |
| Tzakis, A | 1 |
| Sibson, NR | 1 |
| Mason, GF | 1 |
| Shen, J | 1 |
| Cline, GW | 1 |
| Herskovits, AZ | 1 |
| Wall, JE | 1 |
| Behar, KL | 1 |
| Rothman, DL | 1 |
| Shulman, RG | 1 |
| Mathias, RS | 1 |
| Kostiner, D | 1 |
| Packman, S | 1 |
| McEwan, P | 1 |
| Simpson, D | 1 |
| Kirk, JM | 1 |
| Barr, DG | 1 |
| McKenzie, KJ | 1 |
| Barr, J | 1 |
| Eshel, G | 1 |
| Chen-Levy, Z | 1 |
| Lahat, E | 1 |
| Whitelaw, A | 1 |
| Bridges, S | 1 |
| Leaf, A | 1 |
| Evans, D | 1 |
| Seiler, N | 1 |
| Stadler, S | 1 |
| Gempel, K | 1 |
| Bieger, I | 1 |
| Pontz, BF | 1 |
| Gerbitz, KD | 1 |
| Bauer, MF | 1 |
| Hofmann, S | 1 |
| Kelly, A | 1 |
| Ng, D | 1 |
| Ferry, RJ | 1 |
| Grimberg, A | 1 |
| Koo-McCoy, S | 1 |
| Thornton, PS | 1 |
| Vanaja, P | 1 |
| Irie, T | 1 |
| Miyamoto, E | 1 |
| Kitagawa, K | 1 |
| Maruyama, Y | 1 |
| Inagaki, C | 1 |
| Otsuki, T | 1 |
| Wada, H | 1 |
| Nakazawa, N | 1 |
| Taniwaki, M | 1 |
| Kouguchi, K | 1 |
| Ohkura, M | 1 |
| Uehira, K | 1 |
| Isoda, K | 1 |
| Yata, K | 1 |
| Sakaguchi, H | 1 |
| Yawata, Y | 1 |
| Ueki, A | 1 |
| Yamada, O | 1 |
| Vossler, DG | 1 |
| Wilensky, AJ | 1 |
| Cawthon, DF | 1 |
| Kraemer, DL | 1 |
| Ojemann, LM | 1 |
| Caylor, LM | 1 |
| Morgan, JD | 1 |
| Laube, GF | 1 |
| Superti-Furga, A | 1 |
| Losa, M | 1 |
| Büttiker, V | 1 |
| Berger, C | 1 |
| Neuhaus, TJ | 1 |
| Chan, WK | 1 |
| But, WM | 1 |
| Law, CW | 1 |
| Schwarz, S | 1 |
| Georgiadis, D | 1 |
| Schwab, S | 1 |
| Gehlen, F | 1 |
| Mayatepek, E | 1 |
| Zoubaa, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT04771104] | 9 participants (Actual) | Interventional | 2017-01-01 | Completed | |||
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy[NCT00999167] | Phase 2 | 189 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial)[NCT04436601] | Phase 4 | 102 participants (Anticipated) | Interventional | 2020-03-09 | Recruiting | ||
| Plasma Free Amino Acids in Patients With Hepatic Encephalopathy and Its Impact on Disease Outcomes.[NCT03306498] | 100 participants (Anticipated) | Observational | 2017-12-15 | Not yet recruiting | |||
| Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial[NCT01722578] | Phase 4 | 200 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Brain Energy Metabolism in Patients With Acute Hepatic Encephalopathy Measured With PET[NCT00424957] | 18 participants (Anticipated) | Observational | 2006-11-30 | Completed | |||
| Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients[NCT04244877] | Phase 3 | 0 participants (Actual) | Interventional | 2021-09-15 | Withdrawn (stopped due to Study was unable to recruit participants..) | ||
| A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders[NCT00551200] | Phase 2 | 14 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Efficacy of Vitamin E in Hyperinsulinism/Hyperammonemia Syndrome[NCT04984798] | Phase 2 | 0 participants (Actual) | Interventional | 2022-11-30 | Withdrawn (stopped due to No study activity took place. The IND was withdrawn with the FDA by the Sponsor Investigator because of insurmountable hurdles in moving proposed research forward) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"An HE event was defined as occurrences of either a West Haven (WH) Grade ≥2 or a WH Grade 1 and asterixis grade increase of 1 (if baseline WH = 0).~The WH criteria are widely used for rating the severity of HE and are summarized below:~Grade 1: trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired performance of addition Grade 2: lethargy or apathy, minimal disorientation for time or place, subtle personality change, inappropriate behavior, impaired performance of subtraction Grade 3: somnolence to semi-stupor but responsive to verbal stimuli, confusion, gross disorientation Grade 4: coma (unresponsive to verbal or noxious stimuli)~Asterixis was assessed after arm and forearm extension along with wrist dorsiflexion for 30 seconds and assigned a grade according to the following criteria:~Grade 1: rare flaps Grade 2: occasional irregular flaps Grade 3: frequent flaps Grade 4: continuous flaps" (NCT00999167)
Timeframe: Part B: 112 Days
| Intervention | participants (Number) |
|---|---|
| HPN-100 | 19 |
| Placebo | 32 |
Secondary efficacy endpoint. The time to the first HE episode during the treatment period was calculated using the Kaplan-Meier method. Subjects who did not experience an HE episode were censored at the time of their last asterixis assessment. Subjects who had no post-randomization data for the primary endpoint were considered to have an HE episode at Day 1. (NCT00999167)
Timeframe: 112 Days
| Intervention | Days (Median) |
|---|---|
| HPN-100 | NA |
| Placebo | NA |
Secondary efficacy endpoint. The total number of HE events during the treatment phase for subjects in the placebo and active arms. (NCT00999167)
Timeframe: 112 Days
| Intervention | HE event (Number) |
|---|---|
| HPN-100 | 35 |
| Placebo | 57 |
Changes from Baseline to Day 56 and the Final Visit were compared between treatment groups using an ANCOVA model for the total index RBANS score ). The index score is a sum of the scores for each of the 5 individual domains (immediate memory, visuospatial/constructional, language, attention). The minimum and maximum total index scores are 40 and 160, respectively; a higher score is better. (NCT00999167)
Timeframe: Day 56, Final Visit (D112)
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Change from Baseline to D56 (Total Score) | Change from Baseline to Final Visit (Total Score) | |
| HPN-100 | -0.5 | -10.7 |
| Placebo | 3.2 | -9.7 |
Part A: The rate of AEs and tolerability of 6 mL and 9 mL doses of HPN-100 were considered the primary safety endpoints for Part A. Safety assessments included adverse events, laboratory tests (including ammonia, hematology, coagulation, liver function and serum chemistry parameters), vital signs, physical and neurological examinations, and electrocardiograms. (NCT00999167)
Timeframe: Part A: 28 days
| Intervention | Subjects (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any AE | Gastrointestinal disorders | Metabolism and nutrition disorders | Infection and infestations | Nervous system disorders | Blood and lymphatic system disorders | Injury, poisoning and procedural complications | Musculoskeletal and connective tissue disorders | Psychiatric disorders | Any SAE | Death | |
| HPN-100 BID | 11 | 9 | 7 | 4 | 4 | 2 | 2 | 2 | 2 | 5 | 2 |
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
| Intervention | Percent Change (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 41.2 |
| Maximum Dose Level 6.65 g/24h | 16.6 |
| Maximum Dose Level 10 g/24h | 41.8 |
| Maximum Dose Level 20g/24h | 38.4 |
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
| Intervention | micrograms per millileter (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 65.6 |
| Maximum Dose Level 6.65 g/24h | 32.2 |
| Maximum Dose Level 10 g/24h | 33.4 |
| Maximum Dose Level 20g/24h | 104.9 |
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 23.8 |
| Maximum Dose Level 6.65 g/24h | 24.0 |
| Maximum Dose Level 10 g/24h | 24.0 |
| Maximum Dose Level 20g/24h | 24.0 |
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 2.4 |
| Maximum Dose Level 6.65 g/24h | 3.2 |
| Maximum Dose Level 10 g/24h | 1.6 |
| Maximum Dose Level 20g/24h | 1.8 |
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 0 |
| Maximum Dose Level 6.65 g/24h | 0 |
| Maximum Dose Level 10 g/24h | 0 |
| Maximum Dose Level 20g/24h | 0 |
(NCT00551200)
Timeframe: during the period on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
| Intervention | participants (Number) |
|---|---|
| Buphenyl | 7 |
| HPN-100 | 5 |
(NCT00551200)
Timeframe: during the period subjects on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
| Intervention | participants (Number) |
|---|---|
| Buphenyl | 1 |
| HPN-100 | 0 |
(NCT00551200)
Timeframe: End of Study
| Intervention | participants (Number) | |
|---|---|---|
| prefer Buphenyl | prefer HPN-100 | |
| Buphenyl to HPN-100 | 1 | 9 |
measured AUC0-24 (Area under the curve from time 0 (pre-dose) to 24 hours) for each metabolite in plasma. Data were collected at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post-first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone)
| Intervention | μg*h/mL (Mean) | ||
|---|---|---|---|
| AUC0-24 PBA (phenylbutyrate) in plasma | AUC0-24 PAA (phenylacetate) in plasma | AUC0-24 PAGN (phenylacetylglutamine) in plasma | |
| HPN-100 Steady State | 540 | 575 | 1098 |
| NaPBA Steady State | 740 | 596 | 1133 |
Data were collected at pre-first dose and at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone), and at steady state (1 week) after each dose escalation
| Intervention | μmol/L (Mean) | |
|---|---|---|
| in peak | in TNAUC (time-normalized area under the curve) | |
| HPN-100 Steady State | 56.3 | 26.5 |
| NaPBA Steady State | 79.1 | 38.4 |
99 reviews available for ammonium hydroxide and Hyperammonemia
| Article | Year |
|---|---|
Hyperammonemia in Inherited Metabolic Diseases.
Topics: Ammonia; Fatty Acids; Humans; Hyperammonemia; Infant, Newborn; Metabolic Diseases; Urea | 2022 |
Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends.
Topics: Adult; Ammonia; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Sarcopenia | 2022 |
A review of basic to clinical studies of the association between hyperammonemia, methamphetamine.
Topics: Ammonia; Animals; Central Nervous System Stimulants; Glutamic Acid; Hyperammonemia; Methamphetamine | 2022 |
Recommendations for the Diagnosis and Therapeutic Management of Hyperammonaemia in Paediatric and Adult Patients.
Topics: Adult; Aged; Ammonia; Child; Humans; Hyperammonemia; Liver Diseases; Prognosis; Renal Dialysis | 2022 |
Risk factors and outcome of hyperammonaemia in people with epilepsy.
Topics: Adult; Ammonia; Epilepsy; Humans; Hyperammonemia; Observational Studies as Topic; Oxcarbazepine; Ris | 2022 |
Hyperammonemia in a pregnant woman with citrullinemia type I: a case report and literature review.
Topics: Adult; Amino Acids; Ammonia; Citrullinemia; Female; Humans; Hyperammonemia; Pregnancy; Pregnant Wome | 2022 |
Cellular Pathogenesis of Hepatic Encephalopathy: An Update.
Topics: Ammonia; Autophagy; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Failure | 2023 |
Ammonia and nutritional therapy in the critically ill: when to worry, when to test and how to treat?
Topics: Ammonia; Critical Illness; Humans; Hyperammonemia; Nutrition Therapy; Nutritional Support | 2023 |
Drug-induced hyperammonaemia.
Topics: Ammonia; Brain; Child; Humans; Hyperammonemia; Valproic Acid | 2023 |
Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
Topics: Adult; Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risk Factors; Topiramate; Valproi | 2023 |
Expanding the Spectrum of Extracorporeal Strategies in Small Infants with Hyperammonemia.
Topics: Acute Kidney Injury; Adolescent; Ammonia; Child; Child, Preschool; Continuous Renal Replacement Ther | 2023 |
[Molecular basis of hyperammonemia secondary to asparaginase: from therapeutic efficacity to toxicity].
Topics: Ammonia; Antineoplastic Agents; Asparaginase; Humans; Hyperammonemia; Precursor Cell Lymphoblastic L | 2023 |
Zinc and protein metabolism in chronic liver diseases.
Topics: Amino Acids, Branched-Chain; Ammonia; Chronic Disease; Dietary Supplements; Humans; Hyperammonemia; | 2020 |
Astrocyte swelling in hepatic encephalopathy: molecular perspective of cytotoxic edema.
Topics: Ammonia; Astrocytes; Brain; Brain Edema; Cell Size; Hepatic Encephalopathy; Humans; Hyperammonemia; | 2020 |
Skeletal Muscle and the Effects of Ammonia Toxicity in Fish, Mammalian, and Avian Species: A Comparative Review Based on Molecular Research.
Topics: Ammonia; Animals; Birds; Fishes; Hyperammonemia; Liver Cirrhosis; Mammals; Muscle Development; Muscl | 2020 |
Novel aspects of glutamine synthetase in ammonia homeostasis.
Topics: Ammonia; Animals; Brain; Brain Diseases; Glutamate-Ammonia Ligase; Glutamic Acid; Glutamine; Homeost | 2020 |
Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature.
Topics: Amino-Acid N-Acetyltransferase; Ammonia; Humans; Hyperammonemia; Infant, Newborn; Urea Cycle Disorde | 2020 |
Primary hyperammonaemia: Current diagnostic and therapeutic strategies.
Topics: Ammonia; Early Diagnosis; Female; Humans; Hyperammonemia; Infant; Infant, Newborn; Male; Renal Dialy | 2020 |
Extracorporeal Ammonia Clearance for Hyperammonemia in Critically Ill Patients: A Scoping Review.
Topics: Ammonia; Continuous Renal Replacement Therapy; Critical Illness; Humans; Hyperammonemia; Peritoneal | 2021 |
Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis.
Topics: Ammonia; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis | 2021 |
Nonhepatic hyperammonemic encephalopathy complications following bariatric surgery: a case report and review of the literature.
Topics: Adult; Ammonia; Bariatric Surgery; Female; Humans; Hyperammonemia; Obesity; Urea Cycle Disorders, In | 2021 |
Roles of Glutamate and Glutamine Transport in Ammonia Neurotoxicity: State of the Art and Question Marks.
Topics: Amino Acid Transport System X-AG; Amino Acid Transport Systems; Amino Acid Transport Systems, Neutra | 2018 |
The Pharmabiotic Approach to Treat Hyperammonemia.
Topics: Ammonia; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease M | 2018 |
Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders.
Topics: Ammonia; Emergency Treatment; Humans; Hyperammonemia; Infant; Infant, Newborn; Urea; Urea Cycle Diso | 2018 |
The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders.
Topics: Age of Onset; Ammonia; Humans; Hyperammonemia; Infant, Newborn; Renal Dialysis; Treatment Outcome; U | 2018 |
Why and when to measure ammonemia in cirrhosis?
Topics: Ammonia; Diagnosis, Differential; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; L | 2018 |
Blood Ammonia as a Possible Etiological Agent for Alzheimer's Disease.
Topics: Alzheimer Disease; Ammonia; Amyloid beta-Peptides; Diet, Mediterranean; Humans; Hyperammonemia; Lact | 2018 |
Lesson of the month 1: Sodium valproate-induced encephalopathy.
Topics: Aged; Ammonia; Anticonvulsants; Brain Diseases; Carnitine; Consciousness Disorders; Epilepsy; Humans | 2018 |
Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories.
Topics: Ammonia; Glucose; Glutamates; Humans; Hyperammonemia; Propionic Acidemia | 2018 |
Ammonia and autophagy: An emerging relationship with implications for disorders with hyperammonemia.
Topics: Ammonia; Animals; Autophagy; Glutamate-Ammonia Ligase; Glutamine; Homeostasis; Humans; Hyperammonemi | 2019 |
Comprehensive characterization of ureagenesis in the spf
Topics: Age Factors; Aging; Ammonia; Animals; Disease Models, Animal; Humans; Hyperammonemia; Liver; Male; M | 2019 |
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Topics: Aged; Ammonia; Anticonvulsants; Biomarkers; Cardiomyopathies; Carnitine; Consciousness Disorders; Ep | 2019 |
L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
Topics: Ammonia; Dipeptides; End Stage Liver Disease; Humans; Hyperammonemia; Liver; Sarcopenia; Treatment O | 2019 |
Hyperammonemia, the Last Indication of High-Volume Hemodiafiltration in Adult and Children: A Structured Review.
Topics: Adult; Ammonia; Child; Hemodiafiltration; Humans; Hyperammonemia; Prognosis | 2019 |
Clinical and biochemical aspects of primary and secondary hyperammonemic disorders.
Topics: Amino-Acid N-Acetyltransferase; Ammonia; Animals; Glutamate-Ammonia Ligase; Humans; Hyperammonemia; | 2013 |
Contributions of microdialysis to new alternative therapeutics for hepatic encephalopathy.
Topics: Ammonia; Animals; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver; Liver Cirrhosis; Microdialy | 2013 |
Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.
Topics: Amino Acids, Branched-Chain; Ammonia; Brain; Critical Illness; Drug Interactions; Enterocytes; Gluta | 2014 |
α-Ketoglutaramate: an overlooked metabolite of glutamine and a biomarker for hepatic encephalopathy and inborn errors of the urea cycle.
Topics: Amidohydrolases; Aminohydrolases; Ammonia; Animals; Biomarkers; Carbon; Glutamine; Hepatic Encephalo | 2014 |
Treatment of hyperammonemia in liver failure.
Topics: Ammonia; Brain; Glycerol; Hepatic Encephalopathy; Humans; Hyperammonemia; Lactulose; Phenylbutyrates | 2014 |
Cerebral effects of ammonia in liver disease: current hypotheses.
Topics: Ammonia; Animals; Astrocytes; Blood-Brain Barrier; Brain Edema; Diffusion; Energy Metabolism; gamma- | 2014 |
Measurement and interpretation of plasma ammonia.
Topics: Ammonia; Chronic Disease; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Diseases | 2014 |
Pharmacotherapy for hyperammonemia.
Topics: Ammonia; Animals; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Hyperammonemia; Lactulose | 2014 |
Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy.
Topics: Amino Acids, Aromatic; Amino Acids, Branched-Chain; Ammonia; Brain; Dietary Proteins; Glutamine; Hep | 2015 |
Ammonia metabolism and hyperammonemic disorders.
Topics: Ammonia; Animals; Arginine; Biological Transport; Brain; Cell Membrane; Humans; Hyperammonemia; Hype | 2014 |
Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy.
Topics: Ammonia; Clinical Protocols; Hepatic Encephalopathy; Humans; Hyperammonemia | 2015 |
Recent advances in the treatment of hyperammonemia.
Topics: Ammonia; Animals; Humans; Hyperammonemia; Inactivation, Metabolic | 2015 |
Clinical science workshop: targeting the gut-liver-brain axis.
Topics: Ammonia; Animals; Anti-Inflammatory Agents; Brain; Drug Delivery Systems; Education; Gastrointestina | 2016 |
The Importance of Clinical Context When Interpreting Serum Ammonia Levels: A Teachable Moment.
Topics: Adult; Ammonia; Diagnosis, Differential; Fatty Liver; Humans; Hyperammonemia; Male | 2015 |
Roles of renal ammonia metabolism other than in acid-base homeostasis.
Topics: Acid-Base Equilibrium; Ammonia; Humans; Hyperammonemia; Hypokalemia; Kidney Tubules, Collecting; Kid | 2017 |
The Role of RRT in Hyperammonemic Patients.
Topics: Adult; Ammonia; Brain Diseases; Humans; Hyperammonemia; Infant, Newborn; Renal Replacement Therapy | 2016 |
Multifactorial Effects on Different Types of Brain Cells Contribute to Ammonia Toxicity.
Topics: Ammonia; Animals; Astrocytes; Brain; Cyclic GMP; Energy Metabolism; Glutamine; Hepatic Encephalopath | 2017 |
Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
Topics: Ammonia; Animals; Glutamate-Ammonia Ligase; Health Knowledge, Attitudes, Practice; Hepatic Encephalo | 2016 |
Ammonia toxicity: from head to toe?
Topics: Ammonia; Animals; Brain; Brain Chemistry; Hepatic Encephalopathy; Humans; Hyperammonemia; Muscle, Sk | 2017 |
The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema.
Topics: Ammonia; Animals; Brain; Brain Edema; Hepatic Encephalopathy; Humans; Hyperammonemia; Intracranial H | 2009 |
Gut ammonia production and its modulation.
Topics: Ammonia; Animals; Genetic Predisposition to Disease; Glutaminase; Glutamine; Hepatic Encephalopathy; | 2009 |
Interorgan ammonia trafficking in liver disease.
Topics: Amino Acids; Ammonia; Animals; Brain; Glutamine; Humans; Hyperammonemia; Intestinal Mucosa; Intestin | 2009 |
Identifying the direct effects of ammonia on the brain.
Topics: Adenosine Triphosphatases; Ammonia; Animals; Brain; Cation Transport Proteins; Cell Membrane; Hepati | 2009 |
Ammonia toxicity and its prevention in inherited defects of the urea cycle.
Topics: Adult; Ammonia; Animals; Arginine; Genetic Therapy; Humans; Hyperammonemia; Ornithine Carbamoyltrans | 2009 |
Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.
Topics: Adipose Tissue; Amino Acids; Ammonia; Arginine; Brain; Dipeptides; Glutamate-Ammonia Ligase; Glutami | 2011 |
Adult nonhepatic hyperammonemia: a case report and differential diagnosis.
Topics: Ammonia; Diagnosis, Differential; Humans; Hyperammonemia; Liver Diseases; Male; Metabolism, Inborn E | 2010 |
Clinical practice: the management of hyperammonemia.
Topics: Amino Acids; Ammonia; Child; Diagnosis, Differential; Humans; Hyperammonemia; Practice Guidelines as | 2011 |
Noncirrhotic hyperammonaemic encephalopathy.
Topics: Adult; Ammonia; Biomarkers; Brain Diseases, Metabolic; Early Diagnosis; Humans; Hyperammonemia; Live | 2011 |
Alterations of blood brain barrier function in hyperammonemia: an overview.
Topics: Amino Acids; Ammonia; Animals; Biological Transport; Blood-Brain Barrier; Brain; Brain Edema; Humans | 2012 |
Severe hyperammonaemia in adults not explained by liver disease.
Topics: Adult; Amino Acids; Ammonia; Biological Transport; Blood-Brain Barrier; Brain; Glutamine; Humans; Hy | 2012 |
Ammonia-lowering strategies for the treatment of hepatic encephalopathy.
Topics: Ammonia; Brain; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver | 2012 |
Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase.
Topics: Ammonia; Animals; Brain; Enzyme Inhibitors; Glutamate-Ammonia Ligase; Hepatic Encephalopathy; Homeos | 2013 |
Changes in cerebral oxidative metabolism in patients with acute liver failure.
Topics: Amino Acids; Ammonia; Animals; Brain; Brain Chemistry; Humans; Hyperammonemia; Lactic Acid; Liver Fa | 2013 |
Ammonia toxicity to the brain.
Topics: Ammonia; Animals; Brain; Brain Neoplasms; Humans; Hyperammonemia; Neuroprotective Agents | 2013 |
Pathogenesis of hepatic encephalopathy: lessons from nitrogen challenges in man.
Topics: Amino Acids; Ammonia; Animals; Colon; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Nit | 2013 |
Valproate-induced hyperammonaemia superimposed upon severe neuropsychiatric lupus: a case report and review of the literature.
Topics: Ammonia; Antimanic Agents; Fatal Outcome; Female; Humans; Hyperammonemia; Lupus Vasculitis, Central | 2013 |
Branched-chain amino acids and muscle ammonia detoxification in cirrhosis.
Topics: Amino Acids, Branched-Chain; Ammonia; Animals; Humans; Hyperammonemia; Liver Cirrhosis; Liver Diseas | 2013 |
Role of branched chain amino acids in cerebral ammonia homeostasis related to hepatic encephalopathy.
Topics: Amino Acids, Branched-Chain; Ammonia; Animals; Citric Acid Cycle; Energy Metabolism; Hepatic Encepha | 2013 |
Neurobiology of ammonia.
Topics: Ammonia; Brain; Humans; Hyperammonemia | 2002 |
Mechanisms of hyperammonemia.
Topics: Amino Acids; Ammonia; Animals; Brain; Hepatic Encephalopathy; Humans; Hyperammonemia | 2002 |
Hepatic encephalopathy and Helicobacter pylori: a critical reappraisal.
Topics: Ammonia; Animals; Case-Control Studies; Gastric Juice; Helicobacter pylori; Hepatic Encephalopathy; | 2003 |
[Hepatic encephalopathy].
Topics: Ammonia; Biomarkers; Dementia; Diagnosis, Differential; Electroencephalography; Hepatic Encephalopat | 2004 |
[Chronic portal-systemic encephalopathy].
Topics: Ammonia; Biomarkers; Chronic Disease; Dementia; Diagnosis, Differential; Diagnostic Imaging; Hepatic | 2004 |
Helicobacter pylori and hepatic encephalopathy.
Topics: Ammonia; Gastric Juice; Helicobacter Infections; Helicobacter pylori; Hepatic Encephalopathy; Humans | 2003 |
Hyperinsulinism/hyperammonemia syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolism.
Topics: Adolescent; Ammonia; Animals; Female; Glutamate Dehydrogenase; Humans; Hyperammonemia; Hyperinsulini | 2004 |
Ammonia toxicity to the brain and creatine.
Topics: Ammonia; Animals; Brain Chemistry; Creatine; Culture Media, Serum-Free; Glutamic Acid; Hyperammonemi | 2004 |
[New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
Topics: Ammonia; Brain; Brain Edema; Dipeptides; Flumazenil; Glutaminase; Glutamine; Hepatic Encephalopathy; | 2004 |
[Hyperammonemia: causes, diagnosis and therapy. 2. Symptoms and therapy].
Topics: Ammonia; Anticonvulsants; Aspirin; Diagnosis, Differential; Diuretics; Humans; Hyperammonemia; Progn | 2004 |
Ammonia neurotoxicity and the mitochondrial permeability transition.
Topics: Ammonia; Animals; Apoptosis; Astrocytes; Cell Membrane; Cell Membrane Permeability; Hepatic Encephal | 2004 |
Cerebral metabolic disturbances in the brain during acute liver failure: from hyperammonemia to energy failure and proteolysis.
Topics: Ammonia; Animals; Astrocytes; Cerebral Cortex; Citric Acid Cycle; Hepatic Encephalopathy; Humans; Hy | 2005 |
Endogenous neuro-protectants in ammonia toxicity in the central nervous system: facts and hypotheses.
Topics: Ammonia; Animals; Antidotes; Excitatory Amino Acid Antagonists; Glutathione; Humans; Hyperammonemia; | 2005 |
Effect of ammonia on astrocytic glutamate uptake/release mechanisms.
Topics: Ammonia; Animals; Astrocytes; Brain; Calcium; Cell Size; Cells, Cultured; Excitatory Amino Acid Tran | 2006 |
[Disturbances in ammonia metabolism in hepatic failure].
Topics: Ammonia; Animals; Brain; Hepatic Encephalopathy; Humans; Hyperammonemia; Intestinal Mucosa; Kidney; | 2007 |
The anaplerotic flux and ammonia detoxification in hepatic encephalopathy.
Topics: Ammonia; Animals; Astrocytes; Brain; Citric Acid Cycle; Energy Metabolism; Glucose; Glutamine; Hepat | 2007 |
Hyperammonemia-induced toxicity for the developing central nervous system.
Topics: Ammonia; Animals; Brain; Brain Diseases, Metabolic, Inborn; Cerebral Palsy; Child; Energy Metabolism | 2007 |
Energy metabolism in brain cells: effects of elevated ammonia concentrations.
Topics: Ammonia; Animals; Astrocytes; Brain; Citric Acid Cycle; Energy Metabolism; Glucose; Glutamic Acid; G | 2007 |
Hyperammonemia in the ICU.
Topics: Acute Disease; Algorithms; Ammonia; Astrocytes; Brain; Brain Edema; Cerebral Hemorrhage; Critical Ca | 2007 |
Nutritional management of patients with urea cycle disorders.
Topics: Adolescent; Adult; Ammonia; Child; Child, Preschool; Diet Therapy; Enzymes; Female; Humans; Hyperamm | 2007 |
Neurological implications of urea cycle disorders.
Topics: Ammonia; Brain; Cognition; Enzymes; Female; Humans; Hyperammonemia; Magnetic Resonance Imaging; Male | 2007 |
Mechanisms of brain edema in acute liver failure and impact of novel therapeutic interventions.
Topics: Ammonia; Animals; Brain; Brain Diseases, Metabolic; Brain Edema; Energy Metabolism; Glutamine; Hepat | 2007 |
Hyperammonemia in urea cycle disorders: role of the nephrologist.
Topics: Algorithms; Ammonia; Brain Diseases, Metabolic; Child, Preschool; Coma; Developmental Disabilities; | 2001 |
Ornithine aminotransferase, a potential target for the treatment of hyperammonemias.
Topics: Ammonia; Animals; Biogenic Polyamines; Brain; Chorioretinitis; Enzyme Inhibitors; Humans; Hyperammon | 2000 |
Glutamate transporter and receptor function in disorders of ammonia metabolism.
Topics: Adenosine Triphosphate; Amino Acid Transport System X-AG; Ammonia; Apoptosis; Astrocytes; Binding Si | 2001 |
Role of glutamine in cerebral nitrogen metabolism and ammonia neurotoxicity.
Topics: Ammonia; Astrocytes; Brain; Cerebrovascular Circulation; Glutamic Acid; Glutamine; Humans; Hyperammo | 2001 |
Urea cycle disorders.
Topics: Ammonia; Diagnosis, Differential; Emergency Treatment; Humans; Hyperammonemia; Infant, Newborn; Pren | 2002 |
25 trials available for ammonium hydroxide and Hyperammonemia
| Article | Year |
|---|---|
The effect of induced hyperammonaemia on sleep and melanopsin-mediated pupillary light response in patients with liver cirrhosis: A single-blinded randomized crossover trial.
Topics: Amino Acids; Ammonia; Circadian Rhythm; Cross-Over Studies; Glucose; Humans; Hyperammonemia; Liver C | 2022 |
Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.
Topics: Ammonia; Hepatic Encephalopathy; Humans; Hyperammonemia; Lactulose; Liver Cirrhosis; Male; Phenylbut | 2023 |
Intrahepatic Administration of Human Liver Stem Cells in Infants with Inherited Neonatal-Onset Hyperammonemia: A Phase I Study.
Topics: Age of Onset; Amino Acid Metabolism, Inborn Errors; Ammonia; Argininosuccinic Aciduria; Cell Differe | 2020 |
Plasma ammonia concentrations in extremely low birthweight infants in the first week after birth: secondary analysis from the ProVIDe randomized clinical trial.
Topics: Ammonia; Birth Weight; Data Interpretation, Statistical; Female; Gestational Age; Humans; Hyperammon | 2020 |
Efficacy and Safety of Sodium Benzoate in The Management of Hyperammonemia in Decompensated Chronic Liver Disease of the Childhood-A Double-blind Randomized Controlled Trial.
Topics: Ammonia; Child; Double-Blind Method; Hepatic Encephalopathy; Humans; Hyperammonemia; Prospective Stu | 2020 |
Human heterologous liver cells transiently improve hyperammonemia and ureagenesis in individuals with severe urea cycle disorders.
Topics: Ammonia; Biomarkers; Cell Transplantation; Europe; Female; Humans; Hyperammonemia; Infant; Infant, N | 2018 |
Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED.
Topics: Adult; Ammonia; Biomarkers; Diuretics, Osmotic; Drug Administration Routes; End Stage Liver Disease; | 2018 |
Optimal Prescriptions of Continuous Renal Replacement Therapy in Neonates with Hyperammonemia.
Topics: Ammonia; Asian People; Female; Humans; Hyperammonemia; Infant, Newborn; Infant, Newborn, Diseases; M | 2019 |
An engineered
Topics: Ammonia; Animals; Arginine; Biosynthetic Pathways; Disease Models, Animal; Escherichia coli; Feces; | 2019 |
Efficacy of orally administered sodium benzoate and sodium phenylbutyrate in dogs with congenital portosystemic shunts.
Topics: Ammonia; Animals; Bile Acids and Salts; Cross-Over Studies; Dogs; Double-Blind Method; Female; Hyper | 2019 |
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Double-Blind Method; Female; Glutamine; Glycerol; Hepatic Encephalopathy; Huma | 2014 |
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Double-Blind Method; Female; Glutamine; Glycerol; Hepatic Encephalopathy; Huma | 2014 |
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Double-Blind Method; Female; Glutamine; Glycerol; Hepatic Encephalopathy; Huma | 2014 |
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Double-Blind Method; Female; Glutamine; Glycerol; Hepatic Encephalopathy; Huma | 2014 |
Glutamine and hyperammonemic crises in patients with urea cycle disorders.
Topics: Adolescent; Adult; Ammonia; Biomarkers; Child; Child, Preschool; Fasting; Female; Glutamine; Glycero | 2016 |
Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study.
Topics: Amino Acid Metabolism, Inborn Errors; Ammonia; Female; Glutamates; Humans; Hyperammonemia; Infant, N | 2016 |
Ammonia impairs neutrophil phagocytic function in liver disease.
Topics: Amino Acids; Ammonia; Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Double-Blind | 2008 |
L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Cognition; Dipeptides; Female; Health Status Indicators; Hepatic Encephalopath | 2008 |
Hyperammonemia following intravenous valproate loading.
Topics: Adult; Aged; Ammonia; Analysis of Variance; Anticonvulsants; Bilirubin; Dose-Response Relationship, | 2009 |
The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Topics: Adolescent; Ammonia; Anticonvulsants; Carnitine; Child; Epilepsy; Female; Humans; Hyperammonemia; Ma | 2009 |
Overnight glucose infusion suppresses renal ammoniagenesis and reduces hyperammonaemia induced by a simulated bleed in cirrhotic patients.
Topics: Aged; Amino Acids; Ammonia; Cross-Over Studies; Fasting; Female; Gastrointestinal Hemorrhage; Glucag | 2012 |
The dysfunction of ammonia in heart failure increases with an increase in the intensity of resistance exercise, even with the use of appropriate drug therapy.
Topics: Adult; Ammonia; Biomarkers; Brazil; Cardiovascular Agents; Cross-Over Studies; Heart Failure; Humans | 2014 |
Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis.
Topics: Amino Acids; Ammonia; Body Water; Brain; Female; Glutamine; Hemoglobins; Humans; Hyperammonemia; Mag | 2003 |
Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia.
Topics: Adult; Aged; Amino Acids; Ammonia; Basal Ganglia; Brain Chemistry; Choline; Creatinine; Female; Glut | 2004 |
Environmental heat stress, hyperammonemia and nucleotide metabolism during intermittent exercise.
Topics: Adult; Ammonia; Environment, Controlled; Exercise; Heat Stress Disorders; Heat-Shock Response; Human | 2006 |
Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency.
Topics: Age of Onset; Amino Acids; Ammonia; Analysis of Variance; Arginine; Biomarkers; Blood Proteins; Body | 2006 |
Role of ammonia and inflammation in minimal hepatic encephalopathy.
Topics: Adult; Aged; Amino Acids; Ammonia; Biomarkers; C-Reactive Protein; Female; Hepatic Encephalopathy; H | 2007 |
Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Amino Acid Metabolism, Inborn Errors; Ammonia; Carbamo | 2007 |
362 other studies available for ammonium hydroxide and Hyperammonemia
| Article | Year |
|---|---|
Saul Brusilow: Understanding and treating diseases of ammonia toxicity.
Topics: Ammonia; Animals; Hepatic Encephalopathy; History, 20th Century; History, 21st Century; Humans; Hype | 2022 |
Glutaminase 2 knockdown reduces hyperammonemia and associated lethality of urea cycle disorder mouse model.
Topics: Ammonia; Animals; Disease Models, Animal; Glutaminase; Glutamine; Humans; Hyperammonemia; Liver; Mic | 2022 |
Ammonia Clearance with Different Continuous Renal Replacement Therapy Techniques in Patients with Liver Failure.
Topics: Acute Kidney Injury; Adult; Ammonia; Continuous Renal Replacement Therapy; Creatinine; Humans; Hyper | 2022 |
Treatment of Hyperammonemia by Transplanting a Symbiotic Pair of Intestinal Microbes.
Topics: Ammonia; Animals; Hyperammonemia; Limosilactobacillus reuteri; Mice; Probiotics | 2021 |
Interorgan amino acid interchange in propionic acidemia: the missing key to understanding its physiopathology.
Topics: Alanine; Amino Acid Metabolism, Inborn Errors; Amino Acids; Ammonia; Glutamine; Humans; Hyperammonem | 2022 |
Contribution of Uremia to
Topics: Ammonia; Animals; Humans; Hyperammonemia; Immunocompromised Host; Lung; Lung Transplantation; Mice; | 2022 |
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases.
Topics: Ammonia; Brain Diseases; Hepatic Insufficiency; Humans; Hyperammonemia; Liver Neoplasms; Neuroendocr | 2022 |
Desflurane and remifentanil anesthesia in a child with citrin deficiency: A case report.
Topics: Ammonia; Anesthesia, General; Arginine; Blepharoplasty; Calcium-Binding Proteins; Child, Preschool; | 2022 |
Multisite Retrospective Review of Outcomes in Renal Replacement Therapy for Neonates with Inborn Errors of Metabolism.
Topics: Ammonia; Child; Humans; Hyperammonemia; Infant, Newborn; Metabolism, Inborn Errors; Renal Replacemen | 2022 |
Association Between Continuous Kidney Replacement Therapy Clearance and Outcome in Pediatric Patients With Hyperammonemia Not Due to Inborn Error of Metabolism.
Topics: Adult; Ammonia; Brain Edema; Child; Continuous Renal Replacement Therapy; Humans; Hyperammonemia; Re | 2022 |
Ammonia induces amyloidogenesis in astrocytes by promoting amyloid precursor protein translocation into the endoplasmic reticulum.
Topics: Alzheimer Disease; Ammonia; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor | 2022 |
Low cerebral energy metabolism in hepatic encephalopathy reflects low neuronal energy demand. Role of ammonia-induced increased GABAergic tone.
Topics: Ammonia; Brain; Energy Metabolism; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Neuron | 2022 |
Sex is associated with differences in oxidative stress and susceptibility to severe hepatic encephalopathy in bile-duct ligated rats.
Topics: Allopurinol; Ammonia; Animals; Bile; Disease Models, Animal; Female; Hepatic Encephalopathy; Hyperam | 2022 |
Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Lamotrigine; Risk Factors; Seizures; Tri | 2022 |
Establishment of hyperammonemia mode in yellow catfish and the mitigation of exogenous L-ornithine-L-aspartate.
Topics: Ammonia; Animals; Catfishes; Dipeptides; Hyperammonemia; Sodium Chloride | 2022 |
Moving towards a novel therapeutic strategy for hyperammonemia that targets glutamine metabolism.
Topics: Ammonia; Animals; Fibroblasts; Glutamate Dehydrogenase; Glutamine; Hyperammonemia; Mice; Ornithine; | 2022 |
Multiple Myeloma with Hyperammonemia Treated with Novel Agents: A Case Series of Three Patients.
Topics: Ammonia; Consciousness Disorders; Humans; Hyperammonemia; Multiple Myeloma | 2023 |
Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
Topics: Ammonia; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Hospit | 2022 |
HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY.
Topics: Ammonia; Anticonvulsants; Cognitive Dysfunction; Dementia; Epilepsy; Female; Humans; Hyperammonemia; | 2022 |
Multiple Asparaginase Infusions Cause Increasingly Severe Acute Hyperammonemia.
Topics: Ammonia; Animals; Antineoplastic Agents; Asparaginase; Hyperammonemia; Precursor Cell Lymphoblastic | 2022 |
O-GlcNAcylation enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis.
Topics: Acetylglucosamine; Ammonia; Animals; Biocatalysis; Carbamoyl-Phosphate Synthase (Ammonia); Disease M | 2022 |
Clinical findings of patients with hyperammonemia affected by urea cycle disorders with hepatic encephalopathy.
Topics: Ammonia; Hepatic Encephalopathy; Humans; Hyperammonemia; Ornithine Carbamoyltransferase Deficiency D | 2022 |
A mouse model of hepatic encephalopathy: bile duct ligation induces brain ammonia overload, glial cell activation and neuroinflammation.
Topics: Ammonia; Animals; Bile Acids and Salts; Bile Ducts; Brain; Choline; Disease Models, Animal; Glutamin | 2022 |
Hypokalaemia - an active contributor to hepatic encephalopathy?
Topics: Ammonia; Hepatic Encephalopathy; Humans; Hyperammonemia; Hypokalemia; Liver Cirrhosis; Potassium | 2023 |
Hyperammonaemia disrupts daily rhythms reversibly by elevating glutamate in the central circadian pacemaker.
Topics: Ammonia; Animals; Circadian Rhythm; Excitatory Amino Acid Antagonists; Glutamic Acid; Hyperammonemia | 2023 |
Late-Onset Ornithine Transcarbamylase Deficiency Complicated with Extremely High Serum Ammonia Level: Prompt Induction of Hemodialysis as the Key to Successful Treatment.
Topics: Adult; Ammonia; Child; Humans; Hyperammonemia; Infant; Male; Ornithine Carbamoyltransferase; Ornithi | 2022 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
The trend of ammonia levels in patients with glufosinate ammonium poisoning with respect to neurotoxicity.
Topics: Aminobutyrates; Ammonia; Herbicides; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Hyperammonemia in a septic patient with Ureaplasma parvum arthritis: a case report.
Topics: Aged; Ammonia; Anti-Bacterial Agents; Arthritis, Infectious; Humans; Hyperammonemia; Male; Ureaplasm | 2022 |
UK National audit of the measurement of ammonia.
Topics: Ammonia; Humans; Hyperammonemia; Laboratories; Surveys and Questionnaires; United Kingdom | 2023 |
Curcumin-resveratrol nano-formulation counteracting hyperammonemia in rats.
Topics: Ammonia; Animals; Child; Curcumin; Dietary Proteins; Humans; Hyperammonemia; Male; Rats; Resveratrol | 2023 |
Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
Topics: Ammonia; Anticonvulsants; Carnitine; Dietary Supplements; Drug Overdose; Drug-Related Side Effects a | 2023 |
Acute onset of ornithine transcarbamylase deficiency after total anomalous pulmonary venous connection repair to a 2-day-old neonate.
Topics: Ammonia; Humans; Hyperammonemia; Infant, Newborn; Male; Ornithine Carbamoyltransferase Deficiency Di | 2023 |
Hyperammonemia induces microglial NLRP3 inflammasome activation via mitochondrial oxidative stress in hepatic encephalopathy.
Topics: Ammonia; Animals; Hepatic Encephalopathy; Hyperammonemia; Inflammasomes; Lipopolysaccharides; Mice; | 2023 |
Methamphetamine-induced encephalopathy in the absence of hyperammonemia.
Topics: Ammonia; Brain Diseases; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adver | 2023 |
Feline hyperammonemia associated with functional cobalamin deficiency: A case report.
Topics: Amino Acids; Ammonia; Animals; Cat Diseases; Cats; Female; Hyperammonemia; Methylmalonic Acid; Urea; | 2023 |
[Expert consensus on the diagnosis and treatment of neonatal hyperammonemia].
Topics: Ammonia; China; Consensus; Humans; Hyperammonemia; Infant, Newborn | 2023 |
The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis.
Topics: Ammonia; Brain; Fibrosis; Gastrointestinal Microbiome; Hepatic Encephalopathy; Humans; Hyperammonemi | 2023 |
Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia.
Topics: Ammonia; Antineoplastic Agents; Asparaginase; Child; Glutamine; Humans; Hyperammonemia; Phenylbutyra | 2023 |
An orally deliverable ornithine-based self-assembling polymer nanomedicine ameliorates hyperammonemia in acetaminophen-induced acute liver injury.
Topics: Acetaminophen; Ammonia; Animals; Hyperammonemia; Liver; Mice; Nanomedicine; Ornithine; Polyethylene | 2023 |
Relationship between longitudinal changes in neuropsychological outcome and disease biomarkers in urea cycle disorders.
Topics: Ammonia; Biomarkers; Glutamine; Humans; Hyperammonemia; Longitudinal Studies; Neuropsychological Tes | 2023 |
Hyperammonemia induced gut microbiota dysbiosis and motor coordination disturbances in mice: new insight into gut‑brain axis involvement in hepatic encephalopathy.
Topics: Ammonia; Animals; Brain-Gut Axis; Dysbiosis; Gastrointestinal Microbiome; Hepatic Encephalopathy; Hy | 2023 |
The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study.
Topics: Alanine; Ammonia; Animals; Arginine; Brain; Citrulline; gamma-Aminobutyric Acid; Glutamic Acid; Glut | 2023 |
L-Isoleucine reverses hyperammonemia-induced myotube mitochondrial dysfunction and post-mitotic senescence.
Topics: Amino Acids, Branched-Chain; Ammonia; Animals; Humans; Hyperammonemia; Induced Pluripotent Stem Cell | 2024 |
Malnutrition-related hyperammonemic encephalopathy presenting with burst suppression: a case report.
Topics: Aged, 80 and over; Ammonia; Brain Diseases; Coma; Electroencephalography; Humans; Hyperammonemia; Ma | 2019 |
Poly(ornithine)-based self-assembling drug for recovery of hyperammonemia and damage in acute liver injury.
Topics: Acetaminophen; Ammonia; Animals; Cattle; Cell Survival; Chemical and Drug Induced Liver Injury; Chon | 2019 |
Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency.
Topics: Ammonia; Animals; Arginase; Arginine; Codon; Disease Models, Animal; Glutamine; Hyperammonemia; Hype | 2019 |
Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy.
Topics: Aged; Amino Acids; Ammonia; Female; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; | 2019 |
Adult onset type II citrullinemia--a great masquerader.
Topics: Ammonia; Brain Diseases; Citrullinemia; Humans; Hyperammonemia; Liver Transplantation; Magnetic Reso | 2020 |
The Toll of Hyperammonemia on the Brain.
Topics: Ammonia; Brain; Brain Edema; Humans; Hyperammonemia; Macrophages; T-Lymphocytes; Toll-Like Receptor | 2019 |
Valproicacid-induced hyperammonemic encephalopathy in the emergency department.
Topics: Ammonia; Anticonvulsants; Brain Diseases, Metabolic; Female; Humans; Hyperammonemia; Middle Aged; Re | 2019 |
Comparative accuracy and precision of two commercial laboratory analyzers for the quantification of ammonia in cerebrospinal fluid.
Topics: Ammonia; Animals; Blood Chemical Analysis; Hepatic Encephalopathy; Horse Diseases; Horses; Hyperammo | 2020 |
An Investigation of PS-b-PEO Polymersomes for the Oral Treatment and Diagnosis of Hyperammonemia.
Topics: Administration, Oral; Ammonia; Animals; Bile Ducts; Body Fluids; Hydrogels; Hyperammonemia; Ligation | 2019 |
Characteristics and outcomes of critically ill patients with severe hyperammonemia.
Topics: Acute-On-Chronic Liver Failure; Adult; Ammonia; Brain Edema; Critical Illness; Female; Humans; Hyper | 2020 |
Correction and Control of Hyperammonemia in Acute Liver Failure: The Impact of Continuous Renal Replacement Timing, Intensity, and Duration.
Topics: Adult; Age Factors; Ammonia; APACHE; Body Weight; Continuous Renal Replacement Therapy; Female; Huma | 2020 |
Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Ammonia; Arteriovenous M | 2020 |
5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Brain Diseases; Citric Acid Cycle; Dose-Response Rel | 2020 |
Hyperinsulinism hyperammonaemia (HI/HA) syndrome due to GLUD1 mutation: phenotypic variations ranging from late presentation to spontaneous resolution.
Topics: Ammonia; Blood Glucose; Child; Child, Preschool; Diazoxide; Female; Glutamate Dehydrogenase; Humans; | 2020 |
Perioperative management of children with urea cycle disorders.
Topics: Ammonia; Anesthesia, General; Child; Humans; Hyperammonemia; Prognosis; Urea Cycle Disorders, Inborn | 2020 |
Proposed Plasma Ammonia Reference Intervals in a Reference Group of Hospitalized Term and Preterm Neonates.
Topics: Ammonia; Biomarkers; Case-Control Studies; Female; Gestational Age; Humans; Hyperammonemia; Hyperbil | 2020 |
Point-of-Care Analysis of Blood Ammonia with a Gas-Phase Sensor.
Topics: Adult; Ammonia; Child; Humans; Hyperammonemia; Point-of-Care Systems | 2020 |
Clinical and biochemical characteristics of patients with ornithine transcarbamylase deficiency.
Topics: Adolescent; Adult; Ammonia; Arginine; Child; Child, Preschool; China; Creatine; Female; Humans; Hype | 2020 |
A retrospective study of adult patients with noncirrhotic hyperammonemia.
Topics: Adult; Age of Onset; Aged; Ammonia; Female; Humans; Hyperammonemia; Male; Middle Aged; Retrospective | 2020 |
Hyperammonemic Encephalopathy Exacerbated by Parenteral Nutrition in Fibrolamellar Hepatocellular Carcinoma.
Topics: Adult; Ammonia; Brain Diseases; Carcinoma, Hepatocellular; Female; Gastrointestinal Agents; Humans; | 2020 |
Preclinical evaluation of liposome-supported peritoneal dialysis for the treatment of hyperammonemic crises.
Topics: Ammonia; Animals; Ascitic Fluid; Hyperammonemia; Liposomes; Peritoneal Dialysis; Rats; Swine; Swine, | 2020 |
Ammonia inhibits energy metabolism in astrocytes in a rapid and glutamate dehydrogenase 2-dependent manner.
Topics: Amination; Amino Acids; Ammonia; Astrocytes; Cell Line, Tumor; Cell Respiration; Citric Acid Cycle; | 2020 |
Hyperammonemic Encephalopathy Associated with Perampanel: Case Report and Discussion.
Topics: Ammonia; Brain Diseases; Humans; Hyperammonemia; Neurotoxicity Syndromes; Nitriles; Pyridones | 2021 |
Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.
Topics: Aged, 80 and over; Ammonia; Antimetabolites, Antineoplastic; beta-Alanine; Drug Administration Sched | 2020 |
Transient hyperammonaemia following epileptic seizures in cats.
Topics: Ammonia; Animals; Cat Diseases; Cats; Epilepsy; Hyperammonemia; Retrospective Studies; Seizures | 2021 |
Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy.
Topics: Aged; Ammonia; Bilirubin; Body Composition; Carcinoma, Hepatocellular; Female; Hepatic Encephalopath | 2020 |
Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine.
Topics: Adult; Ammonia; Anticonvulsants; Carnitine; Cohort Studies; Dioxolanes; Epilepsies, Myoclonic; Femal | 2020 |
Glucagon Receptor Inhibition Reduces Hyperammonemia and Lethality in Male Mice with Urea Cycle Disorder.
Topics: Amino Acids; Ammonia; Animals; Antibodies, Monoclonal; Body Weight; Gene Expression Regulation; Glut | 2021 |
Nootkatone improves anxiety- and depression-like behavior by targeting hyperammonemia-induced oxidative stress in D-galactosamine model of liver injury.
Topics: Ammonia; Animals; Antidepressive Agents; Antioxidants; Anxiety; Behavior, Animal; Brain; Cell Surviv | 2021 |
Prognosis of Patients with Sepsis and Non-Hepatic Hyperammonemia: A Cohort Study.
Topics: Aged; Ammonia; APACHE; Area Under Curve; Brain Diseases; Cohort Studies; Critical Illness; Escherich | 2020 |
Bile-duct ligation renders the brain susceptible to hypotension-induced neuronal degeneration: Implications of ammonia.
Topics: Ammonia; Animals; Antigens, Nuclear; Anxiety; Apoptosis; Behavior, Animal; Bile Ducts; Caspase 3; Ce | 2021 |
Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Topics: Age of Onset; Ammonia; Child, Preschool; Female; Glycerol; Humans; Hyperammonemia; Infant; Infant, N | 2021 |
Potassium deficiency decreases the capacity for urea synthesis and markedly increases ammonia in rats.
Topics: Ammonia; Animals; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Hyperammo | 2021 |
Analysis of clinical prognosis in patients with non-hepatic hyperammonemia.
Topics: Age Factors; Aged; Ammonia; Critical Illness; Female; Humans; Hyperammonemia; Male; Middle Aged; Nom | 2021 |
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions.
Topics: Ammonia; Antineoplastic Agents; Asparaginase; Child; Drug Hypersensitivity; Humans; Hyperammonemia; | 2022 |
Oral sodium phenylbutyrate for hyperammonemia associated with congenital portosystemic shunt: a case report.
Topics: Administration, Oral; Amino Acids, Branched-Chain; Ammonia; Humans; Hyperammonemia; Infant; Male; Ph | 2021 |
Long-term outcome of urea cycle disorders: Report from a nationwide study in Japan.
Topics: Adolescent; Adult; Ammonia; Child; Child, Preschool; Female; Humans; Hyperammonemia; Japan; Liver Tr | 2021 |
Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid.
Topics: Adult; Ammonia; Anticonvulsants; Humans; Hyperammonemia; Status Epilepticus; Valproic Acid | 2021 |
Hyperammonemia in acetaminophen toxicity.
Topics: Acetaminophen; Ammonia; Animals; Hepatic Encephalopathy; Humans; Hyperammonemia; Retrospective Studi | 2022 |
Use of Lactulose to Treat Hyperammonemia in ICU Patients Without Chronic Liver Disease or Significant Hepatocellular Injury.
Topics: Adult; Ammonia; Carcinoma, Hepatocellular; Humans; Hyperammonemia; Intensive Care Units; Lactulose; | 2022 |
Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
Topics: Adult; Ammonia; Carcinoma, Hepatocellular; Cytoreduction Surgical Procedures; Hepatic Encephalopathy | 2021 |
Capecitabine-induced hyperammonemic encephalopathy.
Topics: Adenocarcinoma; Aged; Ammonia; Brain Diseases; Capecitabine; Humans; Hyperammonemia; Male; Pancreati | 2022 |
Koi sleepy disease as a pathophysiological and immunological consequence of a branchial infection of common carp with carp edema virus.
Topics: Ammonia; Animals; Carps; Edema; Fish Diseases; Hyperammonemia; Hyponatremia; Poxviridae; Poxviridae | 2021 |
Treatment of hyperammonemia using in-line renal replacement and hyperosmolar therapies within an extracorporeal membrane oxygenation circuit.
Topics: Ammonia; Brain Edema; Extracorporeal Membrane Oxygenation; Hemofiltration; Humans; Hyperammonemia; R | 2023 |
Reversible Leukoencephalopathy in a Man with Childhood-onset Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome.
Topics: Ammonia; Child; Humans; Hyperammonemia; Leukoencephalopathies; Male; Middle Aged; Ornithine; Urea Cy | 2022 |
Gait instability in valproate-treated patients: Call to measure ammonia levels.
Topics: Accidental Falls; Adult; Ammonia; Anticonvulsants; Disease Progression; Epilepsy, Frontal Lobe; Fema | 2017 |
Hyperammonemia compromises glutamate metabolism and reduces BDNF in the rat hippocampus.
Topics: Ammonia; Animals; Animals, Newborn; Astrocytes; Brain-Derived Neurotrophic Factor; Cells, Cultured; | 2017 |
TNFα induced up-regulation of Na
Topics: Ammonia; Animals; Brain; Hyperammonemia; Liver; Mice; Mice, Knockout; Receptors, Tumor Necrosis Fact | 2017 |
Refractory hepatic encephalopathy in a patient with hypothyroidism: Another element in ammonia metabolism.
Topics: Adrenergic beta-Antagonists; Alcoholism; Ammonia; Antithyroid Agents; Brain; Carbimazole; Diagnosis, | 2017 |
Lactulose decreases neuronal activation and attenuates motor behavioral deficits in hyperammonemic rats.
Topics: Ammonia; Animals; Aquaporin 4; Aspartate Aminotransferases; Behavior, Animal; Bilirubin; Creatinine; | 2017 |
Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
Topics: Acetates; Adolescent; Adult; Aged; Ammonia; Female; Glutamine; Humans; Hyperammonemia; Kidney Functi | 2018 |
Metabolically based liver damage pathophysiology in patients with urea cycle disorders - A new hypothesis.
Topics: Ammonia; Central Nervous System; Citrullinemia; Enterobacter; Fatal Outcome; Hepatocytes; Humans; Hy | 2017 |
Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
Topics: Aged; Ammonia; Biomarkers; Case-Control Studies; Female; Hepatic Encephalopathy; Hospital Mortality; | 2018 |
Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia.
Topics: Ammonia; Animals; Autophagy; Humans; Hyperammonemia; Liver; Male; Mechanistic Target of Rapamycin Co | 2018 |
Efficacy of peritoneal dialysis in neonates presenting with hyperammonaemia due to urea cycle defects and organic acidaemia.
Topics: Amino Acid Metabolism, Inborn Errors; Ammonia; Female; Humans; Hyperammonemia; Infant, Newborn; Male | 2019 |
Prenatal treatment of ornithine transcarbamylase deficiency.
Topics: Ammonia; Drug Combinations; Female; Glutamine; Humans; Hyperammonemia; Infant, Newborn; Male; Mutati | 2018 |
Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
Topics: Aged; Ammonia; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Rapid resolution of hyperammonemia in neonates using extracorporeal membrane oxygenation as a platform to drive hemodialysis.
Topics: Ammonia; Cohort Studies; Extracorporeal Membrane Oxygenation; Female; Hospitals, Pediatric; Humans; | 2018 |
Plasma ammonia concentration after L-asparaginase therapy in 27 dogs with high-grade lymphoma or leukemia.
Topics: Ammonia; Animals; Antineoplastic Agents; Asparaginase; Case-Control Studies; Dogs; Female; Humans; H | 2018 |
Liposome-supported peritoneal dialysis in the treatment of severe hyperammonemia: An investigation on potential interactions.
Topics: Acute-On-Chronic Liver Failure; Adrenergic beta-Antagonists; Ammonia; Animals; Anti-Bacterial Agents | 2018 |
Medium-chain triglycerides supplement therapy with a low-carbohydrate formula can supply energy and enhance ammonia detoxification in the hepatocytes of patients with adult-onset type II citrullinemia.
Topics: Aged; Ammonia; Argininosuccinate Synthase; Carbohydrates; Citrullinemia; Dietary Supplements; Fatty | 2018 |
Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Topics: Age Factors; Ammonia; Anticonvulsants; Aspartate Aminotransferases; Chemical and Drug Induced Liver | 2018 |
Conditional disruption of hepatic carbamoyl phosphate synthetase 1 in mice results in hyperammonemia without orotic aciduria and can be corrected by liver-directed gene therapy.
Topics: Ammonia; Animals; Carbamoyl-Phosphate Synthase (Ammonia); Carbamoyl-Phosphate Synthase I Deficiency | 2018 |
Ammonia role in glial dysfunction in methylmalonic acidemia.
Topics: Amino Acid Metabolism, Inborn Errors; Ammonia; Ammonium Chloride; Animals; Behavior, Animal; Brain; | 2018 |
An infant with hypercalcemia and hyperammonia: inborn error of metabolism or not? Answers.
Topics: Acidosis, Renal Tubular; Administration, Oral; Ammonia; Diagnosis, Differential; Exome Sequencing; F | 2019 |
Targeting autophagy for therapy of hyperammonemia.
Topics: Ammonia; Autophagy; Humans; Hyperammonemia; Liver; Urea | 2018 |
Effects of branched-chain amino acids on muscles under hyperammonemic conditions.
Topics: Amino Acids, Branched-Chain; Ammonia; Animals; Carbon Radioisotopes; Citric Acid Cycle; Glutamine; H | 2018 |
Keto analogues and amino acid supplementation and its effects on ammonaemia during extenuating endurance exercise in ketogenic diet-fed rats.
Topics: Amino Acids; Ammonia; Animals; Diet; Diet, Ketogenic; Dietary Supplements; Hyperammonemia; Keto Acid | 2018 |
Effect of dietary alanyl-glutamine dipeptide against chronic ammonia stress induced hyperammonemia in the juvenile yellow catfish (Pelteobagrus fulvidraco).
Topics: Ammonia; Animal Nutritional Physiological Phenomena; Animals; Antioxidants; Aquaculture; Catfishes; | 2018 |
The metabolic and molecular mechanisms of hyperammonaemia- and hyperethanolaemia-induced protein catabolism in skeletal muscle cells.
Topics: Ammonia; Animals; Cell Line; Cell Survival; DNA; Ethanol; Hyperammonemia; Mice; Muscle Cells; Muscle | 2018 |
The utility of EEG monitoring in neonates with hyperammonemia due to inborn errors of metabolism.
Topics: Amino Acid Metabolism, Inborn Errors; Ammonia; Argininosuccinate Synthase; Argininosuccinic Aciduria | 2018 |
Progressive resistance training prevents loss of muscle mass and strength in bile duct-ligated rats.
Topics: Ammonia; Animals; Bile Ducts; Body Composition; Disease Models, Animal; Hepatic Encephalopathy; Hype | 2019 |
Acute Presentation and Management of the Encephalopathic Child With an Undiagnosed Inborn Error of Metabolism.
Topics: Ammonia; Brain Diseases; Child; Delayed Diagnosis; Delirium; Emergency Service, Hospital; Humans; Hy | 2019 |
Acute hyperammonemia in children under deferasirox treatment: cutting the Gordian knot.
Topics: Acute Disease; Adolescent; Age Factors; Ammonia; Biomarkers; Child, Preschool; Deferasirox; Female; | 2019 |
Hyperammonemia in a Woman with Late-onset Ornithine Transcarbamylase Deficiency.
Topics: Adolescent; Amino Acids; Ammonia; Arginine; Coma; Female; Humans; Hyperammonemia; Male; Middle Aged; | 2019 |
Hyperammonaemia in Neonates and Young Children: Potential Metabolic Causes, Diagnostic Approaches and Clinical Consequences
Topics: Ammonia; Arginine; Biomarkers; Brain Diseases, Metabolic, Inborn; Carnitine; Critical Illness; Diet, | 2019 |
Hepatic glutamine synthetase augmentation enhances ammonia detoxification.
Topics: Ammonia; Animals; Carbamoyl-Phosphate Synthase (Ammonia); Carbamoyl-Phosphate Synthase I Deficiency | 2019 |
Influence of implementing a protocol for an intravenously administered ammonia scavenger on the management of acute hyperammonemia in a pediatric intensive care unit.
Topics: Acute Disease; Ammonia; Canada; Child; Child, Preschool; Female; Humans; Hyperammonemia; Infant; Inf | 2019 |
Demethylation of the hypoxia induction factor 1 binding site of GPX3 at excess blood ammonia in propionic acidemia.
Topics: Ammonia; Binding Sites; Demethylation; DNA Methylation; Glutathione Peroxidase; Humans; Hyperammonem | 2019 |
Citrullinemia Type 1: Behavioral Improvement with Late Liver Transplantation.
Topics: Amino Acids; Ammonia; Argininosuccinate Synthase; Child; Citrullinemia; Exons; Heterozygote; Humans; | 2019 |
Taurine transporter (TauT) deficiency impairs ammonia detoxification in mouse liver.
Topics: Ammonia; Animals; Deficiency Diseases; Disease Models, Animal; GABA Plasma Membrane Transport Protei | 2019 |
Pivotal role of inter-organ aspartate metabolism for treatment of mitochondrial aspartate-glutamate carrier 2 (citrin) deficiency, based on the mouse model.
Topics: Amino Acids; Ammonia; Ammonium Chloride; Animals; Aspartic Acid; Citrulline; Citrullinemia; Disease | 2019 |
Ethanol sensitizes skeletal muscle to ammonia-induced molecular perturbations.
Topics: Ammonia; Animals; Cell Line; Ethanol; Hepatocytes; Humans; Hyperammonemia; Membrane Transport Protei | 2019 |
Hyperammonemic encephalopathy in a pediatric patient with Salmonella enteritis and after Roux-en-Y surgery.
Topics: Ammonia; Anastomosis, Roux-en-Y; Brain Diseases; Child; Enteritis; Humans; Hyperammonemia; Infant; S | 2019 |
Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
Topics: Adult; Ammonia; Case-Control Studies; Dipeptides; Hepatic Encephalopathy; Hepatitis C, Chronic; Huma | 2019 |
Differential role of interleukin-1β in neuroinflammation-induced impairment of spatial and nonspatial memory in hyperammonemic rats.
Topics: Ammonia; Animal Feed; Animals; Cerebral Cortex; Gene Expression Regulation; Hippocampus; Hyperammone | 2019 |
Acute hyperammonemic encephalopathy due to a portosystemic shunt in a non-cirrhotic adult patient.
Topics: Aged; Ammonia; Diagnosis, Differential; Embolization, Therapeutic; Hepatic Encephalopathy; Humans; H | 2019 |
Ammonia induces calpain-dependent cleavage of CRMP-2 during neurite degeneration in primary cultured neurons.
Topics: Ammonia; Animals; Calcium; Calpain; Hyperammonemia; Intercellular Signaling Peptides and Proteins; N | 2019 |
Extracorporeal Liver Support for the Treatment of Hyperammonemia After Lung Transplantation.
Topics: Ammonia; Brain Diseases, Metabolic; Female; Hemofiltration; Humans; Hyperammonemia; Lung Transplanta | 2020 |
Simultaneous double hemodialysis for the control of refractory hyperammonemia.
Topics: Aged; Ammonia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Encephalit | 2013 |
Hepatic encephalopathy: an enigma from patient to enzyme and back.
Topics: Ammonia; Animals; Hepatic Encephalopathy; Humans; Hyperammonemia; Nitrogen | 2013 |
Use of continuous hemodiafiltration for the treatment of a neonate with hyperammonemia secondary to argininosuccinate lyase (ASAL) deficiency.
Topics: Ammonia; Arginine; Argininosuccinate Lyase; Argininosuccinic Aciduria; Breast Feeding; Combined Moda | 2013 |
Brain alanine formation as an ammonia-scavenging pathway during hyperammonemia: effects of glutamine synthetase inhibition in rats and astrocyte-neuron co-cultures.
Topics: Alanine; Amino Acids; Ammonia; Animals; Astrocytes; Brain Chemistry; Chromatography, High Pressure L | 2013 |
Moderate grade hyperammonemia activates lactate dehydrogenase-4 and 6-phosphofructo-2-kinase to support increased lactate turnover in the brain slices.
Topics: Ammonia; Animals; Brain; Enzyme Activation; Female; Hyperammonemia; Isoenzymes; L-Lactate Dehydrogen | 2013 |
Reducing the risk of hyperammonemia from transfusion of stored red blood cells.
Topics: Ammonia; Blood Preservation; Erythrocyte Transfusion; Erythrocytes; Humans; Hyperammonemia | 2013 |
Ammonia clearance with haemofiltration in adults with liver disease.
Topics: Adult; Ammonia; Female; Hemodiafiltration; Humans; Hyperammonemia; Liver Failure; Male; Middle Aged; | 2014 |
Use of carglumic acid in the treatment of hyperammonaemia during metabolic decompensation of patients with propionic acidaemia.
Topics: Amino Acid Metabolism, Inborn Errors; Ammonia; Carnitine; Child, Preschool; Female; Glutamates; Huma | 2013 |
Hyperammonemia in idiopathic epileptic seizure.
Topics: Acid-Base Imbalance; Adult; Ammonia; Emergency Service, Hospital; Epilepsy; Female; Humans; Hydrogen | 2013 |
Altered mental status in a teenager.
Topics: Adolescent; Ammonia; Child; Confusion; Diagnosis, Differential; Humans; Hyperammonemia; Male; Ornith | 2013 |
Drug-induced removal of nitrogen derivatives in urine: a new concept whose time has come.
Topics: Ammonia; Female; Glycerol; Hepatic Encephalopathy; Humans; Hyperammonemia; Male; Phenylbutyrates | 2014 |
Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: a quantitative modelling study.
Topics: Ammonia; Biomarkers; Computer Simulation; Hemodynamics; Humans; Hyperammonemia; Liver Circulation; L | 2014 |
Continuous hemodialysis therapy for an extremely low-birthweight infant with hyperammonemia.
Topics: Ammonia; Fatal Outcome; Follow-Up Studies; Humans; Hyperammonemia; Infant, Extremely Low Birth Weigh | 2013 |
[Clinical effect of stem cell transplantation via hepatic artery in the treatment of type II hyperammonemia: a report on 6 cases].
Topics: AC133 Antigen; Ammonia; Antigens, CD; Arginine; Citrulline; Female; Glycoproteins; Hepatic Artery; H | 2013 |
Changes in CNS cells in hyperammonemic portal hypertensive rats.
Topics: Alzheimer Disease; Ammonia; Animals; Antigens, Nuclear; Arterial Pressure; Astrocytes; ATP Binding C | 2014 |
[Partial deficiency of ornithine transcarbamylase. A case report].
Topics: Aged; Ammonia; Female; Humans; Hyperammonemia; Ornithine Carbamoyltransferase Deficiency Disease | 2014 |
Disruption of redox homeostasis and brain damage caused in vivo by methylmalonic acid and ammonia in cerebral cortex and striatum of developing rats.
Topics: Ammonia; Animals; Antioxidants; Catalase; Cerebral Cortex; Corpus Striatum; Fluoresceins; Glutathion | 2014 |
Ammonia levels and the severity of hepatic encephalopathy.
Topics: Adult; Ammonia; Female; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Male; Middl | 2014 |
[Reversible hepatic myelopathy: a case report].
Topics: Administration, Oral; Adult; Ammonia; Biomarkers; Evoked Potentials, Somatosensory; Female; Gastroin | 2014 |
Pannexin1 as a novel cerebral target in pathogenesis of hepatic encephalopathy.
Topics: Ammonia; Brain; Connexins; Energy Metabolism; Glutamic Acid; Heart Arrest; Hepatic Encephalopathy; H | 2014 |
Hyperammonemia associated with valproic acid concentrations.
Topics: Adolescent; Adult; Ammonia; Bipolar Disorder; Carnitine; Child; Dietary Supplements; Dose-Response R | 2014 |
Ammonia-induced energy disorders interfere with bilirubin metabolism in hepatocytes.
Topics: Ammonia; Ammonium Chloride; Apoptosis; Bilirubin; Cell Survival; Citric Acid Cycle; Energy Metabolis | 2014 |
4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
Topics: Alleles; Amino-Acid N-Acetyltransferase; Ammonia; Anticonvulsants; Asian People; Biomarkers, Pharmac | 2014 |
Differential up-regulation of ammonia detoxifying enzymes in cerebral cortex, cerebellum, hippocampus, striatum and liver in hyperammonemia.
Topics: Alanine Transaminase; Ammonia; AMP Deaminase; Animals; Aspartate Aminotransferases; Brain; Disease M | 2014 |
Dysbalance of astrocyte calcium under hyperammonemic conditions.
Topics: Ammonia; Animals; Astrocytes; Calcium; Cerebellum; Glutamate-Ammonia Ligase; Hepatic Encephalopathy; | 2014 |
Elevated ammonia concentrations: potential for pre-analytical and analytical contributing factors.
Topics: Ammonia; Humans; Hyperammonemia; Specimen Handling | 2014 |
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ammonia; Anticonvulsants; Antipsychotic Age | 2014 |
L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.
Topics: Ammonia; Animals; Biomarkers; Brain; Disease Models, Animal; Female; Glycine; Hyperammonemia; Kidney | 2014 |
Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia.
Topics: Ammonia; Animals; Baculoviridae; Genetic Therapy; Genetic Vectors; Glutamate-Ammonia Ligase; Hyperam | 2015 |
Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy.
Topics: Ammonia; Animals; Arginase; Dependovirus; Disease Models, Animal; Genetic Therapy; Hyperammonemia; H | 2015 |
Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder.
Topics: Adolescent; Adult; Ammonia; Child; Child, Preschool; Female; Glutamine; Humans; Hyperammonemia; Infa | 2015 |
Idiopathic hyperammonemia after hematopoietic stem cell transplantation: A case report.
Topics: Ammonia; Brain Edema; Child; Fanconi Anemia; Fatal Outcome; Febrile Neutropenia; Female; Hematopoiet | 2015 |
Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans.
Topics: Adult; Ammonia; Carbon Dioxide; Cohort Studies; Drug Resistance, Bacterial; Female; Humans; Hyperamm | 2015 |
Engineering the gut microbiota to treat hyperammonemia.
Topics: Ammonia; Animals; Bacteria; Bacterial Proteins; Bioengineering; Biological Therapy; Chemical and Dru | 2015 |
[Specific expression of CPS-II in hyperammonemia-injured liver cells].
Topics: Ammonia; Apoptosis; Hepatocytes; Humans; Hyperammonemia; Liver; Real-Time Polymerase Chain Reaction; | 2015 |
Hyperammonemia in Urinary Tract Infections.
Topics: Aged; Aged, 80 and over; Ammonia; Anti-Infective Agents; Female; Humans; Hyperammonemia; Male; Middl | 2015 |
Hyperammonemia Syndrome After Lung Transplantation: A Single Center Experience.
Topics: Aged; Ammonia; Arginine; Biomarkers; Carnitine; Combined Modality Therapy; Decontamination; Female; | 2016 |
Carbamoylphosphate synthetase 1 (CPS1) deficiency: clinical, biochemical, and molecular characterization in Malaysian patients.
Topics: Ammonia; Asian People; Carbamoyl-Phosphate Synthase (Ammonia); Carbamoyl-Phosphate Synthase I Defici | 2016 |
Ability of a novel system for neonatal extracorporeal renal replacement therapy with an ultra-small volume circuit to remove solutes in vitro.
Topics: Acute Kidney Injury; Ammonia; Automation; Biomarkers; Blood Urea Nitrogen; Creatinine; Dialysis Solu | 2016 |
Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Topics: Adolescent; Ammonia; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Genotype; Glutamate | 2015 |
Hyperammonemia results in reduced muscle function independent of muscle mass.
Topics: Aged; Ammonia; Animals; Electric Stimulation; Female; Hand Strength; Humans; Hyperammonemia; Liver C | 2016 |
Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
Topics: Ammonia; Animals; Dipeptides; Dog Diseases; Dogs; Female; Hepatic Encephalopathy; Hyperammonemia; Ma | 2016 |
Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma.
Topics: Ablation Techniques; Aged; Aged, 80 and over; Albumins; Amino Acids, Branched-Chain; Ammonia; Carcin | 2015 |
N-Carbamylglutamate Is an Effective Treatment for Acute Neonatal Hyperammonaemia in a Patient with Methylmalonic Aciduria.
Topics: Administration, Oral; Amino Acid Metabolism, Inborn Errors; Ammonia; Glutamates; Humans; Hyperammone | 2016 |
A neuronal disruption in redox homeostasis elicited by ammonia alters the glycine/glutamate (GABA) cycle and contributes to MMA-induced excitability.
Topics: Ammonia; Animals; Cerebral Cortex; Cytokines; Electroencephalography; Glutamic Acid; Glycine; Homeos | 2016 |
Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin.
Topics: Ammonia; Animals; Behavior, Animal; Brain; Coma; Disease Models, Animal; Hepatic Encephalopathy; Hyp | 2016 |
Frequency and Pathophysiology of Acute Liver Failure in Ornithine Transcarbamylase Deficiency (OTCD).
Topics: Adolescent; Adult; Ammonia; Child; Female; Humans; Hyperammonemia; Liver; Liver Failure, Acute; Long | 2016 |
Postictal ammonia as a biomarker for electrographic convulsive seizures: A prospective study.
Topics: Adult; Ammonia; Biomarkers; Cohort Studies; Electroencephalography; Female; Humans; Hyperammonemia; | 2016 |
Cerebral edema induced by hyperammonemia: a case report.
Topics: Aged; Ammonia; Brain Edema; Coma; Female; Hemodiafiltration; Humans; Hyperammonemia | 2016 |
Hyperammonemia: clinical, therapeutic, and educational aspects.
Topics: Ammonia; Humans; Hyperammonemia | 2016 |
A rare cause of postpartum coma: isolated hyperammonemia due to urea cycle disorder.
Topics: Ammonia; Coma; Female; Humans; Hyperammonemia; Ornithine Carbamoyltransferase Deficiency Disease; Po | 2016 |
Ammonium Increases TRPC1 Expression Via Cav-1/PTEN/AKT/GSK3β Pathway.
Topics: Ammonia; Animals; Astrocytes; Caveolin 1; Cell Membrane; Cells, Cultured; Female; Glycogen Synthase | 2017 |
Excessively Long Duodenum of the Pancreatic Graft Segment as a Rare Cause of Hyperammonemia After Simultaneous Pancreas-Kidney Transplant.
Topics: Adult; Ammonia; Anastomosis, Surgical; Anemia, Iron-Deficiency; Biomarkers; Diabetes Mellitus, Type | 2018 |
Chrysin, a flavonoid attenuates histological changes of hyperammonemic rats: A dose dependent study.
Topics: Ammonia; Animals; Bilirubin; Biomarkers; Body Weight; Brain; Creatinine; Dose-Response Relationship, | 2016 |
Ureaplasma urealyticum Causes Hyperammonemia in an Experimental Immunocompromised Murine Model.
Topics: Ammonia; Animals; Disease Models, Animal; Hyperammonemia; Immunocompromised Host; Immunosuppressive | 2016 |
Hyperammonemia induced by prophylactic administration of antiepileptic drugs during the perioperative period of craniotomy.
Topics: Ammonia; Anticonvulsants; Chemoprevention; Craniotomy; Epilepsy; Female; Humans; Hyperammonemia; Mal | 2016 |
Anesthetic experience of an adult male with citrullinemia type II: a case report.
Topics: Ammonia; Anesthesia, Spinal; Brain Diseases; Citrullinemia; Humans; Hyperammonemia; Male; Middle Age | 2016 |
Hyperammonaemia and associated factors in unprovoked convulsive seizures: A cross-sectional study.
Topics: Adult; Aged; Ammonia; Cross-Sectional Studies; Female; Humans; Hyperammonemia; Male; Middle Aged; Mu | 2016 |
Critically High Plasma Ammonia in an Adolescent Girl.
Topics: Ammonia; Arginine; Child; Clinical Chemistry Tests; Diagnostic Errors; Fatigue; Female; Fever; Heada | 2016 |
The bile duct ligated rat: A relevant model to study muscle mass loss in cirrhosis.
Topics: Ammonia; Animals; Base Composition; Bile Ducts; Disease Models, Animal; Eating; Hepatic Encephalopat | 2017 |
Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia.
Topics: Adenosine Triphosphate; Ammonia; Animals; Brain; Hepatic Encephalopathy; Hyperammonemia; Liver; Live | 2017 |
Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.
Topics: Ammonia; Analysis of Variance; Animals; Bile Ducts; Biomarkers; Blotting, Western; Cerebral Cortex; | 2017 |
L-Arginine in the treatment of valproate overdose - five clinical cases.
Topics: Acyl Coenzyme A; Adult; Amino-Acid N-Acetyltransferase; Ammonia; Arginine; Carnitine; Coma; Drug Ove | 2017 |
Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
Topics: Ammonia; Analysis of Variance; Animals; Autophagy; Disease Models, Animal; Homeostasis; Hyperammonem | 2017 |
Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta | 2017 |
Expanding the phenotype in argininosuccinic aciduria: need for new therapies.
Topics: Adolescent; Adult; Ammonia; Argininosuccinic Acid; Argininosuccinic Aciduria; Child; Child, Preschoo | 2017 |
Successful management of immunosuppression in a patient with severe hyperammonemia after lung transplantation.
Topics: Ammonia; Humans; Hyperammonemia; Immunosuppressive Agents; Lung Transplantation; Male; Middle Aged | 2008 |
Can plasma ammonia be measured in patients with acute liver disease?
Topics: Alanine Transaminase; Ammonia; Artifacts; Humans; Hyperammonemia; Liver Diseases; Sensitivity and Sp | 2008 |
Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain.
Topics: Ammonia; Animals; Brain; Disease Models, Animal; Disease Progression; Dizocilpine Maleate; Excitator | 2008 |
Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents.
Topics: Acute Disease; Alanine; Ammonia; Animals; Carbon Tetrachloride; Chronic Disease; Disease Models, Ani | 2008 |
Lactate contributes to ammonia-mediated astroglial dysfunction during hyperammonemia.
Topics: Actin Cytoskeleton; Ammonia; Ammonium Chloride; Animals; Astrocytes; Calcium; Cell Size; Cells, Cult | 2009 |
The effect of short-term hyperammonaemia on milk synthesis in dairy cows.
Topics: Acetates; Amino Acids; Ammonia; Animals; Cattle; Cattle Diseases; Dairying; Eating; Female; Hyperamm | 2009 |
Amino acids in CSF and plasma in hyperammonaemic coma due to arginase1 deficiency.
Topics: Adult; Amino Acids; Ammonia; Arginine; Biomarkers; Chromatography, Ion Exchange; Coma; Glutamine; Hu | 2008 |
Ammonia potentiates the lethal effect of ethanol on rats.
Topics: Ammonia; Animals; Central Nervous System Depressants; Drug Synergism; Ethanol; Hyperammonemia; Inhal | 2008 |
Morin a flavonoid exerts antioxidant potential in chronic hyperammonemic rats: a biochemical and histopathological study.
Topics: Ammonia; Animals; Antioxidants; Brain; Flavonoids; Hyperammonemia; Lipid Peroxidation; Liver; Male; | 2009 |
Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector.
Topics: Adenoviridae; Amino Acids; Ammonia; Animals; Animals, Newborn; Arginase; Genetic Therapy; Genetic Ve | 2009 |
Development of hyperammonemic encephalopathy in patients with multiple myeloma may be associated with the appearance of peripheral blood myeloma cells.
Topics: Aged; Ammonia; Brain Diseases, Metabolic; Female; Humans; Hyperammonemia; Male; Multiple Myeloma; Ne | 2009 |
Inhibitors of the mitochondrial permeability transition reduce ammonia-induced cell swelling in cultured astrocytes.
Topics: Ammonia; Animals; Astrocytes; Blood-Brain Barrier; Brain; Brain Edema; Cell Size; Cells, Cultured; C | 2009 |
Serum biotinidase activity in children treated with valproic acid and carbamazepine.
Topics: Alanine Transaminase; Ammonia; Anticonvulsants; Aspartate Aminotransferases; Biotinidase; Carbamazep | 2010 |
A case of transient hyperammonemia in the newborn transient neonatal hyperammonemia.
Topics: Ammonia; Coma; Gestational Age; Hemodiafiltration; Humans; Hyperammonemia; Infant, Newborn; Infant, | 2010 |
Biochemical efficacy of N-carbamylglutamate in neonatal severe hyperammonaemia due to propionic acidaemia.
Topics: Ammonia; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glutamates; Humans; Hyperammon | 2010 |
N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria.
Topics: Acute Disease; Amino Acid Metabolism, Inborn Errors; Ammonia; Emergency Medical Services; Female; Gl | 2010 |
AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis.
Topics: Acute Disease; Adenine Nucleotides; Adenosine Deaminase; Ammonia; AMP Deaminase; Animals; Brain; Car | 2010 |
Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism.
Topics: Ammonia; Child; Female; Humans; Hyperammonemia; Infant; Infant, Newborn; Male; Metabolism, Inborn Er | 2010 |
Portacaval anastomosis-induced hyperammonemia does not lead to oxidative stress.
Topics: Aldehydes; Ammonia; Animals; Biomarkers; Blotting, Western; Brain; Disease Models, Animal; Frontal L | 2010 |
Human (13)N-ammonia PET studies: the importance of measuring (13)N-ammonia metabolites in blood.
Topics: Ammonia; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Hepatic Encephalopathy; Human | 2010 |
Brain MR imaging and 1H-MR spectroscopy changes in patients with extrahepatic portal vein obstruction from early childhood to adulthood.
Topics: Adolescent; Adult; Age Factors; Ammonia; Basal Ganglia; Child; Female; Hepatic Encephalopathy; Human | 2010 |
Increased Na, K-ATPase alpha2 isoform gene expression by ammonia in astrocytes and in brain in vivo.
Topics: Ammonia; Animals; Astrocytes; Blotting, Western; Brain; Cell Membrane; Cells, Cultured; Dipeptides; | 2010 |
Acute hepatic encephalopathy: diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome.
Topics: Acute Disease; Adolescent; Adult; Aged; Ammonia; Cerebellum; Cerebral Cortex; Child; Diffusion Magne | 2010 |
Carbamyl phosphate synthetase deficiency and postpartum hyperammonemia.
Topics: Adult; Ammonia; Carbamoyl-Phosphate Synthase (Ammonia); Female; Humans; Hyperammonemia; Postpartum P | 2010 |
Continuous hemofiltration in the control of neonatal hyperammonemia: a 10-year experience.
Topics: Ammonia; Anticoagulants; England; Female; Hemodynamics; Hemofiltration; Humans; Hyperammonemia; Infa | 2010 |
A new experimental model for acute hepatic failure in rats.
Topics: Ammonia; Animals; Bilirubin; Creatine; Disease Models, Animal; Hepatectomy; Hepatic Encephalopathy; | 2010 |
Direct exposure to ammonia and hyperammonemia increase the extracellular accumulation and degradation of astroglia-derived glutathione in the rat prefrontal cortex.
Topics: Ammonia; Animals; Astrocytes; Cell Line, Tumor; Extracellular Space; Glutathione; Hyperammonemia; Ma | 2010 |
Postictal transient hyperammonemia as an indicator of seizure disorder.
Topics: Aged; Aged, 80 and over; Ammonia; Epilepsy; Female; Follow-Up Studies; Humans; Hyperammonemia; Male; | 2010 |
Acute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentrations: different sensitivity of red and white muscle.
Topics: Acute Disease; Amino Acids, Branched-Chain; Ammonia; Animals; Disease Models, Animal; Extracellular | 2011 |
Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Ammonia; Antineoplastic Agents; Asparaginase; Child; Female; Humans; Hyperammonemia; Lym | 2011 |
Cyclophosphamide-induced leakage of gastrointestinal ammonia into the common bloodstream in rats.
Topics: Ammonia; Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Cyclophosphamide; Dose-Respon | 2011 |
Hyperammonemia in the pediatric emergency care setting.
Topics: Ammonia; Brain Damage, Chronic; Child; Child, Preschool; Consciousness Disorders; Critical Illness; | 2010 |
New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
Topics: Acyl Coenzyme A; Amino-Acid N-Acetyltransferase; Ammonia; Animals; Anticonvulsants; Citrulline; Dise | 2011 |
Activation of AMP deaminase and adenosine deaminase in the liver during ammonia poisoning and hepatitis.
Topics: Adenosine Deaminase; Ammonia; AMP Deaminase; Analysis of Variance; Animals; Carbon Tetrachloride; He | 2010 |
N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia.
Topics: Acute Disease; Amino Acid Metabolism, Inborn Errors; Ammonia; Glutamates; Humans; Hyperammonemia; In | 2011 |
Ammonia redistribution from the gastrointestinal tract to general circulation after intraperitoneal injection of cyclophosphamide to rats.
Topics: Alanine Transaminase; Ammonia; Animals; Aspartate Aminotransferases; Cyclophosphamide; Dose-Response | 2010 |
Pro-inflammatory cytokines are raised in extrahepatic portal venous obstruction, with minimal hepatic encephalopathy.
Topics: Adolescent; Adult; Ammonia; Brain; Brain Edema; Case-Control Studies; Child; Diffusion Tensor Imagin | 2011 |
Influence of rutin on biochemical alterations in hyperammonemia in rats.
Topics: Administration, Oral; Ammonia; Animals; Antioxidants; Body Weight; Brain; Disease Models, Animal; Hy | 2012 |
Hypermagnesemia does not prevent intracranial hypertension and aggravates cerebral hyperperfusion in a rat model of acute hyperammonemia.
Topics: Ammonia; Animals; Aquaporin 4; Blood Pressure; Brain; Cerebrovascular Circulation; Dose-Response Rel | 2011 |
Inhibition of glutamine synthesis induces glutamate dehydrogenase-dependent ammonia fixation into alanine in co-cultures of astrocytes and neurons.
Topics: Alanine; Alanine Transaminase; Ammonia; Animals; Astrocytes; Cells, Cultured; Cerebral Cortex; Cocul | 2011 |
Threshold for toxicity from hyperammonemia in critically ill children.
Topics: Ammonia; Brain Edema; Child; Child, Preschool; Critical Illness; Encephalocele; Female; Humans; Hype | 2012 |
Urinary ammonia excretion increases acutely during living donor liver transplantation.
Topics: Adult; Aged; Ammonia; Biomarkers; Female; Germany; Hepatectomy; Hepatic Encephalopathy; Homeostasis; | 2011 |
Absence of neuropsychological impairment in hyperammonaemia in healthy young adults; possible synergism in development of hepatic encephalopathy (HE) symptoms?
Topics: Adult; Ammonia; Analysis of Variance; Cross-Over Studies; Double-Blind Method; Fatigue; Hepatic Ence | 2011 |
"Hyperammonemia following glufosinate-containing herbicide poisoning: a potential marker of severe neurotoxicity" by Yan-Chido Mao et al., Clin Toxicol (Phila) 2011; 49:48-52.
Topics: Adult; Aged; Aminobutyrates; Ammonia; Biomarkers; Female; Herbicides; Humans; Hyperammonemia; Male; | 2011 |
Transient hyperammonemia associated with postictal state in generalized convulsion.
Topics: Adult; Ammonia; Consciousness; Epilepsy, Post-Traumatic; Female; Humans; Hyperammonemia; Male; Middl | 2011 |
Transient hyperammonemia in seizures: a prospective study.
Topics: Ammonia; Creatinine; Emergency Service, Hospital; Female; Humans; Hyperammonemia; Male; Middle Aged; | 2011 |
Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Cognitive Dysfunction; Fatty Liver; Female; Hepatic Encephalopathy; Humans; Hy | 2012 |
Exploratory investigation on nitro- and phospho-proteome cerebellum changes in hyperammonemia and hepatic encephalopathy rat models.
Topics: Ammonia; Animals; Cerebellum; Cognition; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hyp | 2012 |
How to use serum ammonia.
Topics: Ammonia; Child; Child, Preschool; Education, Medical, Continuing; Humans; Hyperammonemia; Infant; Me | 2012 |
Cerebral glutamine metabolism under hyperammonemia determined in vivo by localized (1)H and (15)N NMR spectroscopy.
Topics: Ammonia; Animals; Brain; Glutamate-Ammonia Ligase; Glutamic Acid; Glutamine; Hyperammonemia; Magneti | 2012 |
Ammonia-induced brain swelling and neurotoxicity in an organotypic slice model.
Topics: Ammonia; Animals; Animals, Newborn; Brain; Brain Edema; Disease Models, Animal; Hepatic Encephalopat | 2011 |
Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Topics: Administration, Oral; Ammonia; Dipeptides; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia | 2011 |
Systemic oxidative stress is implicated in the pathogenesis of brain edema in rats with chronic liver failure.
Topics: Ammonia; Animals; Blood-Brain Barrier; Brain Edema; Disease Models, Animal; End Stage Liver Disease; | 2012 |
Prognostic value of venous blood ammonia in patients with out-of-hospital cardiac arrest.
Topics: Aged; Ammonia; Biomarkers; Chi-Square Distribution; Confidence Intervals; Emergency Medical Services | 2012 |
Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure.
Topics: Adolescent; Adult; Aged; Ammonia; Blood Chemical Analysis; Brain Edema; Child; Communicable Diseases | 2012 |
Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency.
Topics: Age of Onset; Ammonia; Arginine; Citrulline; Humans; Hyperammonemia; Male; Middle Aged; Ornithine; O | 2012 |
A rare case of hyperammonemia complication of high-protein parenteral nutrition.
Topics: Adult; Ammonia; Brain Edema; Dietary Proteins; Fatal Outcome; Humans; Hyperammonemia; Male; Parenter | 2013 |
A case of valproate-induced encephalopathy.
Topics: Ammonia; Antimanic Agents; Brain Diseases, Metabolic; Female; Humans; Hyperammonemia; Middle Aged; P | 2012 |
Recurrent unexplained hyperammonemia in an adolescent with arginase deficiency.
Topics: Adolescent; Ammonia; Child; Hospitalization; Humans; Hyperammonemia; Hyperargininemia; Male; Recurre | 2012 |
SLC22A5 mutations in a patient with systemic primary carnitine deficiency: the first Korean case confirmed by biochemical and molecular investigation.
Topics: Ammonia; Base Sequence; Cardiomyopathies; Carnitine; Humans; Hyperammonemia; Infant, Newborn; Lactic | 2012 |
Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia.
Topics: Acetates; Ammonia; Animals; Arteries; Bile Ducts; Drug Interactions; Female; Glutamine; Hyperammonem | 2013 |
Impairment of short term memory in rats with hepatic encephalopathy due to bile duct ligation.
Topics: Ammonia; Animals; Bile Ducts; End Stage Liver Disease; Hepatic Encephalopathy; Hyperammonemia; Ligat | 2013 |
Aggravation of cyclophosphamide-induced acute neurological disorders under conditions of artificial acidification of chyme in rats.
Topics: Acute Disease; Administration, Oral; Ammonia; Animals; Boric Acids; Cyclophosphamide; Gastric Juice; | 2012 |
Ammonia inhibits long-term potentiation via neurosteroid synthesis in hippocampal pyramidal neurons.
Topics: Adaptation, Physiological; Ammonia; Animals; CA1 Region, Hippocampal; Cognition; gamma-Aminobutyric | 2013 |
Efficacy of clonidine in hyperammonemia induced hyperexcitability syndrome.
Topics: Adrenergic alpha-Agonists; Ammonia; Brain Chemistry; Clonidine; Glucose; Glutamic Acid; Humans; Hype | 2013 |
Metabolic improvements in intrahepatic porto-systemic venous shunt presenting various metabolic abnormalities by 4-phenylacetate.
Topics: Administration, Intravenous; Adolescent; Ammonia; Child; Female; Hepatic Veins; Humans; Hyperammonem | 2013 |
Comparison of the effects of ammonia on brain mitochondrial function in rats and gulf toadfish.
Topics: Ammonia; Animals; Antimycin A; Batrachoidiformes; Brain; Cyanides; Electron Transport; Glutamine; He | 2002 |
[Fulminant coma: think hyperammonemia and urea cycle disorders].
Topics: Adolescent; Ammonia; Coma; Family; Fatal Outcome; Humans; Hyperammonemia; Male; Ornithine Carbamoylt | 2002 |
Inhibition of acute hyperammonemia-induced convulsions by systemically administered gamma aminobutyric acid in rats.
Topics: Ammonia; Animals; Brain; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Hyperammonemia; | 2003 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Ammonia; Anticonvulsants; Basal Ganglia Diseases; Brain Diseases, Metabolic; Diagnosis, Differential | 2003 |
Hyperammonemia in carnitine-deficient adult JVS mice used by starvation.
Topics: Aging; Amino Acids; Ammonia; Animals; Animals, Newborn; Carbamoyl-Phosphate Synthase (Ammonia); Carn | 2002 |
Ammonia prevents glutamate-induced but not low K(+)-induced apoptosis in cerebellar neurons in culture.
Topics: Ammonia; Animals; Animals, Newborn; Apoptosis; Calcium; Calcium Signaling; Caspase 3; Caspases; Cell | 2003 |
Tolerance of neonatal rat brain to acute hyperammonemia.
Topics: Acute Disease; Adenosine Triphosphate; Age Factors; Ammonia; Animals; Animals, Newborn; Brain; Femal | 2003 |
The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis.
Topics: Adult; Ammonia; Blood Circulation; Female; Gastrointestinal Hemorrhage; Humans; Hyperammonemia; Kidn | 2003 |
Hyperammonaemia as a cause of psychosis in an adolescent.
Topics: Adolescent; Ammonia; Follow-Up Studies; Glutamates; Humans; Hyperammonemia; Male; Psychotic Disorder | 2003 |
Electroencephalographic changes in hyperammonemia.
Topics: Ammonia; Blood; Electroencephalography; Humans; Hyperammonemia | 1956 |
Electroencephalographic changes and hyperammonemia.
Topics: Ammonia; Electroencephalography; Humans; Hyperammonemia | 1958 |
A vulnerable and rate-limiting step in urea synthesis in patients with hyperammoniaemia.
Topics: Amino Acids; Ammonia; Humans; Hyperammonemia; Urea | 1958 |
[Effects of potassium & magnesium salts of DL-aspartic acid on the hyperammoniemia of experimental hemorrhagic shock].
Topics: Ammonia; Aspartic Acid; Humans; Hyperammonemia; Magnesium; Potassium; Potassium Compounds; Salts; Sh | 1958 |
Electroencephalographic observations during experimental hyperammonemia.
Topics: Ammonia; Blood-Brain Barrier; Electroencephalography; Humans; Hyperammonemia | 1958 |
[Glutamate of arginine as medication of hyperammoniemia in grave hepatic insufficiency].
Topics: Ammonia; Arginine; Glutamates; Glutamic Acid; Hepatic Insufficiency; Humans; Hyperammonemia; Liver D | 1960 |
The effect of induced hyperammonemia on renal ammonia metabolism.
Topics: Ammonia; Humans; Hyperammonemia; Kidney | 1961 |
[Electroencephalographic studies in the course of induced hyperammoniemia due to ingestion of ammoniacal salts and by protein ingestion in cirrhotics].
Topics: Ammonia; Eating; Electroencephalography; Hyperammonemia; Liver Cirrhosis; Salts | 1959 |
[Arginase and experimental hyperammoniemia. I. Effect of arginase on hyperammoniemia induced in the rat by amino acid solutions].
Topics: Amidohydrolases; Amino Acids; Ammonia; Animals; Arginase; Hyperammonemia; Rats | 1962 |
[Arginase and experimental hyperammoniemia. II. Action of arginase on experimental portacaval encephalopathy in the dog].
Topics: Amidohydrolases; Ammonia; Animals; Arginase; Brain; Brain Diseases; Dogs; Hepatic Encephalopathy; Hu | 1962 |
[On the pathophysiology of ammonia metabolism. Importance of the bacterial urease effect in the intestinal tract for hyperammoniemia in portacaval shunt].
Topics: Ammonia; Gastrointestinal Tract; Humans; Hyperammonemia; Intestines; Portacaval Shunt, Surgical; Ure | 1962 |
[Hyperammoniemia induced by glutamine in cirrhotics. The renal origin of this hyperammoniemia].
Topics: Ammonia; Glutamine; Humans; Hyperammonemia; Kidney; Liver Cirrhosis | 1962 |
Electromyographic studies on the flapping tremor, especially its relationship to hyperammonemia.
Topics: Ammonia; Dyskinesias; Electromyography; Humans; Hyperammonemia; Liver Diseases; Tremor | 1961 |
[The significance of hyperammoniemia].
Topics: Ammonia; Blood Chemical Analysis; Hyperammonemia | 1963 |
Hyperammonaemia. A new instance of an inborn enzymatic defect of the biosynthesis of urea.
Topics: Amino Acids; Ammonia; Hyperammonemia; Transferases; Urea | 1962 |
[Hyperammonemia and hepatic insufficiency].
Topics: Ammonia; Blood Chemical Analysis; Chemical and Drug Induced Liver Injury; Hepatic Encephalopathy; He | 1963 |
[Protective action of the potassium and magnesium salts of aspartic acid in hyperammonemia induced in animals (dogs) undergoing partial hepatectomy].
Topics: Ammonia; Animals; Aspartic Acid; Dogs; Hepatectomy; Hyperammonemia; Magnesium; Potassium; Salts | 1961 |
[The association of malic acid and arginine in the preventive treatment of hyperammonemia. Experimental study].
Topics: Ammonia; Arginine; Humans; Hyperammonemia; Malates | 1963 |
CEREBRAL ATROPHY IN HYPERAMMONAEMIA.
Topics: Ammonia; Atrophy; Blood Chemical Analysis; Brain Diseases; Cerebral Ventriculography; Diagnostic Ima | 1963 |
[ORAL TREATMENT OF HYPERAMMONIEMIA BY CALCIUM ALPHA-KETOGLUTARATE].
Topics: Administration, Oral; Ammonia; Blood Chemical Analysis; Hepatic Encephalopathy; Humans; Hyperammonem | 1964 |
[ON 3 CASES OF PORTACAVAL ANASTOMOSIS WELL ENDURED DESPITE A PROLONGED HYPERAMMONIEMIA].
Topics: Ammonia; Blood Chemical Analysis; Hyperammonemia; Portacaval Shunt, Surgical | 1964 |
THE PRODUCTION OF HYPERAMMONEMIA IN DOGS WITH ECK FISTULA. EFFECT OF WHOLE BLOOD, CASEIN AND CASEIN HYDROLYSATE.
Topics: Ammonia; Animals; Blood; Blood Chemical Analysis; Blood Transfusion; Caseins; Dogs; Hyperammonemia; | 1964 |
[VENOUS HYPERAMMONIEMIA INDUCED BY PENTETRAZOL AND STRYCHNINE. INFLUENCE OF A CURARIZING AGENT].
Topics: Ammonia; Blood; Gallamine Triethiodide; Hyperammonemia; Pentylenetetrazole; Pharmacology; Rabbits; R | 1964 |
[EXPERIMENTAL STUDY OF ACTION OF ARGININE GLUCOSE-L-PHOSPHATE ON HYPERAMMONIEMIA IN THE COURSE OF RESPIRATORY ACIDOSIS].
Topics: Acidosis; Acidosis, Respiratory; Ammonia; Animals; Arginine; Blood; Dogs; Glucose; Hexosephosphates; | 1965 |
[HYPERAMMONIEMIA OF RESPIRATORY INSUFFICIENCY].
Topics: Ammonia; Blood Chemical Analysis; Humans; Hyperammonemia; Pulmonary Valve Insufficiency; Respiratory | 1964 |
[Autopsy findings of a case, a special type of hepatocerebral disease, with sustained hyperammonemia].
Topics: Ammonia; Autopsy; Brain; Brain Diseases; Humans; Hyperammonemia; Liver Diseases | 1962 |
Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.
Topics: Amino Acids; Ammonia; C-Reactive Protein; Female; Hepatic Encephalopathy; Humans; Hyperammonemia; In | 2004 |
Hyperammonemia impairs long-term potentiation in hippocampus by altering the modulation of cGMP-degrading phosphodiesterase by protein kinase G.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Ammonia; Animals; Cyclic GMP; Cyclic GMP-Dependent Protein Kina | 2004 |
[Primary plasma cell leukemia (IgD-lambda) with hyperammonemia].
Topics: Ammonia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Dexame | 2004 |
Antioxidant defence of the neonatal rat brain against acute hyperammonemia.
Topics: Ammonia; Animals; Animals, Newborn; Antioxidants; Brain; Catalase; Glutathione; Glutathione Disulfid | 2004 |
Acute hemodialysis for hyperammonemia in small neonates.
Topics: Ammonia; Humans; Hyperammonemia; Infant, Newborn; Male; Renal Dialysis; Treatment Outcome | 2004 |
The significance of a high plasma ammonia value.
Topics: Ammonia; Humans; Hyperammonemia; Specimen Handling | 2004 |
[Hyperammonemia: pathogenesis, diagnosis and therapy].
Topics: Acute Disease; Amino Acids; Ammonia; Chronic Disease; Humans; Hyperammonemia | 2004 |
Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
Topics: Aged; Ammonia; Anticonvulsants; Female; Humans; Hyperammonemia; Platelet Count; Thrombocytopenia; Va | 2004 |
Valproic acid-induced hyperammonemia: a case report.
Topics: Ammonia; Anticonvulsants; Blood Urea Nitrogen; Consciousness Disorders; Diagnosis, Differential; Dru | 2004 |
Chronic exposure to ammonia induces isoform-selective alterations in the intracellular distribution and NMDA receptor-mediated translocation of protein kinase C in cerebellar neurons in culture.
Topics: Ammonia; Animals; Cells, Cultured; Cerebellum; Dose-Response Relationship, Drug; Hyperammonemia; Int | 2005 |
Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts.
Topics: Administration, Oral; Ammonia; Animals; Brain; Cyclic GMP; Extracellular Fluid; Glutamic Acid; Hyper | 2005 |
Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
Topics: Ammonia; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Female; Fructose; Huma | 2004 |
Ornithine transcarbamylase deficiency in pregnancy.
Topics: Adult; Ammonia; Female; Heterozygote; Humans; Hyperammonemia; Infant, Newborn; Male; Ornithine Carba | 2005 |
Ammonia effects on pyruvate/lactate production in astrocytes--interaction with glutamate.
Topics: Ammonia; Animals; Animals, Newborn; Aspartic Acid; Astrocytes; Bucladesine; Cells, Cultured; Cerebra | 2005 |
Ammonia toxicity under hyponatremic conditions in astrocytes: de novo synthesis of amino acids for the osmoregulatory response.
Topics: Alanine; Amino Acids; Ammonia; Ammonium Chloride; Animals; Animals, Newborn; Astrocytes; Brain Edema | 2005 |
Role of oxidative stress in the ammonia-induced mitochondrial permeability transition in cultured astrocytes.
Topics: Ammonia; Ammonium Chloride; Animals; Animals, Newborn; Antioxidants; Astrocytes; Brain; Cell Membran | 2005 |
Differential effects of ammonia on the benzodiazepine modulatory site on the GABA-A receptor complex of human brain.
Topics: Ammonia; Binding Sites; Binding, Competitive; Brain; Cell Membrane; Dose-Response Relationship, Drug | 2005 |
Hyperammonaemia reduces intracellular 22Na (sodium) ion and extracellular 86Rb ion concentrations in the blood-brain barrier of the rat.
Topics: Ammonia; Animals; Blood-Brain Barrier; Carbon Radioisotopes; Choroid Plexus; Diffusion; Disease Mode | 2005 |
[Clinical and laboratory screening studies on urea cycle defects].
Topics: Adolescent; Ammonia; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hyperammonemia; Inf | 2005 |
Ammonia-mediated LTP inhibition: effects of NMDA receptor antagonists and L-carnitine.
Topics: Adenosine Triphosphate; Ammonia; Animals; Carnitine; Cell Respiration; Dose-Response Relationship, D | 2005 |
Mechanisms of ammonia-induced cell death in rat cortical neurons: roles of NMDA receptors and glutathione.
Topics: Ammonia; Ammonium Chloride; Animals; Animals, Newborn; Apoptosis; Cell Survival; Cells, Cultured; Ce | 2005 |
Ornithine aminotransferase deficiency: diagnostic difficulties in neonatal presentation.
Topics: Amino Acid Metabolism, Inborn Errors; Ammonia; Arginine; Citrulline; Diagnosis, Differential; Female | 2005 |
A case of hyperinsulinism/hyperammonaemia syndrome with reduced carbamoyl-phosphate synthetase-1 activity in liver: a pitfall in enzymatic diagnosis for hyperammonaemia.
Topics: Adolescent; Ammonia; Carbamoyl-Phosphate Synthase (Ammonia); Diagnosis, Differential; DNA, Complemen | 2005 |
Pyruvate ameliorates the defect in ureogenesis from ammonia in citrin-deficient mice.
Topics: Amino Acids; Ammonia; Animals; Anticoagulants; Aspartic Acid; Calcium-Binding Proteins; Citric Acid; | 2006 |
Fulminant hyperammonaemia induced by thiopental coma in rats.
Topics: Acetates; Ammonia; Animals; Blood Urea Nitrogen; Coma; Defecation; Dose-Response Relationship, Drug; | 2006 |
Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure.
Topics: Ammonia; Animals; Biological Transport, Active; Female; Glutamic Acid; Glutamine; Hyperammonemia; Ki | 2006 |
Acid-sensitive ionic channels in midbrain dopamine neurons are sensitive to ammonium, which may contribute to hyperammonemia damage.
Topics: Acid Sensing Ion Channels; Ammonia; Animals; Arachnida; Central Nervous System; Dopamine; Dose-Respo | 2006 |
Equimolar ammonia interference in potassium measurement on the Osmetech OPTI CCA: a reply.
Topics: Ammonia; Autoanalysis; Child; False Positive Reactions; Humans; Hyperammonemia; Infant, Newborn; Ion | 2006 |
[The effects of Helicobacter pylori infection on hyperammonaemia and hepatic encephalopathy in cirrhotic patients].
Topics: Adult; Aged; Ammonia; Female; Helicobacter Infections; Helicobacter pylori; Hepatic Encephalopathy; | 2006 |
Hyperammonemia and encephalopathy in patients with multiple myeloma.
Topics: Ammonia; Brain; Brain Diseases, Metabolic; Humans; Hyperammonemia; Multiple Myeloma; Retrospective S | 2007 |
Phenylacetate and benzoate clearance in a hyperammonemic infant on sequential hemodialysis and hemofiltration.
Topics: Ammonia; Hemofiltration; Humans; Hyperammonemia; Infant, Newborn; Phenylacetates; Renal Dialysis; So | 2007 |
Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices.
Topics: Ammonia; Animals; Animals, Newborn; Astrocytes; Brain; Brain Edema; Cells, Cultured; Enzyme Inhibito | 2007 |
Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume.
Topics: Amino Acids; Ammonia; Ammonium Chloride; Animals; Arginine Vasopressin; Blood Glucose; Blood Volume; | 2007 |
L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
Topics: Ammonia; Drug Therapy, Combination; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver; Models, B | 2007 |
Endotoxemia produces coma and brain swelling in bile duct ligated rats.
Topics: Ammonia; Animals; Brain; Brain Edema; Capillaries; Cholestasis, Extrahepatic; Coma; Consciousness; C | 2007 |
Hyperammonemia acts synergistically with lipopolysaccharide in inducing changes in cerebral hemodynamics in rats anaesthetised with pentobarbital.
Topics: Amiloride; Ammonia; Anesthesia; Animals; Blood Pressure; Brain; Cerebral Cortex; Cerebrovascular Cir | 2007 |
Magnetic resonance spectroscopy in adult-onset citrullinemia: elevated glutamine levels in comatose patients.
Topics: Adult; Ammonia; Biomarkers; Brain; Brain Mapping; Cerebral Cortex; Choline; Citrulline; Citrullinemi | 2007 |
Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.
Topics: Adult; Ammonia; Anticonvulsants; Brain; Electroencephalography; Hepatic Encephalopathy; Humans; Hype | 2007 |
Effect of ammonia, glutamine, and serum on calcineurin, p38MAPK-diP, GADD153/CHOP10, and CNTF in primary rat astrocyte cultures.
Topics: Ammonia; Animals; Astrocytes; Blood Proteins; Brain; Calcineurin; Cells, Cultured; Ciliary Neurotrop | 2007 |
Peritoneal dialysis in neonates with inborn errors of metabolism: is it really out of date?
Topics: Ammonia; Female; Humans; Hyperammonemia; Infant, Newborn; Male; Metabolism, Inborn Errors; Peritonea | 2008 |
Hyperammonemia is associated with generalized convulsion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ammonia; Child; Female; Humans; Hyperammonemia; Male; Mi | 2008 |
Gene expression profiling of astrocytes from hyperammonemic mice reveals altered pathways for water and potassium homeostasis in vivo.
Topics: Amino Acids; Ammonia; Animals; Aquaporin 4; Astrocytes; Connexin 43; Diet, Reducing; Disease Models, | 2008 |
Ammonia inhibits the C-type natriuretic peptide-dependent cyclic GMP synthesis and calcium accumulation in a rat brain endothelial cell line.
Topics: Ammonia; Aniline Compounds; Animals; Binding Sites; Binding, Competitive; Calcium; Calcium Channel B | 2008 |
Hyperammoniemia in rats with barbiturate coma.
Topics: Ammonia; Animals; Coma; Female; Gastrointestinal Motility; Hyperammonemia; Rats; Thiopental | 2007 |
Effect of atmospheric ammonia on mortality rate of rats with barbiturate intoxication.
Topics: Acetates; Administration, Inhalation; Ammonia; Animals; Drug Synergism; Female; Hyperammonemia; Oxyg | 2007 |
[Metabolic encephalopathy can be a potentially life-threatening complication from valproic acid].
Topics: Aged, 80 and over; Ammonia; Brain Diseases, Metabolic; Consciousness Disorders; Diagnosis, Different | 2008 |
N-carbamylglutamate for neonatal hyperammonaemia in propionic acidaemia.
Topics: Ammonia; Biomarkers; Female; Glutamates; Humans; Hyperammonemia; Infant, Newborn; Intubation, Gastro | 2008 |
Rapidly cycling encephalopathy from an almost forgotten entity.
Topics: Aged, 80 and over; Ammonia; Brain Diseases, Metabolic; Colon, Sigmoid; Consciousness Disorders; Diso | 2008 |
Intravenous ribavirin and hyperammonemia in an immunocompromised patient infected with adenovirus.
Topics: Adenoviridae Infections; Ammonia; Antiviral Agents; Child; Female; Humans; Hyperammonemia; Organ Tra | 2000 |
In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during.
Topics: Acetates; Ammonia; Animals; Astrocytes; Blood Glucose; Brain; Brain Chemistry; Carbon Isotopes; Cere | 2001 |
Short report: Hyperammonaemia in critically ill septic infants.
Topics: Ammonia; Critical Care; Critical Illness; Fatal Outcome; Female; Humans; Hyperammonemia; Hypoxia-Isc | 2001 |
Heliox use in the treatment of acute hyperammonemia.
Topics: Administration, Inhalation; Ammonia; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; | 2001 |
Emergency treatment of neonatal hyperammonaemic coma with mild systemic hypothermia.
Topics: Ammonia; Carbamoyl-Phosphate Synthase (Ammonia); Coma; Electroencephalography; Emergencies; Hemofilt | 2001 |
Detection of neonatal argininosuccinate lyase deficiency by serum tandem mass spectrometry.
Topics: Amino Acid Sequence; Amino Acids; Ammonia; Arginine; Argininosuccinate Lyase; Argininosuccinic Acid; | 2001 |
Acute insulin responses to leucine in children with the hyperinsulinism/hyperammonemia syndrome.
Topics: Adolescent; Adult; Amino Acid Substitution; Ammonia; Blood Glucose; Child; Child, Preschool; Diazoxi | 2001 |
Evidence for an involvement of the ammonia-decreasing action of L-arginine in suppressing picrotoxin-induced convulsions in rats and its additive action with diazepam.
Topics: Ammonia; Animals; Arginine; Brain; Diazepam; Drug Interactions; Epilepsy; GABA Antagonists; GABA Mod | 2001 |
An anxiolytic agent, dihydrohonokiol-B, inhibits ammonia-induced increases in the intracellular Cl(-) of cultured rat hippocampal neurons via GABA(c) receptors.
Topics: Ammonia; Ammonium Chloride; Animals; Anti-Anxiety Agents; Biphenyl Compounds; Chlorides; Dose-Respon | 2001 |
Establishment of CD7+ human myeloma sister cell lines, KMS-21-PE and KMS-21-BM, carrying t(11;14) and t(8;14).
Topics: Adult; Ammonia; Antigens, CD7; Bone Marrow Cells; Chromosomes, Human, Pair 11; Chromosomes, Human, P | 2001 |
Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Brain; Brain Diseases; Electroencephalography; Female; | 2002 |
Hyperammonaemic encephalopathy in a 13-year-old boy.
Topics: Adolescent; Ammonia; Amoxicillin; Brain Diseases; Coma; Corynebacterium diphtheriae; Humans; Hyperam | 2002 |
Ammonia detoxification by continuous venovenous haemofiltration in an infant with urea cycle defect.
Topics: Ammonia; Carbamoyl-Phosphate Synthase I Deficiency Disease; Hemofiltration; Humans; Hyperammonemia; | 2002 |
Fulminant progression of hyperammonaemic encephalopathy after treatment with valproate in a patient with ureterosigmoidostomy.
Topics: Adult; Ammonia; Anastomosis, Surgical; Anticonvulsants; Brain Diseases, Metabolic; Colon, Sigmoid; F | 2002 |